• Prognostic and Predictive Biomarkers in Familial Breast Cancer.
    • Deb S, Chakrabarti A, Fox SB.
    • Cancers (Basel). 2023 Feb 20;15(4):1346. doi: 10.3390/cancers15041346.
    • Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death.
    • Avelar RA, Armstrong AJ, Carvette G, Gupta R, Puleo N, Colina JA, Joseph P, Sobeck AM, O'Connor CM, Raines B, Gandhi A, Dziubinski ML, Ma DS, Resnick K, Singh S, Zanotti K, Nagel C, Waggoner S, Thomas DG, Skala SL, Zhang J, Narla G, DiFeo A.
    • Mol Cancer Ther. 2023 Feb 14:MCT-21-0880. doi: 10.1158/1535-7163.MCT-21-0880. Epub ahead of print.
    • PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
    • Yakovlev V, Sullivan SA, Fields E, Temkin SM.
    • Front Oncol. 2023 Feb 13;13:1124147. doi: 10.3389/fonc.2023.1124147.
    • Molecular dynamics simulations reveal the effect of mutations in the RING domains of BRCA1-BARD1 complex and its relevance to the prognosis of breast cancer.
    • Kiewhuo K, Priyadarsinee L, Sarma H, Sastry GN.
    • J Biomol Struct Dyn. 2023 Feb 12:1-19. doi: 10.1080/07391102.2023.2175383. Epub ahead of print.
    • Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
    • Rosado MM, Pioli C.
    • Cancers (Basel). 2023 Feb 8;15(4):1093. doi: 10.3390/cancers15041093.
    • Design, Synthesis, and Evaluation of 1H-benzo[d]imidazole-4-carboxamide PARP-1 Inhibitors Using Different Saturated Nitrogen-Contained Heterocycle as linker Group.
    • Wu K, Peng X, Li Y, Chen M, Liu Y, Dan L, Jiang L, Yan H, Junmei P, Cao X.
    • Chem Biol Drug Des. 2023 Feb 8. doi: 10.1111/cbdd.14216. Epub ahead of print.
    • Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer.
    • Huang Y, Liu C, You L, Li X, Chen G, Fan J.
    • J Cell Mol Med. 2023 Feb 8. doi: 10.1111/jcmm.17683. Epub ahead of print.
    • ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines.
    • Wikiniyadhanee R, Lerksuthirat T, Stitchantrakul W, Chitphuk S, Takeda S, Dejsuphong D.
    • Biomed Res Int. 2023 Feb 6;2023:7891753. doi: 10.1155/2023/7891753.
    • Germline cancer gene expression quantitative trait loci are associated with local and global tumor mutations.
    • Liu Y, Gusev A, Kraft P.
    • Cancer Res. 2023 Feb 6:CAN-22-2624. doi: 10.1158/0008-5472.CAN-22-2624. Epub ahead of print.
    • Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor.
    • Wang S, Xia Y, Huang P, Xu C, Qian Y, Fang T, Gao Q.
    • J Oncol. 2023 Feb 6;2023:1453739. doi: 10.1155/2023/1453739.
    • APE2: catalytic function and synthetic lethality draw attention as a cancer therapy target.
    • McMahon A, Zhao J, Yan S.
    • NAR Cancer. 2023 Feb 6;5(1):zcad006. doi: 10.1093/narcan/zcad006.
    • PARylation of BRCA1 limits DNA break resection through BRCA2 and EXO1.
    • Lodovichi S, Quadri R, Sertic S, Pellicioli A.
    • Cell Rep. 2023 Feb 1;42(2):112060. doi: 10.1016/j.celrep.2023.112060. Epub ahead of print.
    • BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity.
    • Wu B, Qi L, Chiang HC, Pan H, Zhang X, Greenbaum A, Stark E, Wang LJ, Chen Y, Haddad BR, Clagett D, Isaacs C, Elledge R, Horvath A, Hu Y, Li R.
    • J Immunother Cancer. 2023 Feb;11(2):e005852. doi: 10.1136/jitc-2022-005852.
    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Uterine Cavity Lavage Mutation Analysis in Lithuanian Ovarian Cancer Patients.
    • Žilovic D, Vaicekauskaite I, Ciurliene R, Sabaliauskaite R, Jarmalaite S.
    • Cancers (Basel). 2023 Jan 30;15(3):868. doi: 10.3390/cancers15030868.
    • BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple negative breast cancer severity.
    • Laha S, Muhseena K, Das SP, Das R.
    • Front Genet. 2023 Jan 30;12:1035052. doi: 10.3389/fgene.2023.1035052.
    • Replication gap suppression depends on the double-strand DNA binding activity of BRCA2.
    • Vugic D, Dumoulin I, Martin C, Minello A, Alvaro-Aranda L, Gomez-Escudero J, Chaaban R, Lebdy R, von Nicolai C, Boucherit V, Ribeyre C, Constantinou A, Carreira A.
    • Nat Commun. 2023 Jan 27;14(1):446. doi: 10.1038/s41467-023-36149-0.
    • LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.
    • Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, Birrer MJ, Skates SJ, Burns KH, Carr SA, Drapkin R.
    • Sci Rep. 2023 Jan 27;13(1):1537. doi: 10.1038/s41598-023-28840-5.
    • Inflammatory cytokines-enriched microenvironment plays key roles for the development of breast cancers.
    • Takeuchi Y, Gotoh N.
    • Cancer Sci. 2023 Jan 26. doi: 10.1111/cas.15734. Epub ahead of print.
    • Review
    • DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation.
    • Kwon Y, Rösner H, Zhao W, Selemenakis P, He Z, Kawale AS, Katz JN, Rogers CM, Neal FE, Badamchi Shabestari A, Petrosius V, Singh AK, Joel MZ, Lu L, Holloway SP, Burma S, Mukherjee B, Hromas R, Mazin A, Wiese C, Sørensen CS, Sung P.
    • Nat Commun. 2023 Jan 26;14(1):432. doi: 10.1038/s41467-023-36211-x.
    • Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells.
    • Yusoh NA, Chia SL, Saad N, Ahmad H, Gill MR.
    • Sci Rep. 2023 Jan 26;13(1):1456. doi: 10.1038/s41598-023-28454-x.
    • Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
    • Zheng J, Li Z, Min W.
    • Front Pharmacol. 2023 Jan 23;13:979873. doi: 10.3389/fphar.2022.979873.
    • Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.
    • Guantay L, Garro C, Siri S, Pansa MF, Ghidelli-Disse S, Paviolo N, Racca A, Nicotra V, Radu C, Bocco JL, Felice R, Jansson KH, Remlinger K, Amador A, Stronach E, Coleman K, Muelbaier M, Drewes G, Gloger I, Madauss K, García M, Gottifredi V, Soria G.
    • Drug Resist Updat. 2023 Jan 22;67:100932. doi: 10.1016/j.drup.2023.100932. Epub ahead of print.
    • PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage.
    • Kim C, Wang XD, Jang S, Yu Y.
    • Biochem Biophys Res Commun. 2023 Jan 20;646:78-85. doi: 10.1016/j.bbrc.2023.01.055. Epub ahead of print.
    • Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition.
    • Pelliccia A, Capradossi F, Corsi F, Tarquini GD, Bruni E, Reichle A, Torino F, Ghibelli L.
    • Int J Mol Sci. 2023 Jan 20;24(3):2040. doi: 10.3390/ijms24032040.
    • Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
    • Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, Jia L, Chen HD, Bao XB, Guo N, Huan XJ, Xi Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Chen Y, Ding J, Lang JY, Miao ZH, Zhang A, He JX.
    • EMBO Mol Med. 2023 Jan 18:e16235. doi: 10.15252/emmm.202216235. Epub ahead of print.
    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    • Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
    • Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.
    • Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis.
    • Bak SE, Kim H, Ho JY, Cho EH, Lee J, Youn SM, Park SW, Han MR, Hur SY, Lee SJ, Choi YJ.
    • Cancers (Basel). 2023 Jan 15;15(2):530. doi: 10.3390/cancers15020530.
    • Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
    • Concannon K, Morris BB, Gay CM, Byers LA.
    • Mol Cell. 2023 Jan 14:S1097-2765(22)01214-X. doi: 10.1016/j.molcel.2022.12.031. Epub ahead of print.
    • Review
    • Environmental impact on carcinogenesis under BRCA1 haploinsufficiency.
    • Toyokuni S, Kong Y, Motooka Y, Akatsuka S.
    • Genes Environ. 2023 Jan 13;45(1):2. doi: 10.1186/s41021-023-00258-5.
    • Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes.
    • Ibnat N, Chowdhury EH.
    • Sci Rep. 2023 Jan 11;13(1):536. doi: 10.1038/s41598-022-25511-9.
    • Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis.
    • Liu Y, Shen Z, Zhu T, Lu W, Fu Y.
    • Front Pharmacol. 2023 Jan 10;13:1014933. doi: 10.3389/fphar.2022.1014933.
    • Update: Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations.
    • [No author given]
    • FORCE. XRAY. 2023 Jan 9.

    Related:

    •• Identifier: NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)

    • Discovery of a potent olaparib-chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer.
    • Qin H, Zhang J, Zhao Y, Zhang L, Feng J, Zhang L.
    • Front Pharmacol. 2023 Jan 9;13:1054616. doi: 10.3389/fphar.2022.1054616.
    • Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers.
    • [No author given]
    • Precision Oncology News. 2023 Jan 9.
    • Whole-exome sequencing and bioinformatic analyses revealed differences in gene mutation profiles in papillary thyroid cancer patients with and without benign thyroid goitre background.
    • Eng ZH, Abdullah MI, Ng KL, Abdul Aziz A, Arba'ie NH, Mat Rashid N, Mat Junit S.
    • Front Endocrinol (Lausanne). 2023 Jan 4;13:1039494. doi: 10.3389/fendo.2022.1039494.
    • Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    • Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
    • Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.
    • STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    • Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z, Cheng X, Qian C, Xie S, Kim HJ, Launonen IM, Färkkilä A, Roberts TM, Freeman GJ, Liu JF, Konstantinopoulos PA, Matulonis U, Yu H, Zhao JJ.
    • J Immunother Cancer. 2023 Jan;11(1):e005627. doi: 10.1136/jitc-2022-005627.
    • Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3).
    • Aleissa MS, Al-Zharani M, Alneghery LM, Aleissa AM.
    • Saudi Pharm J. 2023 Jan;31(1):110-118. doi: 10.1016/j.jsps.2022.11.009. Epub 2022 Nov 15.
    • Lestaurtinib induces DNA damage that is related to estrogen receptor activation.
    • Ooka M, Yang S, Zhang L, Kojima K, Huang R, Hirota K, Takeda S, Xia M.
    • Curr Res Toxicol. 2022 Dec 24 [eCollection 2023];4:100102. doi: 10.1016/j.crtox.2022.100102.
    • Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
    • Chang T, Lian Z, Ma S, Liang Z, Ma X, Wen X, Wang Y, Liu R.
    • Prostate. 2022 Dec 28. doi: 10.1002/pros.24479. Epub ahead of print.
    • CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
    • Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCS Group, Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M.
    • Cancer. 2022 Dec 26. doi: 10.1002/cncr.34582. Epub ahead of print.
    • Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
    • Barszczewska-Pietraszek G, Drzewiecka M, Czarny P, Skorski T, Śliwiński T.
    • Int J Mol Sci. 2022 Dec 24;24(1):319. doi: 10.3390/ijms24010319.
    • Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment.
    • Jackson LM, Moldovan GL.
    • NAR Cancer. 2022 Dec 22;4(4):zcac042. doi: 10.1093/narcan/zcac042.
    • Parent-of-origin detection and chromosome-scale haplotyping using long-read DNA methylation sequencing and Strand-seq.
    • Akbari V, Hanlon VCT, O’Neill K, Lefebvre L, Schrader KA, Lansdorp PM, Jones SJM.
    • Cell Genom. 2022 Dec 21. doi: 10.1016/j.xgen.2022.100233. Epub ahead of print.

    Related:

    •• Research news: Genetic Test Identifies Parental Source of Cancer Variant. (Medscape Oncology)

    • CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    • Lu X, He Y, Johnston RL, Nanayakarra D, Sankarasubramanian S, Lopez JA, Friedlander M, Kalimutho M, Hooper JD, Raninga PV, Khanna KK.
    • J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.
    • Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
    • Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
    • J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.
    • Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images.
    • Lazard T, Bataillon G, Naylor P, Popova T, Bidard FC, Stoppa-Lyonnet D, Stern MH, Decencière E, Walter T, Vincent-Salomon A..
    • Cell Rep Med. 2022 Dec 20;3(12):100872. doi: 10.1016/j.xcrm.2022.100872. Epub 2022 Dec 13.

    Related:

    •• Commentary:

    HRD-related morphology discovery in breast cancer by controlling for confounding factors.

    • Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity.
    • Wang W, Xiong Y, Hu X, Lu F, Qin T, Zhang L, Guo E, Yang B, Fu Y, Hu D, Fan J, Qin X, Liu C, Xiao R, Chen G, Li Z, Sun C.
    • Acta Biomater. 2022 Dec 19:S1742-7061(22)00824-8. doi: 10.1016/j.actbio.2022.12.021. Epub ahead of print.
    • PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells.
    • Chivot J, Ferrand N, Fert A, Van Dreden P, Morichon R, Sabbah M.
    • Int J Mol Sci. 2022 Dec 18;23(24):16171. doi: 10.3390/ijms232416171.
    • 53BP1: Keeping It under Control, Even at a Distance from DNA Damage.
    • Rass E, Willaume S, Bertrand P.
    • Genes (Basel). 2022 Dec 16;13(12):2390. doi: 10.3390/genes13122390.
    • Ferroptosis synergistically sensitizes wee1 inhibitors: a bibliometric study.
    • Xu R, Wu X, Zhao Q, Yang Q.
    • Am J Transl Res. 2022 Dec 15;14(12):8473-8488.
    • Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.
    • Ren J, Quan X, Liu Y, Li J, Zhang X, Li Z, Zhang X.
    • Bioorg Med Chem Lett. 2022 Dec 15;78:129046. doi: 10.1016/j.bmcl.2022.129046. Epub 2022 Nov 4.
    • Ovarian cancer mutational processes drive site-specific immune evasion.
    • Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP.
    • Nature. 2022 Dec 14. doi: 10.1038/s41586-022-05496-1. Epub ahead of print.
    • Ideaya Biosciences Files IND With FDA for PARG Inhibitor.
    • [No author goven]
    • Precision Oncology News. 2022 Dec 12.
    • BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.
    • Choi E, Mun GI, Lee J, Lee H, Cho J, Lee YS.
    • Biomed Pharmacother. 2022 Dec 6;158:114090. doi: 10.1016/j.biopha.2022.114090. Epub ahead of print.
    • A Single Variant in Pri-miRNA-155 Associated with Susceptibility to Hereditary Breast Cancer Promotes Aggressiveness in Breast Cancer Cells.
    • Landeros N, Gonzalez-Hormazabal P, Pérez-Moreno P, Tapia JC, Jara L.
    • Int J Mol Sci. 2022 Dec 6;23(23):15418. doi: 10.3390/ijms232315418.
    • CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining.
    • Iyer DR, Harada N, Clairmont C, Jiang L, Martignetti D, Nguyen H, He YJ, Chowdhury D, D'Andrea AD.
    • Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2214935119. doi: 10.1073/pnas.2214935119. Epub 2022 Nov 29.
    • RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer.
    • Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA.
    • Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2136-2147. doi: 10.1158/1055-9965.EPI-22-0590.
    • Signal "on-off-off" strategy for improving the sensitivity of BRCA1 electrochemical detection by combining gold substrate amplification, DNA conformational transformation and DSN enzymatic hydrolysis dual reduction.
    • Li Z, Chen J, Zhang L, Liu Y, Jia Y, Zhou G, Luo L.
    • Anal Chim Acta. 2022 Dec 1;1235:340461. doi: 10.1016/j.aca.2022.340461. Epub 2022 Oct 1.
    • The BRCAness Landscape of Cancer.
    • Guo M, Wang SM.
    • Cells. 2022 Dec 1;11(23):3877. doi: 10.3390/cells11233877.
    • Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.
    • Golder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan RD, McGrail JC, Taylor SS.
    • NAR Cancer. 2022 Nov 12 [eCollection 2022 Dec];4(4):zcac036. doi: 10.1093/narcan/zcac036.
    • Nanoparticle-Mediated PRDX2 Inhibition for Specific Targeting of CHK2-Null Colorectal Cancer.
    • Ahmad A, Prakash R, Khan MS, Altwaijry N, Asghar MN, Raza SS, Khan R.
    • ACS Biomater Sci Eng. 2022 Nov 29. doi: 10.1021/acsbiomaterials.2c01073. Epub ahead of print.
    • ATR Inhibitors in Platinum-Resistant Ovarian Cancer.
    • Li S, Wang T, Fei X, Zhang M.
    • Cancers (Basel). 2022 Nov 29;14(23):5902. doi: 10.3390/cancers14235902.
    • 3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction.
    • Zhang H, Gao H, Gu Y, John A, Wei L, Minhong Huang M, Yu J, Adeosun AA, Weinshilboum RM, Wang L.
    • Front Oncol. 2022 Nov 29;12:999302. doi: 10.3389/fonc.2022.999302.
    • Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes.
    • Gonzalez-Bosquet J, Cardillo ND, Reyes HD, Smith BJ, Leslie KK, Bender DP, Goodheart MJ, Devor EJ.
    • Int J Mol Sci. 2022 Nov 26;23(23):14814. doi: 10.3390/ijms232314814.
    • A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.
    • Bordoloi D, Bhojnagarwala PS, Perales-Puchalt A, Kulkarni AJ, Zhu X, Liaw K, O'Connell RP, Park DH, Kulp DW, Zhang R, Weiner DB.
    • JCI Insight. 2022 Nov 22;7(22):e162553. doi: 10.1172/jci.insight.162553.
    • POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells.
    • Belan O, Sebald M, Adamowicz M, Anand R, Vancevska A, Neves J, Grinkevich V, Hewitt G, Segura-Bayona S, Bellelli R, Robinson HMR, Higgins GS, Smith GCM, West SC, Rueda DS, Boulton SJ.
    • Mol Cell. 2022 Nov 22:S1097-2765(22)01070-X. doi: 10.1016/j.molcel.2022.11.008. Epub ahead of print.
    • Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    • Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A.
    • Gynecol Oncol. 2022 Nov 17;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub ahead of print.
    • Blood Test Signals BRCA Breast Cancer 2 Years Before Diagnosis.
    • Davenport L.
    • Medscape. 2022 Nov 17.
    • Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.
    • Ogony J, Hoskin TL, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad MA, Kannan N, Peña A, Allers T, Brown A, Sherman ME, Visscher DW, Knutson KL, Radisky DC, Degnim AC.
    • Breast Cancer Res Treat. 2022 Nov 16. doi: 10.1007/s10549-022-06786-y. Epub ahead of print.
    • BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy.
    • Soni A, Lin X, Mladenov E, Mladenova V, Stuschke M, Iliakis G.
    • Cancers (Basel). 2022 Nov 16;14(22):5619. doi: 10.3390/cancers14225619.
    • Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
    • Franzese O, Graziani G.
    • Cancers (Basel). 2022 Nov 16;14(22):5633. doi: 10.3390/cancers14225633.
    • Noninvasive Pregestational Genetic Testing of Embryos Using Smart Sensors Array.
    • Abu Raya YS, Srebnik N, Rubinstein E, Schonberger O, Broza YY, Suschinel R, Haick H, Ionescu R.
    • ACS Sens. 2022 Nov 14. doi: 10.1021/acssensors.2c01492. Epub ahead of print.
    • Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation.
    • Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernado-Morales C, Haro N, Giles FJ, Pozo OJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV.
    • Clin Cancer Res. 2022 Nov 14:CCR-22-2551. doi: 10.1158/1078-0432.CCR-22-2551. Epub ahead of print.
    • 3D CRISPR Screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction.
    • Zhang H, Gao H, Gu Y, John A, Wei L, Huang M, Yu J, Adeosun A, Weinshilboum R, Wang L.
    • Front Oncol. 2022 Nov 14;12:999302. doi: 10.3389/fonc.2022.999302.
    • Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.
    • Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ.
    • Cancers (Basel). 2022 Nov 12;14(22):5559. doi: 10.3390/cancers14225559.
    • Investigation of mRNA Expression Levels of Tip60 and Related DNA Repair Genes in Molecular Subtypes of Breast Cancer.
    • Miser-Salihoglu E, Demokan S, Karanlik H, Karahalil B, Önder S, Cömert S, Yardim-Akaydin S.
    • Clin Breast Cancer. 2022 Nov 12:S1526-8209(22)00235-X. doi: 10.1016/j.clbc.2022.10.012. Epub ahead of print.
    • Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
    • Kinneer K, Wortmann P, Cooper ZA, Dickinson NJ, Masterson L, Cailleau T, Hutchinson I, Vijayakrishnan B, McFarlane M, Ball K, Davies M, Lewis A, Huang Y, Rosenbaum AI, Yuan J, Chesebrough J, Anderton J, Monks N, Novick S, Wang J, Dimasi N, Christie RJ, Sabol D, Tosto FA, Wallez Y, Leo E, Albertella MR, Staniszewska AD, Tice DA, Howard PW, Luheshi N, Sapra P.
    • Clin Cancer Res. 2022 Nov 10:CCR-22-2630. doi: 10.1158/1078-0432.CCR-22-2630. Epub ahead of print.

    Related:

    •• Identifier: NCT05123482: First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies. (ClinicalTrials.gov . Accessed 2022 Dec 1.)

    • PARP1 proximity proteomics reveals interaction partners at stressed replication forks.
    • Mosler T, Baymaz HI, Gräf JF, Mikicic I, Blattner G, Bartlett E, Ostermaier M, Piccinno R, Yang J, Voigt A, Gatti M, Pellegrino S, Altmeyer M, Luck K, Ahel I, Roukos V, Beli P.
    • Nucleic Acids Res. 2022 Nov 9:gkac948. doi: 10.1093/nar/gkac948. Epub ahead of print.
    • Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51.
    • Heijink AM, Stok C, Porubsky D, Manolika EM, de Kanter JK, Kok YP, Everts M, de Boer HR, Audrey A, Bakker FJ, Wierenga E, Tijsterman M, Guryev V, Spierings DCJ, Knipscheer P, van Boxtel R, Ray Chaudhuri A, Lansdorp PM, van Vugt MATM.
    • Nat Commun. 2022 Nov 7;13(1):6722. doi: 10.1038/s41467-022-34519-8.
    • Compounds from Diverse Natural Origin against Triple-Negative Breast Cancer: A Comprehensive Review.
    • Ramasamy T, Priyankha S, Kannan M, Prakash M, Selvam C.
    • Chem Biol Drug Des. 2022 Nov 2. doi: 10.1111/cbdd.14172. Epub ahead of print.
    • Review
    • Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
    • Sinha S, Chatterjee S, Paul S, Das B, Dash SR, Das C, Kundu CN.
    • Exp Cell Res. 2022 Nov 1;420(1):113338. doi: 10.1016/j.yexcr.2022.113338. Epub 2022 Sep 6.
    • Partial Reduction in BRCA1 Gene Dose Modulates DNA Replication Stress Level and Thereby Contributes to Sensitivity or Resistance.
    • Classen S, Rahlf E, Jungwirth J, Albers N, Hebestreit LP, Zielinski A, Poole L, Groth M, Koch P, Liehr T, Kankel S, Cordes N, Petersen C, Rothkamm K, Pospiech H, Borgmann K.
    • Int J Mol Sci. 2022 Nov 1;23(21):13363. doi: 10.3390/ijms232113363.
    • Characterization of Oncology Clinical Trials Using Germline Genetic Data.
    • Kammula AV, Schäffer AA, Rajagopal PS.
    • JAMA Netw Open. 2022 Nov 1;5(11):e2242370. doi: 10.1001/jamanetworkopen.2022.42370.
    • Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
    • Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A.
    • Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032.
    • A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
    • Gahlawat AW, Witte T, Haarhuis L, Schott S.
    • Br J Cancer. 2022 Nov;127(8):1550-1556. doi: 10.1038/s41416-022-01925-0. Epub 2022 Aug 5.
    • 18F-FDG Micro PET/CT imaging to evaluate the effect of BRCA1 knockdown on MDA-MB231 breast cancer cell radiosensitivity.
    • Tao W, Wang S, Xu A, Xue Y, Wang H, Xu H.
    • Transl Oncol. 2022 Nov;25:101517. doi: 10.1016/j.tranon.2022.101517. Epub 2022 Aug 17.
    • Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
    • Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
    • Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.
    • DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex.
    • McCarthy-Leo C, Darwiche F, Tainsky MA.
    • Cancers (Basel). 2022 Oct 27;14(21):5278. doi: 10.3390/cancers14215278.
    • A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein.
    • Bhat DS, Spies MA, Spies M.
    • DNA Repair (Amst). 2022 Oct 27;120:103421. doi: 10.1016/j.dnarep.2022.103421. Epub ahead of print.
    • Review
    • Replicative Instability Drives Cancer Progression.
    • Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW.
    • Biomolecules. 2022 Oct 26;12(11):1570. doi: 10.3390/biom12111570.
    • Common germline risk variants impact somatic alterations and clinical features across cancers.
    • Namba S, Saito Y, Kogure Y, Masuda T, Bondy ML, Gharahkhani P, Gockel I, Heider D, Hillmer A, Jankowski J, MacGregor S, Maj C, Melin B, Ostrom QT, Palles C, Schumacher J, Tomlinson I, Whiteman DC, Okada Y, Kataoka K.
    • Cancer Res. 2022 Oct 26:CAN-22-1492. doi: 10.1158/0008-5472.CAN-22-1492. Epub ahead of print.
    • Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy.
    • Widmer CA, Klebic I, Domanitskaya N, Decollogny M, Howald D, Siffert M, Essers P, Nowicka Z, Stokar-Regenscheit N, van de Ven M, de Korte-Grimmerink R, Galván JA, Pritchard CEJ, Huijbers IJ, Fendler W, Vens C, Rottenberg S.
    • Cancer Res Commun. 2022 Oct 26;2(10):1266-1281. doi: 10.1158/2767-9764.CRC-22-0208.
    • TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
    • Khaled NB, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
    • Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.
    • Single-cell genomic variation induced by mutational processes in cancer.
    • Funnell T, O'Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, Zamarin D, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium, Shah SP, Aparicio S.
    • Nature. 2022 Oct 26. doi: 10.1038/s41586-022-05249-0. Epub ahead of print.
    • PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
    • Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G.
    • Int J Mol Sci. 2022 Oct 25;23(21):12876. doi: 10.3390/ijms232112876.
    • Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis.
    • Klotz DM, Kuhlmann JD, Link T, Goeckenjan M, Hofbauer LC, Göbel A, Rachner TD, Wimberger P.
    • Front Oncol. 2022 Oct 21;12:974885. doi: 10.3389/fonc.2022.974885.
    • Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells.
    • Deshpande M, Paniza T, Jalloul N, Nanjangud G, Twarowski J, Koren A, Zaninovic N, Zhan Q, Chadalavada K, Malkova A, Khiabanian H, Madireddy A, Rosenwaks Z, Gerhardt J.
    • Mol Cell. 2022 Oct 20;82(20):3781-3793.e7. doi: 10.1016/j.molcel.2022.08.017. Epub 2022 Sep 12.

    Related:

    Commentary:

    BRCA1 protects against its own fragility.

    • DNA-PKcs promotes fork reversal and chemoresistance.
    • Dibitetto D, Marshall S, Sanchi A, Liptay M, Badar J, Lopes M, Rottenberg S, Smolka MB.
    • Mol Cell. 2022 Oct 20;82(20):3932-3942.e6. doi: 10.1016/j.molcel.2022.08.028. Epub 2022 Sep 20.
    • IN VIVO ASSIGNMENT OF METHYLMALONIC ACID IN BREAST TISSUE USING 2D MAGNETIC RESONANCE SPECTROSCOPY AND RELATIONSHIP WITH BREAST DENSITY, MENOPAUSAL STATUS AND CANCER RISK.
    • Santamaría G, Naude N, Bennett I, Vosburgh K, Ganau S, Bargalló X, Malycha P, Mountford C.
    • NMR Biomed. 2022 Oct 19:e4851. doi: 10.1002/nbm.4851. Epub ahead of print.
    • RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    • Haynes BM, Cunningham K, Shekhar MPV.
    • BMC Cancer. 2022 Oct 18;22(1):1073. doi: 10.1186/s12885-022-10119-z.
    • Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    • Cheng A, Rao Q, Liu Y, Huang C, Li J, Huo C, Lin Z, Lu H.
    • Gynecol Oncol. 2022 Oct 18:S0090-8258(22)01888-1. doi: 10.1016/j.ygyno.2022.10.011. Epub ahead of print.
    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    Related:

    •• Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

    •• Research news: Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer. (OncLive)

    • Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer.
    • Karlan BY.
    • OncLive. OncLive TV. 2022 Oct 18.
    • Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study.
    • Hagenaars SC, Dekker LJM, Ravesteijn B, van Vlierberghe RLP, Romijn FPHTM, Verhoeff L, Witkamp AJ, Schenk KE, Keymeulen KBIM, Menke-Pluijmers MBE, Dassen AE, Kortmann BA, de Vries J, Rutgers EJT, van der Burgt YEM, Meershoek-Klein Kranenbarg E, Cobbaert CM, Luider TM, Mesker WE, Tollenaar RAEM.
    • Int J Mol Sci. 2022 Oct 17;23(20):12399. doi: 10.3390/ijms232012399.
    • Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
    • Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes A, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodríguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow S, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan E, Lord CJ, Cruz C, Balmaña J, O'Connor MJ.
    • Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568.
    • Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Pol?.
    • Bubenik M, Mader P, Mochirian P, Vallée F, Clark J, Truchon JF, Perryman AL, Pau V, Kurinov I, Zahn KE, Leclaire ME, Papp R, Mathieu MC, Hamel M, Duffy NM, Godbout C, Casas-Selves M, Falgueyret JP, Baruah PS, Nicolas O, Stocco R, Poirier H, Martino G, Fortin AB, Roulston A, Chefson A, Dorich S, St-Onge M, Patel P, Pellerin C, Ciblat S, Pinter T, Barabé F, El Bakkouri M, Parikh P, Gervais C, Sfeir A, Mamane Y, Morris SJ, Black WC, Sicheri F, Gallant M.
    • J Med Chem. 2022 Oct 13;65(19):13198-13215. doi: 10.1021/acs.jmedchem.2c00998. Epub 2022 Sep 20.
    • Ubiquitinated PCNA drives USP1 synthetic lethality in cancer.
    • Simoneau A, Engel JL, Bandi M, Lazarides K, Liu S, Meier SR, Choi AH, Zhang H, Shen B, Martires L, Gotur D, Pham TV, Li F, Gu L, Gong S, Zhang M, Wilker E, Pan X, Whittington DA, Throner S, Maxwell JP, Chen Y, Yu Y, Huang A, Andersen JN, Feng T.
    • Mol Cancer Ther. 2022 Oct 12:MCT-22-0409. doi: 10.1158/1535-7163.MCT-22-0409. Epub ahead of print.
    • Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
    • Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR.
    • Oncogene. 2022 Oct 12. doi: 10.1038/s41388-022-02491-8. Epub ahead of print.
    • PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.
    • Wang L, Wang D, Sonzogni O, Ke S, Wang Q, Thavamani A, Batalini F, Stopka SA, Regan MS, Vandal S, Tian S, Pinto J, Cyr AM, Bret-Mounet VC, Baquer G, Eikesdal HP, Yuan M, Asara JM, Heng YJ, Bai P, Agar NYR, Wulf GM.
    • Cell Rep. 2022 Oct 11;41(2):111462. doi: 10.1016/j.celrep.2022.111462.
    • SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
    • Lin S, Tian J, He Q, Yang M, Chen Z, Belogurov AA Jr, Li X, Zhang F, Liu Y, Chen G.
    • Dis Markers. 2022 Oct 11;2022:7243146. doi: 10.1155/2022/7243146.
    • CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    • Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
    • Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.
    • Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone.
    • Kayumov M, Jia L, Pardaev A, Song SS, Mirzaakhmedov S, Ding C, Cheng YJ, Zhang RI, Bao X, Miao ZH, He JX, Zhang A.
    • Eur J Med Chem. 2022 Oct 5;240:114574. doi: 10.1016/j.ejmech.2022.114574. Epub 2022 Jun 28.
    • Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer.
    • Chen OJ, Castellsagué E, Moustafa-Kamal M, Nadaf J, Rivera B, Fahiminiya S, Wang Y, Gamache I, Pacifico C, Jiang L, Carrot-Zhang J, Witkowski L, Berghuis AM, Schoenberger S, Schneider D, Hillmer M, Bens S, Siebert R, Stewart CJR, Zhang Z, Chao WCH, Greenwood CMT, Barford D, Tischkowitz M, Majewski J, Foulkes WD, Teodoro JG.
    • Cancer Res. 2022 Oct 4;82(19):3499-3515. doi: 10.1158/0008-5472.CAN-21-3956.
    • Case report

    Related:

    Commentary:

    Mitotic Checkpoint Imbalances in Familial Cancer.

    • RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity.
    • Maybee DV, Psaras AM, Brooks TA, Ali MAM.
    • Int J Mol Sci. 2022 Oct 4;23(19):11764. doi: 10.3390/ijms231911764.
    • Differential histone deacetylase inhibitor-induced perturbations of the global proteome landscape in the setting of high-grade serous ovarian cancer.
    • Duda JM, Twigg CAI, Thomas SN.
    • Proteomics. 2022 Oct 4:e2100372. doi: 10.1002/pmic.202100372. Epub ahead of print.
    • The DNA damage induced immune response: Implications for cancer therapy.
    • Barros EM, McIntosh SA, Savage KI.
    • DNA Repair (Amst). 2022 Oct 3;120:103409. doi: 10.1016/j.dnarep.2022.103409. Epub ahead of print.
    • Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
    • Zhang X, Huo X, Guo H, Xue L.
    • Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.
    • NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer.
    • Devanaboyina M, Kaur J, Whiteley E, Lin L, Einloth K, Morand S, Stanbery L, Hamouda D, Nemunaitis J.
    • Oncol Rev. 2022 Oct 3;16:10568. doi: 10.3389/or.2022.10568.
    • A First-in-Class Clinical G-Quadruplex-Targeting Drug. The Bench-to-Bedside Translation of the Fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
    • Xu H, Hurley LH.
    • Bioorg Med Chem Lett. 2022 Oct 1:129016. doi: 10.1016/j.bmcl.2022.129016. Epub ahead of print.
    • Review

    Related:

    Original research:

    Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov)

    • Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma.
    • Abbas Z, Nouroz F, Ejaz S.
    • J Cancer Res Ther. 2022 Oct-Dec;18(6):1743-1753. doi: 10.4103/jcrt.JCRT_1310_20.
    • Brca1L63X/+ rat is a novel model of human BRCA1 deficiency displaying susceptibility to radiation-induced mammary cancer.
    • Nakamura Y, Kubota J, Nishimura Y, Nagata K, Nishimura M, Daino K, Ishikawa A, Kaneko T, Mashimo T, Kokubo T, Takabatake M, Inoue K, Fukushi M, Arai M, Saito M, Shimada Y, Kakinuma S, Imaoka T.
    • Cancer Sci. 2022 Oct;113(10):3362-3375. doi: 10.1111/cas.15485. Epub 2022 Aug 21.
    • Unpaved roads: How the DNA damage response navigates endogenous genotoxins.
    • Thada V, Greenberg RA.
    • DNA Repair (Amst). 2022 Oct;118:103383. doi: 10.1016/j.dnarep.2022.103383. Epub 2022 Aug 2.
    • Review
    • An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation.
    • Mahima M, Mahmood T, Ved A, Siddiqui MH, Ahsan F, Shamim A, Ansari VA, Ahmad A, Kashyap MK.
    • Drug Res (Stuttg). 2022 Oct;72(8):424-434. doi: 10.1055/a-1867-4654. Epub 2022 Jun 27. Erratum in: Drug Res (Stuttg). 2022 Jul 26;:
    • Review
    • Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors.
    • Wu K, Chen M, Peng X, Li Y, Tang G, Peng J, Cao X.
    • Mini Rev Med Chem. [2022 Oct];22(19):2438-2462. doi: 10.2174/1389557522666220321150700.
    • Review
    • Modulation of DNA Methylation/Demethylation Reactions Induced by Nutraceuticals and Pollutants of Exposome Can Promote a C > T Mutation in the Breast Cancer Predisposing Gene PALB2.
    • Courant F, Bougras-Cartron G, Abadie C, Frenel JS, Cartron PF.
    • Epigenomes. 2022 Sep 30;6(4):32. doi: 10.3390/epigenomes6040032.
    • Signatures associated with homologous recombination deficiency and immune regulation to improve clinical outcomes in patients with lung adenocarcinoma.
    • Shang X, Qi K, Liu X, Liu Q, Zhang X, Wang D, Huang W.
    • Front Oncol. 2022 Sep 30;12:854999. doi: 10.3389/fonc.2022.854999.
    • Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient HCC.
    • An J, Oh JH, Oh B, Oh YJ, Ju JS, Kim W, Kang HJ, Sung CO, Shim JH.
    • Hepatology. 2022 Sep 30. doi: 10.1002/hep.32812. Epub ahead of print.
    • Integrated proteomics identifies PARP inhibitor-induced pro-survival signaling changes as potential vulnerabilities in ovarian cancer.
    • Deng O, Dash S, Nepomuceno TC, Fang B, Yun SY, Welsh EA, Lawrence HR, Marchion D, Koomen JM, Monteiro AN, Rix U.
    • J Biol Chem. 2022 Sep 29:102550. doi: 10.1016/j.jbc.2022.102550. Epub ahead of print.
    • RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer.
    • Han GH, Shim JE, Yun H, Kim J, Kim JH, Cho H.
    • J Gene Med. 2022 Sep 28:e3452. doi: 10.1002/jgm.3452. Epub ahead of print.
    • BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway.
    • Liu X, Liu H, Zeng L, Lv Y.
    • PeerJ. 2022 Sep 28;10:e14052. doi: 10.7717/peerj.14052.
    • Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial.
    • Chen J, Li Y, Wang H, Li T, Gu Y, Wang W, Shan Y, Yin J, Wang Y, Qin M, Li S, Pan L, Peng S, Jin Y.
    • Cancers (Basel). 2022 Sep 24;14(19):4649. doi: 10.3390/cancers14194649.
    • A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes.
    • Alkhayyat S, Khan M, Ahmad T, Haroon, Tariq H, Baig M.
    • Medicine (Baltimore). 2022 Sep 23;101(38):e30576. doi: 10.1097/MD.0000000000030576.
    • What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.
    • Perrone E, Tudisco R, Pafundi PC, Guido D, Ciucci A, Martinelli E, Zannoni GF, Piermattei A, Spadola S, Ferrante G, Marchetti C, Scambia G, Fagotti A, Gallo D.
    • Cancers (Basel). 2022 Sep 22;14(19):4588. doi: 10.3390/cancers14194588.
    • Identification of Shared Neoantigens in BRCA1-Related Breast Cancer.
    • Ruangapirom L, Sutivijit N, Teerapakpinyo C, Mutirangura A, Doungkamchan C.
    • Vaccines (Basel). 2022 Sep 22;10(10):1597. doi: 10.3390/vaccines10101597.
    • Niraparib-induced STAT3 inhibition increases its antitumor effects.
    • Yu HE, Rodriguez-Rodriguez L, Zhao Q, Kohut A, Li YJ, Martincuks A, Austria T, Zhang C, Santiago NL, Borrero RM, Phan XT, Melstrom L.
    • Front Oncol. 2022 Sep 21;12:966492. doi: 10.3389/fonc.2022.966492.
    • Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293.
    • [No author given]
    • Precision Oncology News. 2022 Sep 21.

    Related:

    Identifier: NCT04182516: Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors. (ClinicalTrials.gov)

    • TSG101 associates with PARP1 and is essential for PARylation and DNA damage-induced NF-?B activation.
    • Tufan AB, Lazarow K, Kolesnichenko M, Sporbert A, von Kries JP, Scheidereit C.
    • EMBO J. 2022 Sep 20:e110372. doi: 10.15252/embj.2021110372. Epub ahead of print.
    • KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45a Pathway.
    • Jiang L, Liu Y, Su X, Wang J, Zhao Y, Tumbath S, Kilgore JA, Williams NS, Chen Y, Wang X, Mendonca MS, Lu T, Fu YX, Huang X.
    • Front Oncol. 2022 Sep 20;12:976292. doi: 10.3389/fonc.2022.976292.
    • Detection of Breast Cancer Lump and BRCA1/2 Genetic Mutation under Deep Learning.
    • Miao Y, Tang S.
    • Comput Intell Neurosci. 2022 Sep 19;2022:9591781. doi: 10.1155/2022/9591781.
    • Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    • Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, Sanhaji M.
    • Int J Mol Sci. 2022 Sep 17;23(18):10892. doi: 10.3390/ijms231810892.
    • BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.
    • Foo TK, Xia B.
    • Cancer Res. 2022 Sep 16;82(18):3191-3197. doi: 10.1158/0008-5472.CAN-22-1535.
    • Review
    • Prostate cancer transcriptomic regulation by the interplay of germline risk alleles, somatic mutations and 3D-genomic architecture.
    • Yuan J, Houlahan KE, Ramanand SG, Lee S, Baek G, Yang Y, Chen Y, Strand DW, Zhang MQ, Boutros PC, Mani RS.
    • Cancer Discov. 2022 Sep 15:CD-22-0027. doi: 10.1158/2159-8290.CD-22-0027. Epub ahead of print.
    • Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers.
    • Juan A, Noblejas-López MDM, Bravo I, Arenas-Moreira M, Blasco-Navarro C, Clemente-Casares P, Lara-Sánchez A, Pandiella A, Alonso-Moreno C, Ocaña A.
    • Cancers (Basel). 2022 Sep 15;14(18):4474. doi: 10.3390/cancers14184474.
    • Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.
    • Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N.
    • Front Oncol. 2022 Sep 15;12:966534. doi: 10.3389/fonc.2022.966534.

    Related:

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells.
    • Groelly FJ, Dagg RA, Petropoulos M, Rossetti GG, Prasad B, Panagopoulos A, Paulsen T, Karamichali A, Jones SE, Ochs F, Dionellis VS, Puig Lombardi E, Miossec MJ, Lockstone H, Legube G, Blackford AN, Altmeyer M, Halazonetis TD, Tarsounas M.
    • Mol Cell. 2022 Sep 15;82(18):3382-3397.e7. doi: 10.1016/j.molcel.2022.07.011. Epub 2022 Aug 23.
    • Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
    • Hamid AB, Frank LE, Bouley RA, Petreaca RC.
    • PLoS One. 2022 Sep 15;17(9):e0273736. doi: 10.1371/journal.pone.0273736.
    • PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer.
    • Ambur Sankaranarayana R, Florea A, Allekotte S, Vogg ATJ, Maurer J, Schäfer L, Bolm C, Terhorst S, Classen A, Bauwens M, Morgenroth A, Mottaghy FM.
    • EJNMMI Res. 2022 Sep 14;12(1):60. doi: 10.1186/s13550-022-00932-9.
    • B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    • Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS.
    • Eur Urol. 2022 Sep 13:S0302-2838(22)02633-1. doi: 10.1016/j.eururo.2022.09.004. Epub ahead of print.
    • Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response.
    • Hopkins C.
    • Precision Oncology News. 2022 Sep 13.
    • Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors.
    • Al-Sanea MM, Chilingaryan G, Abelyan N, Mamikonyan M, Gasparyan H, Hovhannisyan S, Hamdi A, Ali AR, Selim S, Mohamed AAB.
    • PLoS One. 2022 Sep 12;17(9):e0272065. doi: 10.1371/journal.pone.0272065.
    • Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer.
    • Flörkemeier I, Hillmann JS, Weimer JP, Hildebrandt J, Hedemann N, Rogmans C, Dempfle A, Arnold N, Clement B, Bauerschlag DO.
    • Int J Mol Sci. 2022 Sep 10;23(18):10503. doi: 10.3390/ijms231810503.
    • UBE2T regulates epithelial-mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer.
    • Cui P, Li H, Wang C, Liu Y, Zhang M, Yin Y, Sun Z, Wang Y, Chen X.
    • J Ovarian Res. 2022 Sep 10;15(1):103. doi: 10.1186/s13048-022-01034-9.
    • Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
    • Bound NT, Vandenberg CJ, Kartikasari AER, Plebanski M, Scott CL.
    • Front Genet. 2022 Sep 9;13:886170. doi: 10.3389/fgene.2022.886170.
    • From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
    • De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Franceschini R, Tancredi R, Pedrazzoli P, Santoro A, Zambelli A.
    • Front Pharmacol. 2022 Sep 8;13:909566. doi: 10.3389/fphar.2022.909566.
    • STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer.
    • Pantelidou C, Jadhav H, Kothari A, Liu R, Wulf GM, Guerriero JL, Shapiro GI.
    • NPJ Breast Cancer. 2022 Sep 6;8(1):102. doi: 10.1038/s41523-022-00471-5.
    • Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor.
    • Liu X, Wei X, Li X, Yu R, Jiang T, Zhao C.
    • Bioorg Med Chem. 2022 Sep 1;69:116892. doi: 10.1016/j.bmc.2022.116892. Epub 2022 Jun 20.
    • Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
    • Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK.
    • Clin Cancer Res. 2022 Sep 1;28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278.
    • Imaging PARP with [18F]rucaparib in pancreatic cancer models.
    • Chan CY, Chen Z, Destro G, Veal M, Lau D, O'Neill E, Dias G, Mosley M, Kersemans V, Guibbal F, Gouverneur V, Cornelissen B.
    • Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3668-3678. doi: 10.1007/s00259-022-05835-4. Epub 2022 May 26.
    • Effects of the Methylation Levels for the Breast Cancer Associated Genes BCSG1 and BRCA1 on Cellular Proliferation and Migration.
    • Li J, Li P, Li J, Yang H, Liu G, Shen P, Jiang G.
    • Genet Test Mol Biomarkers. 2022 Sep;26(9):422-429. doi: 10.1089/gtmb.2021.0304.
    • RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
    • Liu P, Lin C, Liu L, Lu Z, Tu Z, Liu H.
    • J Biol Chem. 2022 Sep;298(9):102354. doi: 10.1016/j.jbc.2022.102354. Epub 2022 Aug 9.
    • Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
    • Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M; Kyoto Study Group for Ovarian Cancer Research.
    • J Gynecol Oncol. 2022 Sep;33(5):e83. doi: 10.3802/jgo.2022.33.e83.
    • PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.
    • Pauwels EKJ, Bourguignon MH.
    • Med Princ Pract. 2022 [Sep];31(4):303-312. doi: 10.1159/000525281. Epub 2022 May 30.
    • Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.
    • Zhang H, Lin X, Zha S.
    • Biochem Soc Trans. 2022 Aug 31;50(4):1169-1177. doi: 10.1042/BST20220366.
    • Review
    • Computational Biology of BRCA2 in Male Breast Cancer, through Prediction of Probable nsSNPs, and Hit Identification.
    • Shinde SD, Satpute DP, Behera SK, Kumar D.
    • ACS Omega. 2022 Aug 17 [eCollection 2022 Aug 30];7(34):30447-30461. doi: 10.1021/acsomega.2c03851.
    • Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy.
    • Trivedi MS, Arber N, Friedman E, Garber JE, Holcomb K, Horowitz NS, Wright JD, Lee JJ, Vornik LA, Abutaseh S, Castile T, Sauter ER, Dimond E, Heckman-Stoddard BM, House M, Samimi G, Brown PH, Crew KD.
    • Cancer Prev Res (Phila). 2022 Aug 24:OF1-OF6. doi: 10.1158/1940-6207.CAPR-22-0051. Epub ahead of print.
    • Commentary

    Related:

    Identifier: NCT03382574: Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy. (ClinicalTrials.gov)

    • Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.
    • Roering P, Siddiqui A, Heuser VD, Potdar S, Mikkonen P, Oikkonen J, Li Y, Pikkusaari S, Wennerberg K, Hynninen J, Grenman S, Huhtinen K, Auranen A, Carpén O, Kaipio K.
    • Front Oncol. 2022 Aug 23;12:954430. doi: 10.3389/fonc.2022.954430.
    • PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
    • Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV.
    • Mol Cancer Ther. 2022 Aug 23:MCT-22-0217. doi: 10.1158/1535-7163.MCT-22-0217. Epub ahead of print.
    • The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    • Morra F, Merolla F, Damia G, Ricci F, Varricchio S, Ilardi G, Arenare L, Califano D, Napolitano V, Fruscio R, Melillo RM, Palazzo L, Celetti A.
    • J Exp Clin Cancer Res. 2022 Aug 13;41(1):245. doi: 10.1186/s13046-022-02459-2.
    • Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
    • Zhao Y, Zhou K, Xia X, Guo Y, Tao L.
    • Cell Cycle. 2022 Aug 12:1-13. doi: 10.1080/15384101.2022.2111769. Epub ahead of print.
    • Editorial: Protecting the code: DNA double-strand break repair pathway choice.
    • Singh JK, Noordermeer SM, Jimenez-Sainz J, Maranon DG, Altmeyer M.
    • Front Genet. 2022 Aug 12;13:993889. doi: 10.3389/fgene.2022.993889.

    Related:

    Original research:

    The Pathogenic R3052W BRCA2 Variant Disrupts Homology-Directed Repair by Failing to Localize to the Nucleus.

    • Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance.
    • Cahuzac M, Péant B, Mes-Masson AM, Saad F.
    • Cancers (Basel). 2022 Aug 11;14(16):3877. doi: 10.3390/cancers14163877.
    • Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer.
    • Stenckova M, Nenutil R, Vojtesek B, Coates PJ.
    • Pathol Oncol Res. 2022 Aug 9;28:1610592. doi: 10.3389/pore.2022.1610592.
    • Preclinical characterization of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper.
    • Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkil J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E.
    • Clin Cancer Res. 2022 Aug 5:CCR-22-0301. doi: 10.1158/1078-0432.CCR-22-0301. Epub ahead of print.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy.
    • Oplawski M, Srednicka A, Niewiadomska E, Boron D, Januszyk P, Grabarek BO.
    • Front Oncol. 2022 Aug 5;12:954008. doi: 10.3389/fonc.2022.954008.
    • Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.
    • Van Nyen T, Planque M, van Wagensveld L, Duarte JAG, Zaal EA, Talebi A, Rossi M, Körner PR, Rizzotto L, Moens S, De Wispelaere W, Baiden-Amissah REM, Sonke GS, Horlings HM, Eelen G, Berardi E, Swinnen JV, Berkers CR, Carmeliet P, Lambrechts D, Davidson B, Agami R, Fendt SM, Annibali D, Amant F.
    • Nat Commun. 2022 Aug 5;13(1):4578. doi: 10.1038/s41467-022-32272-6.
    • The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.
    • Bradbury A, Zenke FT, Curtin NJ, Drew Y.
    • Cells. 2022 Aug 1;11(15):2361. doi: 10.3390/cells11152361.
    • WRN rescues replication forks compromised by a BRCA2 deficiency: Predictions for how inhibition of a helicase that suppresses premature aging tilts the balance to fork demise and chromosomal instability in cancer.
    • Datta A, Brosh RM Jr.
    • Bioessays. 2022 Aug;44(8):e2200057. doi: 10.1002/bies.202200057. Epub 2022 Jun 25.
    • Review
    • BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    • Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT.
    • Br J Cancer. 2022 Aug;127(3):488-499. doi: 10.1038/s41416-022-01823-5. Epub 2022 Apr 30.
    • MicroRNA-126 expression in the peripheral white blood cells of patients with breast and ovarian cancer is a potential biomarker for the early prediction of cancer risk in the carriers of methylated BRCA1.
    • Al-Showimi M, Al-Yousef N, Alharbi W, Alkhezayem S, Almalik O, Alhusaini H, Alghamdi A, Al-Moghrabi N.
    • Oncol Lett. 2022 Jun 22 [eCollection 2022 Aug];24(2):276. doi: 10.3892/ol.2022.13396.
    • BRCA1 haploinsufficiency promotes chromosomal amplification under Fenton reaction-based carcinogenesis through ferroptosis-resistance.
    • Kong Y, Akatsuka S, Motooka Y, Zheng H, Cheng Z, Shiraki Y, Mashimo T, Imaoka T, Toyokuni S.
    • Redox Biol. 2022 Aug;54:102356. doi: 10.1016/j.redox.2022.102356. Epub 2022 May 28.
    • PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.
    • Kim D, Nam HJ.
    • Int J Mol Sci. 2022 Jul 29;23(15):8412. doi: 10.3390/ijms23158412.
    • Identification of RAD51-BRCA2 Inhibitors Using N-Acylhydrazone-Based Dynamic Combinatorial Chemistry.
    • Bagnolini G, Balboni B, Schipani F, Gioia D, Veronesi M, De Franco F, Kaya C, Jumde RP, Ortega JA, Girotto S, Hirsch AKH, Roberti M, Cavalli A.
    • ACS Med Chem Lett. 2022 Jul 28;13(8):1262-1269. doi: 10.1021/acsmedchemlett.2c00063.
    • Live Cell Detection of Poly(ADP-Ribose) for Use in Genetic and Genotoxic Compound Screens.
    • Koczor CA, Haider AJ, Saville KM, Li J, Andrews JF, Beiser AV, Sobol RW.
    • Cancers (Basel). 2022 Jul 28;14(15):3676. doi: 10.3390/cancers14153676.
    • The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination.
    • Schipani F, Manerba M, Marotta R, Poppi L, Gennari A, Rinaldi F, Armirotti A, Farabegoli F, Roberti M, Di Stefano G, Rocchia W, Girotto S, Tirelli N, Cavalli A.
    • Int J Mol Sci. 2022 Jul 28;23(15):8338. doi: 10.3390/ijms23158338.
    • The Differential Metabolic Signature of Breast Cancer Cellular Response to Olaparib Treatment.
    • Berardi D, Hunter Y, van den Driest L, Farrell G, Rattray NJW, Rattray Z.
    • Cancers (Basel). 2022 Jul 27;14(15):3661. doi: 10.3390/cancers14153661.
    • DNA nicks induce mutational signatures associated with BRCA1 deficiency.
    • Feng YL, Liu Q, Chen RD, Liu SC, Huang ZC, Liu KM, Yang XY, Xie AY.
    • Nat Commun. 2022 Jul 25;13(1):4285. doi: 10.1038/s41467-022-32011-x.
    • The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    • Lau CH, Seow KM, Chen KH.
    • Int J Mol Sci. 2022 Jul 23;23(15):8125. doi: 10.3390/ijms23158125.
    • Heterozygotic Brca1 mutation initiates mouse genome instability at embryonic stage.
    • Wu X, Guo M, Cui J, Cai H, Wang SM.
    • Oncogenesis. 2022 Jul 22;11(1):41. doi: 10.1038/s41389-022-00417-3.
    • Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
    • Ruigrok EAM, Verkaik NS, de Blois E, de Ridder C, Stuurman D, Roobol SJ, Van Gent DC, de Jong M, Van Weerden WM, Nonnekens J.
    • Int J Mol Sci. 2022 Jul 21;23(14):8037. doi: 10.3390/ijms23148037.
    • PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
    • Ding X, Zhu Z, Lapek J, McMillan EA, Zhang A, Chung CY, Dubbury S, Lapira J, Firdaus S, Kang X, Gao J, Oyer J, Chionis J, Rollins RA, Li L, Niessen S, Bagrodia S, Zhang L, VanArsdale T.
    • Sci Rep. 2022 Jul 21;12(1):12501. doi: 10.1038/s41598-022-16623-3.
    • Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer.
    • Bagnoli M, Nicoletti R, Valitutti M, Rizzo A, Napoli A, Montalvão De Azevedo R, Tomassetti A, Mezzanzanica D.
    • Front Oncol. 2022 Jul 18;12:923508. doi: 10.3389/fonc.2022.923508.
    • Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
    • Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M, Boussios S.
    • Int J Environ Res Public Health. 2022 Jul 14;19(14):8577. doi: 10.3390/ijerph19148577.
    • Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment.
    • Chilà R, Chiappa M, Guffanti F, Panini N, Conconi D, Rinaldi A, Cascione L, Bertoni F, Fratelli M, Damia G.
    • Front Oncol. 2022 Jul 13;12:903536. doi: 10.3389/fonc.2022.903536.
    • A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers.
    • Du T, Zhang Z, Zhou J, Sheng L, Yao H, Ji M, Xu B, Chen X.
    • Front Pharmacol. 2022 Jul 13;13:865085. doi: 10.3389/fphar.2022.865085.
    • Estrogen and BRCA1 deficiency synergistically induce breast cancer mutation-related DNA damage.
    • Chen J, Liu J, Zeng P, Zhao C, Liu X, Sun J, Wang J, Fang P, Chen W, Ding J.
    • Biochem Biophys Res Commun. 2022 Jul 12;613:140-145. doi: 10.1016/j.bbrc.2022.04.142. Epub 2022 May 2.
    • Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    • Long M, Liu H, Wu J, Wang S, Liao X, Liu Y, Hu T.
    • Comput Math Methods Med. 2022 Jul 9;2022:5508301. doi: 10.1155/2022/5508301.
    • Somatic DNA Damage Response and Homologous Repair Gene Alterations and Its Association With Tumor Variant Burden in Breast Cancer Patients With Occupational Exposure to Pesticides.
    • Scandolara TB, Valle SF, Teixeira CE, Scherer NM, de Armas EM, Furtado C, Boroni M, Jaques HDS, Alves FM, Rech D, Panis C, Bonvicino CR.
    • Front Oncol. 2022 Jul 8;12:904813. doi: 10.3389/fonc.2022.904813.
    • High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer.
    • Zuo WW, Zhao CF, Li Y, Sun HY, Ma GM, Liu YP, Kang S.
    • Front Oncol. 2022 Jul 7;12:931445. doi: 10.3389/fonc.2022.931445.
    • Exploiting replication gaps for cancer therapy.
    • Cong K, Cantor SB.
    • Mol Cell. 2022 Jul 7;82(13):2363-2369. doi: 10.1016/j.molcel.2022.04.023. Epub 2022 May 13.
    • AZD5305 More Tolerable than Earlier PARP Agents.
    • [No author given]
    • Cancer Discov. 2022 Jul 6;12(7):1602. doi: 10.1158/2159-8290.CD-NB2022-0039.
    • News
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Related:

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
    • Xu Y, Wu H, Huang L, Zhai B, Li X, Xu S, Wu X, Zhu Q, Xu Q.
    • Eur J Med Chem. 2022 Jul 5;237:114417. doi: 10.1016/j.ejmech.2022.114417. Epub 2022 Apr 27.
    • A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor.
    • Chen H, Diolaiti ME, O'Leary PC, Rojc A, Krogan NJ, Kim M, Ashworth A.
    • Mol Cancer Ther. 2022 Jul 5;21(7):1076-1089. doi: 10.1158/1535-7163.MCT-21-0841.
    • RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair.
    • Gou R, Li X, Dong H, Hu Y, Liu O, Liu J, Lin B.
    • Front Oncol. 2022 Jul 4;12:936550. doi: 10.3389/fonc.2022.936550.
    • Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.
    • Zhang X, Wang L, Chen S, Huang P, Ma L, Ding H, Basappa B, Zhu T, Lobie PE, Pandey V.
    • Commun Med (Lond). 2022 Jul 2;2:82. doi: 10.1038/s43856-022-00142-3.
    • Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment.
    • Moyret-Lalle C, Prodhomme MK, Burlet D, Kashiwagi A, Petrilli V, Puisieux A, Seimiya H, Tissier A.
    • Cancer Sci. 2022 Jul;113(7):2214-2223. doi: 10.1111/cas.15389. Epub 2022 May 24.
    • Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    • Fedier A, Maggi N, Tozzi A, Disler M, Coelho R, Jacob F, Heinzelmann-Schwarz V.
    • Int J Oncol. 2022 Jul;61(1):89. doi: 10.3892/ijo.2022.5379. Epub 2022 Jun 1.
    • Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
    • Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T.
    • J Gynecol Oncol. 2022 Jul;33(4):e55. doi: 10.3802/jgo.2022.33.e55. Epub 2022 May 3.

    Related:

    Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)

    • Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
    • Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP.
    • J Pathol. 2022 Jul;257(3):255-261. doi: 10.1002/path.5891. Epub 2022 Apr 18.
    • Review
    • BRCA1/BARD1 is a nucleosome reader and writer.
    • Witus SR, Zhao W, Brzovic PS, Klevit RE.
    • Trends Biochem Sci. 2022 Jul;47(7):582-595. doi: 10.1016/j.tibs.2022.03.001. Epub 2022 Mar 26.
    • Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
    • Casolino R, Corbo V, Beer P, Hwang CI, Paiella S, Silvestri V, Ottini L, Biankin AV.
    • Cancers (Basel). 2022 Jun 30;14(13):3239. doi: 10.3390/cancers14133239.
    • Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers.
    • Su Y, Dang NM, Depypere H, Santucci-Pereira J, Gutiérrez-Díez PJ, Kanefsky J, Janssens JP, Russo J.
    • Eur J Cancer Prev. 2022 Jun 30. doi: 10.1097/CEJ.0000000000000763. Epub ahead of print.
    • Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance.
    • Uddin MH, Zhou JY, Pimentel J, Patrick SM, Kim S, Shekhar MP, Wu GS.
    • Front Oncol. 2022 Jun 29;12:908603. doi: 10.3389/fonc.2022.908603.
    • An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide Study): Rationale, Study Design and Pilot Study.
    • Peremiquel-Trillas P, Paytubi S, Pelegrina B, Frias-Gomez J, Carmona Á, Martínez JM, de Francisco J, Benavente Y, Barahona M, Briansó F, Canet-Hermida J, Caño V, Vidal A, Zanca A, Baixeras N, Rodríguez A, Fernández-Gonzalez S, Dueñas N, Càrdenas L, Aytés Á, Bianchi I, Pavón MÀ, Reventós J, Capellà G, Gómez D, Diaz M, Ponce J, Brunet J, Matias-Guiu X, Bosch FX, de Sanjosé S, Alemany L, Pineda M, Marin F, Costas L.
    • J Pers Med. 2022 Jun 29;12(7):1074. doi: 10.3390/jpm12071074.
    • PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.
    • Dillon KM, Bekele RT, Sztupinszki Z, Hanlon T, Rafiei S, Szallasi Z, Choudhury AD, Mouw KW.
    • NPJ Precis Oncol. 2022 Jun 29;6(1):49. doi: 10.1038/s41698-022-00291-7.
    • Functional Restoration of BRCA1 Nonsense Mutations by Aminoglycoside-Induced Readthrough.
    • Abreu RBV, Gomes TT, Nepomuceno TC, Li X, Fuchshuber-Moraes M, De Gregoriis G, Suarez-Kurtz G, Monteiro ANA, Carvalho MA.
    • Front Pharmacol. 2022 Jun 28;13:935995. doi: 10.3389/fphar.2022.935995.
    • The impact of rare germline variants on human somatic mutation processes.
    • Vali-Pour M, Lehner B, Supek F.
    • Nat Commun. 2022 Jun 28;13(1):3724. doi: 10.1038/s41467-022-31483-1.

    Related:

    Research news: Cancer Risk May Be Influenced by Rare Germline Variants. (Inside Precision Medicine)

    • A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking.
    • Huang Y, Dai X, Guan Z, Liu D, Ren L, Chen M, Zeng Z, Jiang J, Luo Y, He Y, Huang M, Zhao C.
    • Int J Pharm. 2022 Jun 25;622:121897. doi: 10.1016/j.ijpharm.2022.121897. Epub 2022 Jun 8.
    • Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses.
    • Green-Tripp G, Nattress C, Halldén G.
    • Front Mol Biosci. 2022 Jun 24;9:901392. doi: 10.3389/fmolb.2022.901392.
    • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
    • Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, Goodwin R, Laurie SA, Jonker D, Hansen AR, Veitch ZW, Renouf DJ, Hagerman L, Lui H, Chen B, Kellar D, Li I, Lee SE, Kono T, Cheng BYC, Yap D, Lai D, Beatty S, Soong J, Pritchard KI, Soria-Bretones I, Chen E, Feilotter H, Rushton M, Seymour L, Aparicio S, Cescon DW.
    • Nat Commun. 2022 Jun 24;13(1):3607. doi: 10.1038/s41467-022-31199-2.

    Related:

    Identifier: NCT02719977: A Phase I Study of CX5461. (ClinicalTrials.gov)

    • Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumor-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer.
    • Vysyaraju NR, Paul M, Ch S, Ghosh B, Biswas S.
    • J Drug Target. 2022 Jun 19:1-27. doi: 10.1080/1061186X.2022.2092623. Epub ahead of print.
    • The TIP60-ATM axis regulates replication fork stability in BRCA-deficient cells.
    • Schleicher EM, Dhoonmoon A, Jackson LM, Khatib JB, Nicolae CM, Moldovan GL.
    • Oncogenesis. 2022 Jun 18;11(1):33. doi: 10.1038/s41389-022-00410-w.
    • PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
    • Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V.
    • Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755.
    • The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.
    • Lin K, Baritaki S, Vivarelli S, Falzone L, Scalisi A, Libra M, Bonavida B.
    • Antioxidants (Basel). 2022 Jun 17;11(6):1195. doi: 10.3390/antiox11061195.
    • Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    • Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J.
    • Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y.
    • Integrative multi-omic analysis identifies genetically influenced DNA methylation biomarkers for breast and prostate cancers.
    • Sathyanarayanan A, Tanha HM, Mehta D, Nyholt DR.
    • Commun Biol. 2022 Jun 16;5(1):594. doi: 10.1038/s42003-022-03540-4.
    • Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
    • Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M.
    • Genome Med. 2022 Jun 15;14(1):64. doi: 10.1186/s13073-022-01063-5.

    Related:

    EudraCT number: 2009-009014-40: Pre-treatment with Mifepristone prior to Mirena insertion for optimizing bleeding pattern in pre-menopausal women. (EU Clinical Trials Register)

    Identifier: NCT01898312: BRCA1/2 and Effect of Mifepristone on the Breast. (ClinicalTrials.gov)

    EudraCT number: 2015-001587-19: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk. (EU Clinical Trials Register)

    • Kinase Activity of PAR1b, Which Mediates Nuclear Translocation of the BRCA1 Tumor Suppressor, Is Potentiated by Nucleic Acid-Mediated PAR1b Multimerization.
    • Nishikawa H, Christiany P, Hayashi T, Iizasa H, Yoshiyama H, Hatakeyama M.
    • Int J Mol Sci. 2022 Jun 14;23(12):6634. doi: 10.3390/ijms23126634.
    • Dynamic interaction of BRCA2 with telomeric G-quadruplexes underlies telomere replication homeostasis.
    • Lee J, Sung K, Joo SY, Jeong JH, Kim SK, Lee H.
    • Nat Commun. 2022 Jun 13;13(1):3396. doi: 10.1038/s41467-022-31156-z.
    • The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCAMUT and BRCAWT Ovarian Cancer Cells.
    • Gralewska P, Gajek A, Rybaczek D, Marczak A, Rogalska A.
    • Cells. 2022 Jun 10;11(12):1889. doi: 10.3390/cells11121889.
    • Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    • Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, Baldassarre G, Califano D, Capoluongo E, Costi MP, D'Incalci M, Marchini S, Mezzanzanica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S.
    • Int J Gynecol Cancer. 2022 Jun 6;32(6):799-803. doi: 10.1136/ijgc-2022-003435.
    • Study protocol

    Related:

    Clinical Trials: MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B) (ClinicalTrials.gov)

    • Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors.
    • Piombino C, Cortesi L.
    • Cancers (Basel). 2022 Jun 5;14(11):2804. doi: 10.3390/cancers14112804.
    • Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer.
    • Welslau M, Müller V, Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Thomssen C, Witzel I, Fehm TN, Belleville E, Bader S, Seitz K, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Schneeweiss A, Harbeck N, Würstlein R, Hartkopf AD, Wöckel A, Seliger B, Massa C, Kolberg HC.
    • Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):580-589. doi: 10.1055/a-1811-6106.
    • BARD1 mystery: tumor suppressors are cancer susceptibility genes.
    • Hawsawi YM, Shams A, Theyab A, Abdali WA, Hussien NA, Alatwi HE, Alzahrani OR, Oyouni AAA, Babalghith AO, Alreshidi M.
    • BMC Cancer. 2022 Jun 1;22(1):599. doi: 10.1186/s12885-022-09567-4.
    • PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    • Nicum S, Blagden SP.
    • Clin Cancer Res. 2022 Jun 1;28(11):2201-2203. doi: 10.1158/1078-0432.CCR-22-0442.
    • Commentary

    Related:

    Original research:

    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).

    • PARP mediated DNA damage response, genomic stability and immune responses.
    • Zong C, Zhu T, He J, Huang R, Jia R, Shen J.
    • Int J Cancer. 2022 Jun 1;150(11):1745-1759. doi: 10.1002/ijc.33918. Epub 2022 Jan 12.
    • SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    • Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr.
    • J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471.
    • ATM Pathway Is Essential for HPV-Positive Human Cervical Cancer-Derived Cell Lines Viability and Proliferation.
    • Abjaude W, Prati B, Munford V, Montenegro A, Lino V, Herbster S, Rabachini T, Termini L, Menck CFM, Boccardo E.
    • Pathogens. 2022 Jun 1;11(6):637. doi: 10.3390/pathogens11060637.
    • CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
    • Seitz S, Dreyer TF, Stange C, Steiger K, Bräuer R, Scheutz L, Multhoff G, Weichert W, Kiechle M, Magdolen V, Bronger H.
    • Br J Cancer. 2022 Jun;126(10):1470-1480. doi: 10.1038/s41416-022-01763-0. Epub 2022 Mar 21.
    • Analytical tools to support detection of homologous recombination deficiency (HRD) using cytogenomic scar markers.
    • Saul D, Roytman M, Sherman W, Nasanovsky L.
    • Cancer Genet. 2022 Jun;264-265 (Suppl 1):2. doi: 10.1016/j.cancergen.2022.05.005.
    • Conference abstract
    • Histone chaperone ASF1 acts with RIF1 to promote DNA end-joining in BRCA1-deficient cells.
    • Tang M, Chen Z, Wang C, Feng X, Lee N, Huang M, Zhang H, Li S, Xiong Y, Chen J.
    • J Biol Chem. 2022 Jun;298(6):101979. doi: 10.1016/j.jbc.2022.101979. Epub 2022 Apr 25.
    • The role of BRCA2 in the fragility of interstitial telomeric sites.
    • Gozaly-Chianea Y, Roberts T, Slijepcevic P.
    • Mutat Res Genet Toxicol Environ Mutagen. 2022 Jun;878:503476. doi: 10.1016/j.mrgentox.2022.503476. Epub 2022 Feb 24.
    • DNA damage response proteins in canine cancer as potential research targets in comparative oncology.
    • Hernández-Suárez B, Gillespie DA, Pawlak A.
    • Vet Comp Oncol. 2022 Jun;20(2):347-361. doi: 10.1111/vco.12795. Epub 2022 Jan 10.
    • STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
    • Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ.
    • Nat Commun. 2022 May 31;13(1):3022. doi: 10.1038/s41467-022-30568-1.
    • The Pathogenic R3052W BRCA2 Variant Disrupts Homology-Directed Repair by Failing to Localize to the Nucleus.
    • Jimenez-Sainz J, Krysztofiak A, Garbarino J, Rogers F, Jensen RB.
    • Front Genet. 2022 May 30;13:884210. doi: 10.3389/fgene.2022.884210.
    • Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use.
    • Abbotts R, Dellomo AJ, Rassool FV.
    • Cancers (Basel). 2022 May 26;14(11):2640. doi: 10.3390/cancers14112640.
    • Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells.
    • El Naggar O, Doyle B, Mariner K, Gilmour SK.
    • Med Sci (Basel). 2022 May 26;10(2):28. doi: 10.3390/medsci10020028.
    • H3K4 methylation by SETD1A/BOD1L facilitates RIF1-dependent NHEJ.
    • Bayley R, Borel V, Moss RJ, Sweatman E, Ruis P, Ormrod A, Goula A, Mottram RMA, Stanage T, Hewitt G, Saponaro M, Stewart GS, Boulton SJ, Higgs MR.
    • Mol Cell. 2022 May 19;82(10):1924-1939.e10. doi: 10.1016/j.molcel.2022.03.030. Epub 2022 Apr 18.
    • Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors.
    • Gu P, Xue L, Zhao C, Li W, Jiang Z, Liu A, Li T, Liu L, Decker M, Cheng X, Yang W, Tang R.
    • Front Oncol. 2022 May 13;12:885186. doi: 10.3389/fonc.2022.885186.
    • XGBG: A Novel Method for Identifying Ovarian Carcinoma Susceptible Genes Based on Deep Learning.
    • Sun KF, Sun LM, Zhou D, Chen YY, Hao XW, Liu HR, Liu X, Chen JJ.
    • Front Oncol. 2022 May 12;12:897503. doi: 10.3389/fonc.2022.897503.
    • Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
    • Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L.
    • J Med Chem. 2022 May 12;65(9):6803-6825. doi: 10.1021/acs.jmedchem.2c00135. Epub 2022 Apr 20.
    • OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.
    • Baquero JM, Marchena-Perea E, Mirabet R, Torres-Ruiz R, Blanco-Aparicio C, Rodríguez-Perales S, Helleday T, Benítez-Buelga C, Benítez J, Osorio A.
    • Front Oncol. 2022 May 10;12:888810. doi: 10.3389/fonc.2022.888810.
    • Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
    • Feng L, Yang W, Zhao H, Bakkum-Gamez J, Sherman ME, Kannan N.
    • Methods Mol Biol. 2022 [First Online: 2022 May 5];2429:445-454. doi: 10.1007/978-1-0716-1979-7_30.
    • MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation.
    • Vajen B, Bhowmick R, Greiwe L, Schäffer V, Eilers M, Reinkens T, Stalke A, Schmidt G, Fiedler J, Thum T, DeLuca DS, Hickson ID, Schlegelberger B, Illig T, Skawran B.
    • Int J Mol Sci. 2022 May 4;23(9):5131. doi: 10.3390/ijms23095131.
    • Alterations in homologous recombination repair genes in prostate cancer brain metastases.
    • Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins SA, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Ng CKY, Gillessen S, Piscuoglio S, Rubin MA.
    • Nat Commun. 2022 May 3;13(1):2400. doi: 10.1038/s41467-022-30003-5.
    • Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.
    • Lin S, Zhang X, Yu Z, Huang X, Xu J, Liu Y, Wu L.
    • Bioorg Med Chem. 2022 May 1;61:116739. doi: 10.1016/j.bmc.2022.116739. Epub 2022 Apr 1.
    • Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
    • Pai Bellare G, Sankar Patro B.
    • Biochem Pharmacol. 2022 May;199:115024. doi: 10.1016/j.bcp.2022.115024. Epub 2022 Mar 31.
    • High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.
    • Wu R, Patel A, Tokumaru Y, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K.
    • Breast Cancer Res Treat. 2022 May;193(1):49-63. doi: 10.1007/s10549-022-06552-0. Epub 2022 Mar 6.
    • Pregnancy Hormone Mediated Tumorigenesis in BRCA1 Defective Breast Cancers.
    • Krishnan N, Yadev I, Anandan J, Patra D, Rajan A, Srinivas P.
    • FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.0R373.
    • Conference abstract
    • DNA comethylation analysis reveals a functional association between BRCA1 and sperm DNA fragmentation.
    • Zhu W, Jiang L, Li Y, Sun J, Lin C, Huang X, Ni W.
    • Fertil Steril. 2022 May;117(5):963-973. doi: 10.1016/j.fertnstert.2022.01.025. Epub 2022 Mar 4.
    • Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice.
    • Mahdi AH, Huo Y, Chen Y, Selenica P, Sharma A, Merritt E, Barnard N, Chan C, Ganesan S, Reis-Filho JS, Weigelt B, De S, Xia B.
    • Genes Dis. 2020 Sep 5 [eCollection 2022 May];9(3):807-813. doi: 10.1016/j.gendis.2020.08.012.
    • Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    • Shim JI, Ryu JY, Jeong SY, Cho YJ, Choi JJ, Hwang JR, Choi JY, Sa JK, Lee JW.
    • Gynecol Oncol. 2022 May;165(2):270-280. doi: 10.1016/j.ygyno.2022.03.005. Epub 2022 Mar 16.
    • Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
    • Li J, Lan M, Peng J, Xiong Q, Xu Y, Yang Y, Zhou Y, Liu J, Zeng Z, Yang X, Zhang Z, Zhang P, Zhu Q, Wu W.
    • Genes (Basel). 2022 Apr 30;13(5):803. doi: 10.3390/genes13050803.
    • International LAGENO-BC Consortium Spurring Breast Cancer Genetics Research Across Latin America.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 26.
    • News
    • Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    • Golesworthy B, Wang Y, Tanti A, Pacis A, Romero JM, Cuggia A, Domecq C, Bourdel G, Denroche RE, Jang GH, Grant RC, Borgida A, Grünwald BT, Dodd A, Wilson JM, Bourque G, O'Kane GM, Fischer SE, Kron CM, Fiset PO, Omeroglu A, Foulkes WD, Gallinger S, Guiot MC, Gao ZH, Zogopoulos G.
    • Front Oncol. 2022 Apr 25;12:860767. doi: 10.3389/fonc.2022.860767.
    • Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation.
    • He Z, Ghorayeb R, Tan S, Chen K, Lorentzian AC, Bottyan J, Aalam SMM, Pujana MA, Lange PF, Kannan N, Eaves CJ, Maxwell CA.
    • Nat Commun. 2022 Apr 22;13(1):2200. doi: 10.1038/s41467-022-29885-2.
    • Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    • Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O'Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V.
    • Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409.
    • A South African Indian population group dataset for breast cancer and BRCA1/2 variants.
    • Combrink HMVE, van der Merwe NC, Katarya R, de Wet K, Motloung MH.
    • Data Brief. 2022 Apr 14;42:108180. doi: 10.1016/j.dib.2022.108180.

    Related:

    Original research:

    Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.

    • Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer.
    • Duan Y, Du Y, Gu Z, Zheng X, Wang C.
    • Front Cell Dev Biol. 2022 Apr 13;10:887385. doi: 10.3389/fcell.2022.887385.
    • Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.
    • Park SS, Uzelac A, Kotsopoulos J.
    • Hered Cancer Clin Pract. 2022 Apr 13;20(1):14. doi: 10.1186/s13053-022-00223-3.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 11.

    Related:

    Identifier: NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers. (ClinicalTrials.gov)

    • Modification of BRCA1-associated breast cancer risk by HMMR overexpression.
    • Mateo F, He Z, Mei L, de Garibay GR, Herranz C, García N, Lorentzian A, Baiges A, Blommaert E, Gómez A, Mirallas O, Garrido-Utrilla A, Palomero L, Espín R, Extremera AI, Soler-Monsó MT, Petit A, Li R, Brunet J, Chen K, Tan S, Eaves CJ, McCloskey C, Hakem R, Khokha R, Lange PF, Lázaro C, Maxwell CA, Pujana MA.
    • Nat Commun. 2022 Apr 7;13(1):1895. doi: 10.1038/s41467-022-29335-z.
    • BRCA2 C-Terminal RAD51-Binding Domain Confers Resistance to DNA-Damaging Agents.
    • Zhu Z, Kitano T, Morimatsu M, Tanaka A, Morioka R, Lin X, Orino K, Yoshikawa Y.
    • Int J Mol Sci. 2022 Apr 6;23(7):4060. doi: 10.3390/ijms23074060.
    • Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells.
    • Chiappa M, Guffanti F, Anselmi M, Lupi M, Panini N, Wiesmüller L, Damia G.
    • Cancers (Basel). 2022 Apr 1;14(7):1807. doi: 10.3390/cancers14071807.
    • The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
    • Anastasia A, Dellavedova G, Ramos-Montoya A, James N, Chiorino G, Russo M, Baakza H, Wilson J, Ghilardi C, Cadogan EB, Giavazzi R, Bani MR.
    • Mol Cancer Ther. 2022 Apr 1;21(4):555-567. doi: 10.1158/1535-7163.MCT-21-0420.
    • Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
    • Zammarchi F, Havenith KE, Chivers S, Hogg P, Bertelli F, Tyrer P, Janghra N, Reinert HW, Hartley JA, van Berkel PH.
    • Mol Cancer Ther. 2022 Apr 1;21(4):582-593. doi: 10.1158/1535-7163.MCT-21-0715.
    • Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    • Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_351186.
    • The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    • Murphy AD, Morgan RD, Clamp AR, Jayson GC.
    • Br J Cancer. 2022 Apr;126(6):851-864. doi: 10.1038/s41416-021-01605-5. Epub 2021 Oct 29.
    • Review
    • Functional annotation of breast cancer risk loci: current progress and future directions.
    • Romualdo Cardoso S, Gillespie A, Haider S, Fletcher O.
    • Br J Cancer. 2022 Apr;126(7):981-993. doi: 10.1038/s41416-021-01612-6. Epub 2021 Nov 5.
    • Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    • Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI.
    • Br J Cancer. 2022 Apr;126(7):1027-1036. doi: 10.1038/s41416-021-01664-8. Epub 2021 Dec 9.
    • Immunotherapy for ovarian cancer.
    • Porter R, Matulonis UA.
    • Clin Adv Hematol Oncol. 2022 Apr;20(4):240-253.
    • BRCA2 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms.
    • Yang C, Zhang Q, Tang X, Wang B, Guan M, Tang G, Wu Z.
    • Epigenomics. 2022 Apr;14(7):391-403. doi: 10.2217/epi-2022-0025. Epub 2022 Mar 9.
    • Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
    • Cheng X, Zhang B, Guo F, Wu H, Jin X.
    • Mol Oncol. 2022 Apr;16(7):1591-1607. doi: 10.1002/1878-0261.13149. Epub 2021 Dec 17.
    • Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.
    • Turdo A, Gaggianesi M, Di Franco S, Veschi V, D'Accardo C, Porcelli G, Lo Iacono M, Pillitteri I, Verona F, Militello G, Zippo A, Poli V, Fagnocchi L, Beyes S, Stella S, Lattanzio R, Faldetta N, Lentini VL, Porcasi R, Pistone G, Bongiorno MR, Stassi G, De Maria R, Todaro M.
    • Oncogene. 2022 Apr;41(15):2196-2209. doi: 10.1038/s41388-022-02239-4. Epub 2022 Feb 25.
    • Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
    • Gupta N, Huang TT, Horibata S, Lee JM.
    • Pharmacol Res. 2022 Apr;178:106162. doi: 10.1016/j.phrs.2022.106162. Epub 2022 Mar 5.
    • Review
    • BRCA1: An Endocrine and Metabolic Regulator.
    • Werner H.
    • Front Endocrinol (Lausanne). 2022 Mar 31;13:844575. doi: 10.3389/fendo.2022.844575.
    • The Biphasic Effect of Flavonoids on Oxidative Stress and Cell Proliferation in Breast Cancer Cells.
    • Xi X, Wang J, Qin Y, You Y, Huang W, Zhan J.
    • Antioxidants (Basel). 2022 Mar 24;11(4):622. doi: 10.3390/antiox11040622.
    • Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    • Kawanishi M, Fujita M, Karasawa K.
    • Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080553. doi: 10.1177/11782234221080553.
    • E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib.
    • Bougen-Zhukov N, Decourtye-Espiard L, Mitchell W, Redpath K, Perkinson J, Godwin T, Black MA, Guilford P.
    • Cancers (Basel). 2022 Mar 22;14(7):1609. doi: 10.3390/cancers14071609.
    • Pre-activation of autophagy impacts response to olaparib in prostate cancer cells.
    • Cahuzac M, Langlois P, Péant B, Fleury H, Mes-Masson AM, Saad F.
    • Commun Biol. 2022 Mar 22;5(1):251. doi: 10.1038/s42003-022-03210-5.
    • Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma.
    • Wu J, Raz Y, Recouvreux MS, Diniz MA, Lester J, Karlan BY, Walts AE, Gertych A, Orsulic S.
    • Front Oncol. 2022 Mar 21;12:853755. doi: 10.3389/fonc.2022.853755.
    • S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy.
    • Li J, Shu X, Xu J, Su SM, Chan UI, Mo L, Liu J, Zhang X, Adhav R, Chen Q, Wang Y, An T, Zhang X, Lyu X, Li X, Lei JH, Miao K, Sun H, Xing F, Zhang A, Deng C, Xu X.
    • Nat Commun. 2022 Mar 18;13(1):1481. doi: 10.1038/s41467-022-29151-5.
    • Influence of cellular models and individual factor in the biological response to chest CT scan exams.
    • Devic C, Bodgi L, Sonzogni L, Pilleul F, Ribot H, Charry C, Le Moigne F, Paul D, Carbillet F, Munier M, Foray N.
    • Eur Radiol Exp. 2022 Mar 17;6(1):14. doi: 10.1186/s41747-022-00266-0.
    • Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?
    • Garner IM, Brown R.
    • Cancers (Basel). 2022 Mar 16;14(6):1533. doi: 10.3390/cancers14061533.
    • MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of BRCA1.
    • Ho JC, Chen J, Cheuk IW, Siu MT, Shin VY, Kwong A.
    • Am J Transl Res. 2022 Mar 15;14(3):2021-2036.
    • Integrated Microfluidic System for Cell-Free DNA Extraction from Plasma for Mutant Gene Detection and Quantification.
    • Cheng YH, Wang CH, Hsu KF, Lee GB.
    • Anal Chem. 2022 Mar 15;94(10):4311-4318. doi: 10.1021/acs.analchem.1c04988. Epub 2022 Mar 2.
    • ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    • Wilson Z, Odedra R, Wallez Y, Wijnhoven PWG, Hughes AM, Gerrard J, Jones GN, Bargh-Dawson H, Brown E, Young LA, O'Connor MJ, Lau A.
    • Cancer Res. 2022 Mar 15;82(6):1140-1152. doi: 10.1158/0008-5472.CAN-21-2997.
    • Inhibitors of PARP: Number crunching and structure gazing.
    • Rudolph J, Jung K, Luger K.
    • Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2121979119. doi: 10.1073/pnas.2121979119. Epub 2022 Mar 8.
    • BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling.
    • Bradbury M, Borràs E, Castellví J, Méndez O, Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Sabidó E, Santamaria A.
    • Sci Rep. 2022 Mar 15;12(1):4445. doi: 10.1038/s41598-022-08461-0.
    • Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2.
    • Sangree AK, Griffith AL, Szegletes ZM, Roy P, DeWeirdt PC, Hegde M, McGee AV, Hanna RE, Doench JG.
    • Nat Commun. 2022 Mar 14;13(1):1318. doi: 10.1038/s41467-022-28884-7.
    • PARP Inhibitors Resistance: Mechanisms and Perspectives.
    • Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D.
    • Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420.
    • Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.
    • Catalano F, Borea R, Puglisi S, Boutros A, Gandini A, Cremante M, Martelli V, Sciallero S, Puccini A.
    • Cancers (Basel). 2022 Mar 9;14(6):1388. doi: 10.3390/cancers14061388.
    • Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.
    • Groelly FJ, Porru M, Zimmer J, Benainous H, De Visser Y, Kosova AA, Di Vito S, Serra V, Ryan A, Leonetti C, Bruna A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2022 Mar 7;14(3):e14501. doi: 10.15252/emmm.202114501. Epub 2022 Feb 2.
    • Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFßR2 signaling pathway.
    • Bai F, Wang C, Liu X, Hollern D, Liu S, Fan C, Liu C, Ren S, Herschkowitz JI, Zhu WG, Pei XH.
    • Cell Death Dis. 2022 Mar 2;13(3):195. doi: 10.1038/s41419-022-04646-7.
    • Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers.
    • Sun S, Brazhnik K, Lee M, Maslov AY, Zhang Y, Huang Z, Klugman S, Park BH, Vijg J, Montagna C.
    • J Clin Invest. 2022 Mar 1;132(5):e148113. doi: 10.1172/JCI148113.
    • Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
    • Guney Eskiler G, Ozturk M.
    • Cell Signal. 2022 Mar;91:110229. doi: 10.1016/j.cellsig.2021.110229. Epub 2021 Dec 24.
    • DNA damage-induced sumoylation of Sp1 induces its interaction with RNF4 and degradation in S phase to remove 53BP1 from DSBs and permit HR.
    • Swift ML, Azizkhan-Clifford J.
    • DNA Repair (Amst). 2022 Mar;111:103289. doi: 10.1016/j.dnarep.2022.103289. Epub 2022 Feb 1.
    • A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    • Park J, Lim MC, Lee JK, Jeong DH, Kim SI, Choi MC, Kim BG, Lee JY.
    • J Gynecol Oncol. 2022 Mar;33(2):e12. doi: 10.3802/jgo.2022.33.e12. Epub 2021 Dec 6.
    • Screening and identification of phytochemical drug molecules against mutant BRCA1 receptor of breast cancer using computational approaches.
    • Singh J, Sangwan N, Chauhan A, Sarma P, Prakash A, Medhi B, Avti PK.
    • Mol Cell Biochem. 2022 Mar;477(3):885-896. doi: 10.1007/s11010-021-04338-4. Epub 2022 Jan 24.
    • When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
    • van Vugt MATM, Parkes EE.
    • Trends Cancer. 2022 Mar;8(3):174-189. doi: 10.1016/j.trecan.2021.12.003. Epub 2022 Jan 6.
    • Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer.
    • Maity J, Horibata S, Zurcher G, Lee JM.
    • Cancers (Basel). 2022 Feb 26;14(5):1219. doi: 10.3390/cancers14051219.
    • Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
    • Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A.
    • Cancers (Basel). 2022 Feb 25;14(5):1189. doi: 10.3390/cancers14051189.
    • DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
    • Nguyen NT, Pacelli A, Nader M, Kossatz S.
    • Cancers (Basel). 2022 Feb 23;14(5):1129. doi: 10.3390/cancers14051129.
    • Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives.
    • Musacchio L, Cicala CM, Salutari V, Camarda F, Carbone MV, Ghizzoni V, Giudice E, Nero C, Perri MT, Ricci C, Tronconi F, Scambia G, Lorusso D.
    • Front Oncol. 2022 Feb 23;12:831612. doi: 10.3389/fonc.2022.831612.
    • G-Quadruplex Matters in Tissue-Specific Tumorigenesis by BRCA1 Deficiency.
    • Kim S, Hwang S.
    • Genes (Basel). 2022 Feb 22;13(3):391. doi: 10.3390/genes13030391.
    • Preferential Involvement of BRCA1/BARD1, Not Tip60/Fe65, in DNA Double-Strand Break Repair in Presenilin-1 P117L Alzheimer Models.
    • Authiat MM, Gruz-Gibelli E, Colas J, Bianchi E, Garcia-Arauzo M, Marin P, Herrmann FR, Savioz A.
    • Neural Plast. 2022 Feb 21;2022:3172861. doi: 10.1155/2022/3172861.
    • RNA Interference Induces BRCA1 Gene Methylation and Increases the Radiosensitivity of Breast Cancer Cells.
    • Shi Y, Huang R, Zhang Y, Feng Q, Pan X, Wang L.
    • Cancer Biother Radiopharm. 2022 Feb 18. doi: 10.1089/cbr.2021.0346. Epub ahead of print.
    • VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.
    • Romeo MA, Gilardini Montani MS, Benedetti R, Arena A, D'Orazi G, Cirone M.
    • Int J Mol Sci. 2022 Feb 18;23(4):2268. doi: 10.3390/ijms23042268.
    • Tetrahedral DNA Framework-Programmed Electrochemical Biosenors with Gold Nanoparticles for Ultrasensitive Cell-Free DNA Detection.
    • Wang C, Wang W, Xu Y, Zhao X, Li S, Qian Q, Mi X.
    • Nanomaterials (Basel). 2022 Feb 16;12(4):666. doi: 10.3390/nano12040666.
    • Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities.
    • Hu X, Zhang J, Zhang Y, Jiao F, Wang J, Chen H, Ouyang L, Wang Y.
    • Eur J Med Chem. 2022 Feb 15;230:114094. doi: 10.1016/j.ejmech.2021.114094. Epub 2021 Dec 30.
    • Review
    • Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    • Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z.
    • Eur J Med Chem. 2022 Feb 15;230:114109. doi: 10.1016/j.ejmech.2022.114109. Epub 2022 Jan 12.
    • Review
    • Human BRCA pathogenic variants were originated during recent human history.
    • Li J, Zhao B, Huang T, Qin Z, Wang SM.
    • Life Sci Alliance. 2022 Feb 14;5(5):e202101263. doi: 10.26508/lsa.202101263.
    • Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
    • Launonen IM, Lyytikäinen N, Casado J, Anttila EA, Szabó A, Haltia UM, Jacobson CA, Lin JR, Maliga Z, Howitt BE, Strickland KC, Santagata S, Elias K, D'Andrea AD, Konstantinopoulos PA, Sorger PK, Färkkilä A.
    • Nat Commun. 2022 Feb 11;13(1):835. doi: 10.1038/s41467-022-28389-3.
    • Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2022 Feb 7.

    Related:

    Original research:

    A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.

    • Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    • Perez JM, Twigg CAI, Guan W, Thomas SN.
    • J Am Soc Mass Spectrom. 2022 Feb 2;33(2):242-250. doi: 10.1021/jasms.1c00215. Epub 2021 Dec 27.
    • Cell-type-specific epigenomic variations associated with BRCA1 mutation in pre-cancer human breast tissues.
    • Hsieh YP, Naler LB, Ma S, Lu C.
    • NAR Genom Bioinform. 2022 Feb 2;4(1):lqac006. doi: 10.1093/nargab/lqac006.
    • Therapeutic Targeting of DNA Damage Response in Cancer.
    • Choi W, Lee ES.
    • Int J Mol Sci. 2022 Feb 1;23(3):1701. doi: 10.3390/ijms23031701.
    • The DNA methylome of cervical cells can predict the presence of ovarian cancer.
    • Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, Manchanda R, Bjørge L, Zikan M, Cibula D, Widschwendter M.
    • Nat Commun. 2022 Feb 1;13(1):448. doi: 10.1038/s41467-021-26615-y.

    Related:

    Press: Methylation Signatures Within Cervical Cells Capture Ovarian, Breast Cancer Risk. (GenomeWeb)

    • The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.
    • Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim YN, Franchi D, Ryan A, Franks J, Bjørge L, Zikan M, Cibula D, Harbeck N, Colombo N, Dudbridge F, Jones L, Sundström K, Dillner J, Rådestad AF, Gemzell-Danielsson K, Pashayan N, Widschwendter M.
    • Nat Commun. 2022 Feb 1;13(1):449. doi: 10.1038/s41467-021-27918-w.

    Related:

    Press: Methylation Signatures Within Cervical Cells Capture Ovarian, Breast Cancer Risk. (GenomeWeb)

    • Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells.
    • Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y.
    • Pancreas. 2022 Feb 1;51(2):183-189. doi: 10.1097/MPA.0000000000001975.
    • Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
    • Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW.
    • Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2117754119. doi: 10.1073/pnas.2117754119.

    Related:

    Commentary:

    Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.

    • Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.
    • Ntemou E, Vidal PD, Alexandri C, Van den Steen G, Lambertini M, Demeestere I.
    • Sci Rep. 2022 Feb 1;12(1):1658. doi: 10.1038/s41598-022-05357-x.
    • Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.
    • Hirt CK, Booij TH, Grob L, Simmler P, Toussaint NC, Keller D, Taube D, Ludwig V, Goryachkin A, Pauli C, Lenggenhager D, Stekhoven DJ, Stirnimann CU, Endhardt K, Ringnalda F, Villiger L, Siebenhüner A, Karkampouna S, De Menna M, Beshay J, Klett H, Kruithof-de Julio M, Schüler J, Schwank G.
    • Cell Genom. 2022 Feb;2(2):100095. doi: 10.1016/j.xgen.2022.100095.
    • Interaction of Wwox with Brca1 and associated complex proteins prevents premature resection at double-strand breaks and aberrant homologous recombination.
    • Park D, Gharghabi M, Schrock MS, Plow R, Druck T, Yungvirt C, Aldaz CM, Huebner K.
    • DNA Repair (Amst). 2022 Feb;110:103264. doi: 10.1016/j.dnarep.2021.103264. Epub 2021 Dec 26.
    • A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.
    • Johnson K, Saylor K, Guynn I, Hicklin K, Berg JS, Lich KH.
    • Genet Med. 2022 Feb;24(2):262-288. doi: 10.1016/j.gim.2021.10.008. Epub 2021 Dec 7.
    • Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study.
    • Meiser B, Monnik M, Austin R, Nichols C, Cops E, Salmon L, Spurdle AB, Macrae F, Taylor N, Pachter N, James P, Kaur R.
    • J Community Genet. 2022 Feb;13(1):59-73. doi: 10.1007/s12687-021-00559-8. Epub 2021 Nov 2.
    • The BRCA2 missense mutation K2497R suppressed self-degradation and increased ATP production and cell proliferation.
    • Enkhbat G, Nakanishi A, Miki Y.
    • Biochem Biophys Res Commun. 2022 Jan 29;590:27-33. doi: 10.1016/j.bbrc.2021.12.073. Epub 2021 Dec 23.
    • Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells.
    • Jia Y, Wang M, Sang X, Liu P, Gao J, Jiang K, Cheng H.
    • Front Oncol. 2022 Jan 26;11:812264. doi: 10.3389/fonc.2021.812264.
    • Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
    • Cosgrove N, Varešlija D, Keelan S, Elangovan A, Atkinson JM, Cocchiglia S, Bane FT, Singh V, Furney S, Hu C, Carter JM, Hart SN, Yadav S, Goetz MP, Hill ADK, Oesterreich S, Lee AV, Couch FJ, Young LS.
    • Nat Commun. 2022 Jan 26;13(1):514. doi: 10.1038/s41467-022-27987-5.
    • DNA damage and repair in the hematopoietic system.
    • Li N, Chen H, Wang J.
    • Acta Biochim Biophys Sin (Shanghai). 2022 Jan 25;54(6):847-857. doi: 10.3724/abbs.2022053.
    • FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations.
    • Rosa K.
    • OncLive. 2022 Jan 25.

    Related:

    News release: Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations. (Senhwa Biosciences. Accessed 2022 Oct 5.)

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov . Accessed 2022 Oct 5.)

    • CRL4-DCAF8L1 Regulates BRCA1 and BARD1 Protein Stability.
    • Liu F, Han Q, Zhang T, Chang F, Deng J, Huang X, Wang W, Xu Y, Li Q, Xu L, Zhang B, Li W, Li L, Su Y, Li Y, Shao G.
    • Int J Biol Sci. 2022 Jan 24;18(4):1434-1450. doi: 10.7150/ijbs.57178.
    • Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage.
    • Zhou S, Li D, Xiao D, Wu T, Hu X, Zhang Y, Deng J, Long J, Xu S, Wu J, Li G, Peng M, Yang X.
    • Int J Biol Sci. 2022 Jan 24;18(4):1555-1568. doi: 10.7150/ijbs.62947.
    • Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
    • Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM.
    • Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. Epub 2021 Nov 22.
    • CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival.
    • Minguillón J, Ramírez MJ, Rovirosa L, Bustamante-Madrid P, Camps-Fajol C, Ruiz de Garibay G, Shimelis H, Montanuy H, Pujol R, Hernandez G, Bogliolo M, Castillo P, Soucy P, Martrat G, Gómez A, Cuadras D, García MJ, Gayarre J, Cimba, Lázaro C, Benítez J, Couch FJ, Pujana MA, Surrallés J.
    • Cancers (Basel). 2022 Jan 12;14(2):353. doi: 10.3390/cancers14020353.
    • Harnessing Synthetic Lethal Interactions for Personalized Medicine.
    • Shieh GS.
    • J Pers Med. 2022 Jan 12;12(1):98. doi: 10.3390/jpm12010098.
    • Construction and Validation of a Prognostic Risk Model for Triple Negative Breast Cancer Based on Autophagy-Related Genes.
    • Jia R, Yan C, Liu Q.
    • Front Oncol. 2022 Jan 10;10:829045. doi: 10.3389/fonc.2022.829045.
    • Disrupted BRCA1-PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in Hepatocellular Carcinoma Through cGAS-STING Pathway.
    • Ma H, Kang Z, Foo TK, Shen Z, Xia B.
    • Hepatology. 2022 Jan 10. doi: 10.1002/hep.32335. Epub ahead of print.
    • AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization.
    • Azzalini E, Tierno D, Bartoletti M, Barbazza R, Giorda G, Puglisi F, Cecere SC, Losito NS, Russo D, Stanta G, Canzonieri V, Bonin S.
    • Cancers (Basel). 2022 Jan 8;14(2):304. doi: 10.3390/cancers14020304.
    • Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
    • Yu J, Luo L, Hu T, Cui Y, Sun X, Gou W, Hou W, Li Y, Sun T.
    • Eur J Med Chem. 2022 Jan 5;227:113898. doi: 10.1016/j.ejmech.2021.113898. Epub 2021 Oct 9.
    • Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.
    • Sankaranarayanan RA, Peil J, Vogg ATJ, Bolm C, Terhorst S, Classen A, Bauwens M, Maurer J, Mottaghy F, Morgenroth A.
    • Cancers (Basel). 2022 Jan 4;14(1):230. doi: 10.3390/cancers14010230.
    • A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
    • Park SJ, Chang SJ, Suh DH, Kong TW, Song H, Kim TH, Kim JW, Kim HS, Lee SJ.
    • BMC Cancer. 2022 Jan 3;22(1):28. doi: 10.1186/s12885-021-09138-z.
    • Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis.
    • Hao KJ, Jia X, Dai WT, Huo ZM, Zhang HQ, Liu JW, Wang XB.
    • Front Oncol. 2022 Jan 3;11:689553. doi: 10.3389/fonc.2021.689553.
    • Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    • Suzuki Y, Wenwen W, Ohta T, Hayashi SI.
    • Breast Cancer. 2022 Jan;29(1):77-91. doi: 10.1007/s12282-021-01282-5. Epub 2021 Aug 3.
    • FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
    • Wu SQ, Huang SH, Lin QW, Tang YX, Huang L, Xu YG, Wang SP.
    • Pharmacol Res. 2022 Jan;175:106040. doi: 10.1016/j.phrs.2021.106040. Epub 2021 Dec 22.
    • Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma.
    • Klapp V, Galluzzi L.
    • Trends Cancer. 2022 Jan;8(1):1-3. doi: 10.1016/j.trecan.2021.11.006. Epub 2021 Nov 25.
    • Research news

    Related:

    Original research:

    Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.

    • Computational structural assessment of BReast CAncer type 1 susceptibility protein (BRCA1) and BRCA1-Associated Ring Domain protein 1 (BARD1) mutations on the protein-protein interface.
    • Thirumal Kumar D, Udhaya Kumar S, Jain N, Sowmya B, Balsekar K, Siva R, Kamaraj B, Sidenna M, George Priya Doss C, Zayed H.
    • Adv Protein Chem Struct Biol. 2022;130:375-397. doi: 10.1016/bs.apcsb.2022.02.003. Epub 2022 Apr 21.
    • Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.
    • Garrido MP, Fredes AN, Lobos-González L, Valenzuela-Valderrama M, Vera DB, Romero C.
    • Biomedicines. 2021 Dec 31;10(1):77. doi: 10.3390/biomedicines10010077.
    • DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
    • Stefanou DT, Souliotis VL, Zakopoulou R, Liontos M, Bamias A.
    • Biomedicines. 2021 Dec 31;10(1):82. doi: 10.3390/biomedicines10010082.
    • Dual targeting, a new strategy for novel PARP inhibitor discovery.
    • Wei L, Wang M, Wang Q, Han Z.
    • Drug Discov Ther. 2021 [Published: December 31, 2021];15(6):300-309. doi: 10.5582/ddt.2021.01100.
    • E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors.
    • Decourtye-Espiard L, Bougen-Zhukov N, Godwin T, Brew T, Schulpen E, Black MA, Guilford P.
    • Cancers (Basel). 2021 Dec 30;14(1):175. doi: 10.3390/cancers14010175.
    • Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells.
    • Morales-Pison S, Jara L, Carrasco V, Gutiérrez-Vera C, Reyes JM, Gonzalez-Hormazabal P, Carreño LJ, Tapia JC, Contreras HR.
    • Int J Mol Sci. 2021 Dec 29;23(1):380. doi: 10.3390/ijms23010380.
    • Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
    • Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, Naboulsi DJ, Liang V, Qu Y, Plummer JT, Gayther SA, Orsulic S, Karlan BY, Svendsen CN.
    • Cell Rep. 2021 Dec 28;37(13):110146. doi: 10.1016/j.celrep.2021.110146.

    Related:

    Research news: Researchers Create Organoids that Model BRCA-Positive Ovarian Cancer. (Clinical OMICs)

    • BRCA2 Haploinsufficiency in Telomere Maintenance.
    • Gunnarsdottir SR, Bjarnason H, Thorvaldsdottir B, Paland F, Steinarsdottir M, Eyfjörd JE, Bödvarsdottir SK.
    • Genes (Basel). 2021 Dec 28;13(1):83. doi: 10.3390/genes13010083.
    • BRCA1 and Metastasis: Outcome of Defective DNA Repair.
    • Krishnan R, Patel PS, Hakem R.
    • Cancers (Basel). 2021 Dec 27;14(1):108. doi: 10.3390/cancers14010108.
    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • BRCA role changes with association: tissue-specific impact on the prognosis.
    • Gupta B, Somasundaram K.
    • Oncotarget. 2021 Dec 21;12(26):2541-2542. doi: 10.18632/oncotarget.28149.

    Related:

    Original research:

    Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients.

    • LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells.
    • Xiang J, Zhou L, He Y, Wu S.
    • Aging (Albany NY). 2021 Dec 16;13(24):25920-25930. doi: 10.18632/aging.203780. Epub 2021 Dec 16.
    • Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer.
    • Sha H, Gan Y, Zou R, Wu J, Feng J.
    • Front Oncol. 2021 Dec 16;11:790967. doi: 10.3389/fonc.2021.790967.
    • Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells.
    • Batenburg NL, Mersaoui SY, Walker JR, Coulombe Y, Hammond-Martel I, Wurtele H, Masson JY, Zhu XD.
    • Nucleic Acids Res. 2021 Dec 16;49(22):12836-12854. doi: 10.1093/nar/gkab1173.
    • Loss of MED12 activates the TGFß pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells.
    • Jackson LM, Dhoonmoon A, Hale A, Dennis KA, Schleicher EM, Nicolae CM, Moldovan GL.
    • Nucleic Acids Res. 2021 Dec 16;49(22):12855-12869. doi: 10.1093/nar/gkab1184.
    • Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
    • Wang SP, Li Y, Huang SH, Wu SQ, Gao LL, Sun Q, Lin QW, Huang L, Meng LQ, Zou Y, Zhu QH, Xu YG.
    • J Med Chem. 2021 Dec 9;64(23):17413-17435. doi: 10.1021/acs.jmedchem.1c01535. Epub 2021 Nov 23.
    • Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1.
    • Chen N, Higashiyama N, Hoyos V.
    • Biomedicines. 2021 Dec 8;9(12):1863. doi: 10.3390/biomedicines9121863.
    • FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
    • Wang SP, Wu SQ, Huang SH, Tang YX, Meng LQ, Liu F, Zhu QH, Xu YG.
    • Cell Death Dis. 2021 Dec 8;12(12):1138. doi: 10.1038/s41419-021-04434-9.
    • PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.
    • Martincuks A, Song J, Kohut A, Zhang C, Li YJ, Zhao Q, Mak E, Rodriguez-Rodriguez L, Yu H, Cristea M.
    • Front Oncol. 2021 Dec 7;11:724104. doi: 10.3389/fonc.2021.724104.
    • Two redundant ubiquitin-dependent pathways of BRCA1 localization to DNA damage sites.
    • Sherker A, Chaudhary N, Adam S, Heijink AM, Noordermeer SM, Fradet-Turcotte A, Durocher D.
    • EMBO Rep. 2021 Dec 6;22(12):e53679. doi: 10.15252/embr.202153679. Epub 2021 Nov 2.

    Related:

    Commentary:

    When the RAP (80) fades out, you can hear BRCA1 RING.

    • A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    • Park J, Lim MC, Lee JK, Jeong DH, Kim SI, Choi MC, Kim BG, Lee JY.
    • J Gynecol Oncol. 2021 Dec 6. doi: 10.3802/jgo.2022.33.e12. Epub ahead of print.
    • Filling in the gaps in PARP inhibitor-induced synthetic lethality.
    • Paes Dias M, Jonkers J.
    • Mol Cell Oncol. 2021 Dec 6;8(6):2010512. doi: 10.1080/23723556.2021.2010512.
    • Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
    • Kang M, Lee H, Byeon SJ, Kwon GY, Jeon SS.
    • Int J Mol Sci. 2021 Dec 4;22(23):13125. doi: 10.3390/ijms222313125.
    • Long Non-Coding RNA Neighbor of BRCA1 Gene 2: A Crucial Regulator in Cancer Biology.
    • Wang T, Li Z, Yan L, Yan F, Shen H, Tian X.
    • Front Oncol. 2021 Dec 2;11:783526. doi: 10.3389/fonc.2021.783526.
    • DNA Repair Genes as Drug Candidates for Early Breast Cancer Onset in Latin America: A Systematic Review.
    • Urbina-Jara LK, Martinez-Ledesma E, Rojas-Martinez A, Rodriguez-Recio FR, Ortiz-Lopez R.
    • Int J Mol Sci. 2021 Dec 2;22(23):13030. doi: 10.3390/ijms222313030.
    • Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance.
    • Ozgencil M, Barwell J, Tischkowitz M, Izatt L, Kesterton I, Simpson M, Sharpe P, de Sepulveda P, Voisset E, Solomon E.
    • PLoS One. 2021 Dec 2;16(12):e0260852. doi: 10.1371/journal.pone.0260852.
    • Prolonged recombinant pregnancy hormone use for breast cancer prevention in BRCA1 And 2 mutation carriers.
    • Depypere H, Su Y, Dang N, Poppe B, Stanczyk FZ, Janssens J, Russo J.
    • Eur J Cancer Prev. 2021 Dec 1;31(Suppl 1):S3-S4. doi: 10.1097/01.cej.0000816644.52776.6e. Epub 2021 Dec 30.
    • An Update on the effect of Recombinant Human Chorionic Gonadotropin in Breast Cancer Prevention.
    • Russo J.
    • Eur J Cancer Prev. 2021 Dec 1;31(Suppl 1):S4-S5. doi: 10.1097/01.cej.0000816656.58097.71. Epub 2021 Dec 30.
    • A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
    • Pavone G, Motta L, Martorana F, Motta G, Vigneri P.
    • Molecules. 2021 Dec 1;26(23):7294. doi: 10.3390/molecules26237294.
    • Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
    • Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN.
    • Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18.
    • Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair.
    • Tang J, Casey PJ, Wang M.
    • Life Sci Alliance. 2021 Oct 5;4(12):e202101144. doi: 10.26508/lsa.202101144. Print 2021 Dec.
    • BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
    • Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B, Pantel K, Joosse SA.
    • Mol Oncol. 2021 Dec;15(12):3615-3625. doi: 10.1002/1878-0261.13108. Epub 2021 Oct 12.
    • The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.
    • Adam S, Rossi SE, Moatti N, De Marco Zompit M, Xue Y, Ng TF, Álvarez-Quilón A, Desjardins J, Bhaskaran V, Martino G, Setiaputra D, Noordermeer SM, Ohsumi TK, Hustedt N, Szilard RK, Chaudhary N, Munro M, Veloso A, Melo H, Yin SY, Papp R, Young JTF, Zinda M, Stucki M, Durocher D.
    • Nat Cancer. 2021 Dec;2(12):1357-1371. doi: 10.1038/s43018-021-00266-w. Epub 2021 Nov 11.

    Related:

    Commentary:

    Targeting BRCA-mutated tumors in mitosis.

    • Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
    • Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Carrillo Albornoz PB, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N.
    • Nat Cancer. 2021 Dec;1(12):1188-1203. doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16.

    Related:

    Research news: Cancer Patients With BRCA1/2 Mutations Respond Differently to Immunotherapy, Study Shows. (Precision Oncology News; subscription required)

    • Tackling PARP inhibitor resistance.
    • Fugger K, Hewitt G, West SC, Boulton SJ.
    • Trends Cancer. 2021 Dec;7(12):1102-1118. doi: 10.1016/j.trecan.2021.08.007. Epub 2021 Sep 22.
    • Epigenetic Dysregulation of KCNK9 Imprinting and Triple-Negative Breast Cancer.
    • Skaar DA, Dietze EC, Alva-Ornelas JA, Ann D, Schones DE, Hyslop T, Sistrunk C, Zalles C, Ambrose A, Kennedy K, Idassi O, Miranda Carboni G, Gould MN, Jirtle RL, Seewaldt VL.
    • Cancers (Basel). 2021 Nov 30;13(23):6031. doi: 10.3390/cancers13236031.
    • Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images
    • Mingzhu L, Yaqiong G, Mengru L, Wei W.
    • BMC Med Imaging. 2021 Nov 26;21(1):180. doi: 10.1186/s12880-021-00711-3.
    • RAD52: Paradigm of Synthetic Lethality and New Developments.
    • Rossi MJ, DiDomenico SF, Patel M, Mazin AV.
    • Front Genet. 2021 Nov 23;12:780293. doi: 10.3389/fgene.2021.780293.
    • Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies.
    • Paracchini L, Mannarino L, Craparotta I, Romualdi C, Fruscio R, Grassi T, Fotia V, Caratti G, Perego P, Calura E, Clivio L, D'Incalci M, Beltrame L, Marchini S.
    • Oncotarget. 2016 Jul 9;12(24):2404-2417. doi: 10.18632/oncotarget.10505. eCollection 2021 Nov 23.
    • Quantitative analysis of biochemical processes in living cells at a single-molecule level: a case of olaparib-PARP1 (DNA repair protein) interactions.
    • Karpinska A, Pilz M, Buczkowska J, Zuk PJ, Kucharska K, Magiera G, Kwapiszewska K, Holyst R.
    • Analyst. 2021 Nov 22;146(23):7131-7143. doi: 10.1039/d1an01769a.
    • Case report
    • WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells.
    • Datta A, Biswas K, Sommers JA, Thompson H, Awate S, Nicolae CM, Thakar T, Moldovan GL, Shoemaker RH, Sharan SK, Brosh RM Jr.
    • Nat Commun. 2021 Nov 12;12(1):6561. doi: 10.1038/s41467-021-26811-w.
    • DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma.
    • Barenboim M, Kovac M, Ameline B, Jones DTW, Witt O, Bielack S, Burdach S, Baumhoer D, Nathrath M.
    • PLoS Comput Biol. 2021 Nov 11;17(11):e1009562. doi: 10.1371/journal.pcbi.1009562.
    • Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
    • Bajrami I, Walker C, Krastev DB, Weekes D, Song F, Wicks AJ, Alexander J, Haider S, Brough R, Pettitt SJ, Tutt ANJ, Lord CJ.
    • Commun Biol. 2021 Nov 8;4(1):1270. doi: 10.1038/s42003-021-02770-2.
    • VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
    • Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, Hattersley MM, Arnold S, Ramos-Montoya A, Williamson SC, Galbiati A, Urosevic J, Leo E, Cavallaro U, Ghilardi C, Barry ST, Bani MR, Giavazzi R.
    • J Hematol Oncol. 2021 Nov 6;14(1):186. doi: 10.1186/s13045-021-01196-x.
    • Functional annotation of breast cancer risk loci: current progress and future directions.
    • Romualdo Cardoso S, Gillespie A, Haider S, Fletcher O.
    • Br J Cancer. 2021 Nov 5. doi: 10.1038/s41416-021-01612-6. Epub ahead of print.
    • TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
    • Bronder D, Tighe A, Wangsa D, Zong D, Meyer TJ, Wardenaar R, Minshall P, Hirsch D, Heselmeyer-Haddad K, Nelson L, Spierings D, McGrail JC, Cam M, Nussenzweig A, Foijer F, Ried T, Taylor SS.
    • Dis Model Mech. 2021 Nov 1;14(11):dmm049001. doi: 10.1242/dmm.049001. Epub 2021 Nov 30.
    • Signal amplification of novel sandwich-type genosensor via catalytic redox-recycling on platform MWCNTs/Fe3O4@TMU-21 for BRCA1 gene detection.
    • Ehzari H, Safari M, Samimi M.
    • Talanta. 2021 Nov 1;234:122698. doi: 10.1016/j.talanta.2021.122698. Epub 2021 Jul 9.
    • Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    • Moore KN, Pothuri B.
    • Cancer J. 2021 Nov-Dec 01;27(6):432-440. doi: 10.1097/PPO.0000000000000558.
    • Review
    • New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
    • Harvey-Jones E, Vinas Villaro G, Tutt A.
    • Cancer J. 2021 Nov-Dec 01;27(6):441-456. doi: 10.1097/PPO.0000000000000559.
    • Review
    • PARP Inhibition in Advanced Prostate Cancer.
    • Fenton SE, Chalmers ZR, Hussain M.
    • Cancer J. 2021 Nov-Dec 01;27(6):457-464. doi: 10.1097/PPO.0000000000000560.
    • Review
    • PARP Inhibitors in Pancreatic Cancer.
    • Brown TJ, Reiss KA.
    • Cancer J. 2021 Nov-Dec 01;27(6):465-475. doi: 10.1097/PPO.0000000000000554.
    • Review
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
    • Satyananda V, Oshi M, Endo I, Takabe K.
    • Ann Surg Oncol. 2021 Nov;28(12):7356-7365. doi: 10.1245/s10434-021-10063-5. Epub 2021 May 8.

    Related:

    Commentary:

    ASO Author Reflections: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    Commentary:

    ASO Visual Abstract: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    • Synthetic Lethality in Ovarian Cancer.
    • Chandrasekaran A, Elias KM.
    • Mol Cancer Ther. 2021 Nov;20(11):2117-2128. doi: 10.1158/1535-7163.MCT-21-0500. Epub 2021 Sep 13.
    • Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations.
    • Guan Z, Shen R, Begg CB.
    • Hum Hered. 2021;86(1-4):34-44. doi: 10.1159/000519355. Epub 2021 Oct 29.
    • Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents.
    • Matanes E, López-Ozuna VM, Octeau D, Baloch T, Racovitan F, Dhillon AK, Kessous R, Raban O, Kogan L, Salvador S, Lau S, Gotlieb WH, Yasmeen A.
    • Front Oncol. 2021 Oct 27;11:745981. doi: 10.3389/fonc.2021.745981.
    • The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    • Tao M, Wu X.
    • J Exp Clin Cancer Res. 2021 Oct 26;40(1):338. doi: 10.1186/s13046-021-02139-7.
    • Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
    • Sun H, Zeng J, Miao Z, Lei KC, Huang C, Hu L, Su SM, Chan UI, Miao K, Zhang X, Zhang A, Guo S, Chen S, Meng Y, Deng M, Hao W, Lei H, Lin Y, Yang Z, Tang D, Wong KH, Zhang XD, Xu X, Deng CX.
    • Theranostics. 2021 Oct 25;11(20):9967-9987. doi: 10.7150/thno.63995.
    • Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
    • Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI.
    • NPJ Precis Oncol. 2021 Oct 19;5(1):92. doi: 10.1038/s41698-021-00232-w.
    • Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and BRCA1/2 Mutation-Type-Specific Critical Regulation in Breast Cancer.
    • Li Y, Dong W, Zhang P, Zhang T, Ma L, Qu M, Ma X, Zhou X, He Q.
    • Front Cell Dev Biol. 2021 Oct 18;9:750897. doi: 10.3389/fcell.2021.750897.
    • Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    • Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, Spierings DCJ, Schlecht H, Burghel GJ, Foijer F, Desai S, McGrail JC, Taylor SS.
    • J Exp Clin Cancer Res. 2021 Oct 16;40(1):323. doi: 10.1186/s13046-021-02124-0.
    • BET Proteins as Attractive Targets for Cancer Therapeutics.
    • Sarnik J, Poplawski T, Tokarz P.
    • Int J Mol Sci. 2021 Oct 14;22(20):11102. doi: 10.3390/ijms222011102.
    • Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.
    • Johannes JW, Balazs A, Barratt D, Bista M, Chuba MD, Cosulich S, Critchlow SE, Degorce SL, Di Fruscia P, Edmondson SD, Embrey K, Fawell S, Ghosh A, Gill SJ, Gunnarsson A, Hande SM, Heightman TD, Hemsley P, Illuzzi G, Lane J, Larner C, Leo E, Liu L, Madin A, Martin S, McWilliams L, O'Connor MJ, Orme JP, Pachl F, Packer MJ, Pei X, Pike A, Schimpl M, She H, Staniszewska AD, Talbot V, Underwood E, Varnes JG, Xue L, Yao T, Zhang K, Zhang AX, Zheng X.
    • J Med Chem. 2021 Oct 14;64(19):14498-14512. doi: 10.1021/acs.jmedchem.1c01012. Epub 2021 Sep 27.
    • BRCA1/Trp53 heterozygosity and replication stress drive esophageal cancer development in a mouse model.
    • He Y, Rivera J, Diossy M, Duan H, Bowman-Colin C, Reed R, Jennings R, Novak J, Tran SV, Cohen EF, Szuts D, Giobbie-Hurder A, Bronson RT, Bass AJ, Signoretti S, Szallasi Z, Livingston DM, Pathania S.
    • Proc Natl Acad Sci U S A. 2021 Oct 12;118(41):e2108421118. doi: 10.1073/pnas.2108421118.
    • PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer.
    • Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI YH, Lin CW.
    • J Pers Med. 2021 Oct 8;11(10):1009. doi: 10.3390/jpm11101009.
    • BRCA2 in mammalian meiosis.
    • Zhang J, Nandakumar J, Shibuya H.
    • Trends Cell Biol. 2021 Oct 5:S0962-8924(21)00182-3. doi: 10.1016/j.tcb.2021.09.003. Epub ahead of print.
    • Skeletal Muscle Function Is Dependent Upon BRCA1 to Maintain Genomic Stability.
    • Tarpey MD, Amorese AJ, LaFave ER, Minchew EC, Fisher-Wellman KH, McClung JM, Hvastkovs EG, Spangenburg EE.
    • Exerc Sport Sci Rev. 2021 Oct 1;49(4):267-273. doi: 10.1249/JES.0000000000000265.
    • Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
    • Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C.
    • Acta Pharm Sin B. 2021 Oct;11(10):2983-2994. doi: 10.1016/j.apsb.2021.01.003. Epub 2021 Jan 6.
    • Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
    • Wu Z, Tao H, Zhang S, Wang X, Ma J, Li R, Liu Z, Wang J, Cui P, Chen S, Di H, Huang Z, Zheng X, Hu Y.
    • Cancer Immunol Immunother. 2021 Oct;70(10):2971-2980. doi: 10.1007/s00262-021-02852-4. Epub 2021 Mar 19.
    • Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.
    • Li MZ, Meng T, Song SS, Bao XB, Ma LP, Zhang N, Yu T, Zhang YL, Xiong B, Shen JK, Miao ZH, He JX.
    • Invest New Drugs. 2021 Oct;39(5):1213-1221. doi: 10.1007/s10637-021-01096-4. Epub 2021 Mar 12.
    • Histological Findings of Mammary Gland Development and Risk of Breast Cancer in BRCA1 Mutant Mouse Models.
    • Kim H, Moon WK.
    • J Breast Cancer. 2021 Oct;24(5):455-462. doi: 10.4048/jbc.2021.24.e44. Epub 2021 Oct 5.
    • A complex of BRCA2 and PP2A-B56 is required for DNA repair by homologous recombination.
    • Ambjørn SM, Duxin JP, Hertz EPT, Nasa I, Duro J, Kruse T, Lopez-Mendez B, Rymarczyk B, Cressey LE, van Overeem Hansen T, Kettenbach AN, Oestergaard VH, Lisby M, Nilsson J.
    • Nat Commun. 2021 Sep 30;12(1):5748. doi: 10.1038/s41467-021-26079-0.
    • Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients.
    • Leaf S, Carlsen L, El-Deiry WS.
    • Oncotarget. 2021 Sep 28;12(20):1992-2005. doi: 10.18632/oncotarget.28082.

    Related:

    •• Commentary:

    BRCA role changes with association: tissue-specific impact on the prognosis.

    •• Commentary:

    Redefining and expanding the sphere of influence of BRCA in breast and colorectal cancers and beyond.

    • Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.
    • Hayward SB, Ciccia A.
    • Curr Opin Genet Dev. 2021 Sep 25;71:171-181. doi: 10.1016/j.gde.2021.08.006. Epub ahead of print.
    • Review
    • Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review.
    • Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual AM.
    • Int J Mol Sci. 2021 Sep 25;22(19):10319. doi: 10.3390/ijms221910319.
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Novel mechanisms in alcohol neurodevelopmental disorders via BRCA1 depletion and BRCA1-dependent NADPH oxidase regulation.
    • Drake DM, Wells PG.
    • Redox Biol. 2021 Sep 23;48:102148. doi: 10.1016/j.redox.2021.102148. Epub ahead of print.
    • Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    • Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, Andújar-Sánchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J.
    • Mol Cell. 2021 Sep 18:S1097-2765(21)00739-5. doi: 10.1016/j.molcel.2021.09.005. Epub ahead of print.
    • Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells.
    • Chirshev E, Suzuki T, Wang H, Nguyen A, Hojo N, Sanderman L, Mirshahidi S, Ioffe YJ, Unternaehrer JJ.
    • Cancers (Basel). 2021 Sep 15;13(18):4617. doi: 10.3390/cancers13184617.
    • Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
    • Saravi S, Alizzi Z, Tosi S, Hall M, Karteris E.
    • Cells. 2021 Sep 15;10(9):2434. doi: 10.3390/cells10092434.
    • Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.
    • Wen W, Chen Z, Bao J, Long Q, Shu XO, Zheng W, Guo X.
    • Nat Commun. 2021 Sep 13;12(1):5318. doi: 10.1038/s41467-021-25670-9.
    • REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
    • Taglialatela A, Leuzzi G, Sannino V, Cuella-Martin R, Huang JW, Wu-Baer F, Baer R, Costanzo V, Ciccia A.
    • Mol Cell. 2021 Sep 7:S1097-2765(21)00683-3. doi: 10.1016/j.molcel.2021.08.016. Epub ahead of print.
    • Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.
    • Tommasi C, Pellegrino B, Boggiani D, Sikokis A, Michiara M, Uliana V, Bortesi B, Bonatti F, Mozzoni P, Pinelli S, Squadrilli A, Viani MV, Cassi D, Maglietta G, Meleti M, Musolino A.
    • Front Oncol. 2021 Sep 6;11:700853. doi: 10.3389/fonc.2021.700853.
    • Quantification of dynamic contrast-enhanced ultrasound (CEUS) in non-cystic breast lesions using external perfusion software.
    • Jung EM, Jung F, Stroszczynski C, Wiesinger I.
    • Sci Rep. 2021 Sep 3;11(1):17677. doi: 10.1038/s41598-021-96137-6.
    • A polygenic-score-based approach for identification of gene-drug interactions stratifying breast cancer risk.
    • Marderstein AR, Kulm S, Peng C, Tamimi R, Clark AG, Elemento O.
    • Am J Hum Genet. 2021 Sep 2;108(9):1752-1764. doi: 10.1016/j.ajhg.2021.07.008. Epub 2021 Aug 6.

    Related:

    News: Breast Cancer Genetic Risk Modified by Corticosteroid Use. (GenomeWeb)

    • The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells.
    • Simoneau A, Xiong R, Zou L.
    • Genes Dev. 2021 Sep 1;35(17-18):1271-1289. doi: 10.1101/gad.348479.121. Epub 2021 Aug 12.
    • Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations.
    • Shalabi SF, Miyano M, Sayaman RW, Lopez JC, Jokela TA, Todhunter ME, Hinz S, Garbe JC, Stampfer MR, Kessenbrock K, Seewaldt VE, LaBarge MA.
    • Nat Aging. 2021 Sep;1(9):838-849. doi: 10.1038/s43587-021-00104-9. Epub 2021 Sep 14.
    • Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
    • Mani C, Tripathi K, Chaudhary S, Somasagara RR, Rocconi RP, Crasto C, Reedy M, Athar M, Palle K.
    • Neoplasia. 2021 Sep;23(9):1002-1015. doi: 10.1016/j.neo.2021.06.010. Epub 2021 Aug 8.
    • Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
    • Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators, Serra V, Waring P, Lim E, Caldon CE.
    • NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x.
    • Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
    • Marijon H, Gery S, Chang H, Landesman Y, Shacham S, Lee DH, de Gramont A, Koeffler HP.
    • Oncotarget. 2021 Aug 31;12(18):1749-1762. doi: 10.18632/oncotarget.28047.
    • G-quadruplex DNA: a novel target for drug design.
    • Teng FY, Jiang ZZ, Guo M, Tan XZ, Chen F, Xi XG, Xu Y.
    • Cell Mol Life Sci. 2021 Aug 30. doi: 10.1007/s00018-021-03921-8. Epub ahead of print.
    • Review
    • Copper-Mediated Radiosynthesis of [18F]Rucaparib.
    • Chen Z, Destro G, Guibbal F, Chan CY, Cornelissen B, Gouverneur V.
    • Org Lett. 2021 Aug 30. doi: 10.1021/acs.orglett.1c02770. Epub ahead of print.
    • Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.
    • Wang C, Qu L, Li S, Yin F, Ji L, Peng W, Luo H, Lu D, Liu X, Chen X, Kong L, Wang X.
    • J Med Chem. 2021 Aug 29. doi: 10.1021/acs.jmedchem.1c00567. Epub ahead of print.
    • Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
    • Benfatto S, Serçin Ö, Dejure FR, Abdollahi A, Zenke FT, Mardin BR.
    • Mol Cancer. 2021 Aug 28;20(1):111. doi: 10.1186/s12943-021-01405-8.
    • Polymerase θ Coordinates Multiple Intrinsic Enzymatic Activities during DNA Repair.
    • Zahn KE, Jensen RB.
    • Genes (Basel). 2021 Aug 25;12(9):1310. doi: 10.3390/genes12091310.
    • Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
    • Long H, Hu X, Wang B, Wang Q, Wang R, Liu S, Xiong F, Jiang Z, Zhang XQ, Ye WC, Wang H.
    • J Med Chem. 2021 Aug 18. doi: 10.1021/acs.jmedchem.1c00735. Epub ahead of print.
    • Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay.
    • Nikoleousakos N, Dalezis P, Polonifi A, Geromichalou EG, Sagredou S, Alifieris CE, Deligiorgi MV, Sarli V, Trafalis DT.
    • Biomedicines. 2021 Aug 17;9(8):1028. doi: 10.3390/biomedicines9081028.
    • Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
    • Franchet C, Hoffmann JS, Dalenc F.
    • Cancers (Basel). 2021 Aug 17;13(16):4132. doi: 10.3390/cancers13164132.
    • Revisiting the BRCA-pathway through the lens of replication gap suppression: "Gaps determine therapy response in BRCA mutant cancer".
    • Cantor SB.
    • DNA Repair (Amst). 2021 Aug 13;107:103209. doi: 10.1016/j.dnarep.2021.103209. Epub ahead of print.
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2021 Aug 11;5:PO.21.00141. doi: 10.1200/PO.21.00141.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
    • Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome.
    • Dong Q, Liu M, Chen B, Zhao Z, Chen T, Wang C, Zhuang S, Li Y, Wang Y, Ai L, Liu Y, Liang H, Qi L, Gu Y.
    • Comput Struct Biotechnol J. 2021 Aug 10;19:4435-4446. doi: 10.1016/j.csbj.2021.08.007.
    • CEACAM Gene Family Mutations Associated With Inherited Breast Cancer Risk - A Comparative Oncology Approach to Discovery.
    • Huskey ALW, McNeely I, Merner ND.
    • Front Genet. 2021 Aug 10;12:702889. doi: 10.3389/fgene.2021.702889.
    • Guardians of the Genome: BRCA2 and Its Partners.
    • Le HP, Heyer WD, Liu J.
    • Genes (Basel). 2021 Aug 10;12(8):1229. doi: 10.3390/genes12081229.
    • Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib.
    • Hongthong K, Nhukeaw T, Temboot P, Dyson PJ, Ratanaphan A.
    • Heliyon. 2021 Aug 10;7(8):e07749. doi: 10.1016/j.heliyon.2021.e07749.
    • PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
    • Dickson KA, Xie T, Evenhuis C, Ma Y, Marsh DJ.
    • Int J Mol Sci. 2021 Aug 7;22(16):8506. doi: 10.3390/ijms22168506.
    • Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity.
    • Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodriguez Martin B, Haase K, Woodcock DJ, Tubio J, Wedge DC, Nykter M, Bova GS.
    • Cancer Res. 2021 Aug 4:canres.0371.2021. doi: 10.1158/0008-5472.CAN-21-0371. Epub ahead of print.
    • BRCA2 deficiency reveals that oxidative stress impairs RNaseH1 function to cripple mitochondrial DNA maintenance.
    • Renaudin X, Lee M, Shehata M, Surmann EM, Venkitaraman AR.
    • Cell Rep. 2021 Aug 3;36(5):109478. doi: 10.1016/j.celrep.2021.109478.
    • PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
    • Bosnjak M, Jesenko T, Markelc B, Janzic L, Cemazar M, Sersa G.
    • Bioelectrochemistry. 2021 Aug;140:107832. doi: 10.1016/j.bioelechem.2021.107832. Epub 2021 May 1. Erratum in: Bioelectrochemistry. 2021 Oct;141:107865.
    • Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.
    • Gondo N, Sakai Y, Zhang Z, Hato Y, Kuzushima K, Phimsen S, Kawashima Y, Kuroda M, Suzuki M, Okada S, Iwata H, Toyama T, Rezano A, Kuwahara K.
    • Lab Invest. 2021 Aug;101(8):1048-1059. doi: 10.1038/s41374-021-00613-6. Epub 2021 May 24.

    Related:

    •• Original research:

    Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.

    • MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells.
    • Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J.
    • Mol Med Rep. 2021 Aug;24(2):548. doi: 10.3892/mmr.2021.12187. Epub 2021 Jun 3.
    • Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    • Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Eftekhariyan Ghamsari MR, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Cancer Study AO, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.
    • Cancer Res. 2021 Jul 28:canres.0774.2021. doi: 10.1158/0008-5472.CAN-21-0774. Epub ahead of print.
    • Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    • Lee O, Bosland MC, Wang M, Shidfar A, Hosseini O, Xuei X, Patel P, Schipma MJ, Helenowski I, Kim JJ, Clare SE, Khan SA.
    • Cancer Lett. 2021 Jul 27:S0304-3835(21)00361-X. doi: 10.1016/j.canlet.2021.07.034. Epub ahead of print.
    • ATR/ATM-mediated phosphorylation of BRCA1 T1394 promotes homologous recombinational repair and G2/M checkpoint maintenance.
    • Foo TK, Vincelli G, Huselid E, Her J, Zheng H, Simhadri S, Wang M, Huo Y, Li T, Yu X, Li H, Zhao W, Bunting SF, Xia B.
    • Cancer Res. 2021 Jul 23:canres.2723.2020. doi: 10.1158/0008-5472.CAN-20-2723. Epub ahead of print.
    • Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    • Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S, Reni M.
    • Cancer Treat Rev. 2021 Jul 23;100:102262. doi: 10.1016/j.ctrv.2021.102262. Epub ahead of print.
    • Review
    • Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.
    • Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP.
    • Front Oncol. 2021 Jul 22;11:694793. doi: 10.3389/fonc.2021.694793.
    • Increased gene expression variability in BRCA1-associated and basal-like breast tumours.
    • Wiggins GAR, Black MA, Dunbier A, Morley-Bunker AE; kConFab Investigators, Pearson JF, Walker LC.
    • Breast Cancer Res Treat. 2021 Jul 21. doi: 10.1007/s10549-021-06328-y. Epub ahead of print.
    • BRCA2 Promotes Spontaneous Homologous Recombination In Vivo.
    • Brown AD, Greenman S, Claybon AB, Bishop AJR.
    • Cancers (Basel). 2021 Jul 21;13(15):3663. doi: 10.3390/cancers13153663.
    • Intrinsic Disorder and Phosphorylation in BRCA2 Facilitate Tight Regulation of Multiple Conserved Binding Events.
    • Julien M, Ghouil R, Petitalot A, Caputo SM, Carreira A, Zinn-Justin S.
    • Biomolecules. 2021 Jul 20;11(7):1060. doi: 10.3390/biom11071060.
    • Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
    • Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, Fahr N, Desbuisson M, Grimm A, Zhang H, Chong C, Dagher J, Chee S, Tsianou T, Dorier J, Stevenson BJ, Iseli C, Ronet C, Bobisse S, Genolet R, Walton J, Bassani-Sternberg M, Kandalaft LE, Ren B, McNeish I, Swisher E, Harari A, Delorenzi M, Ciriello G, Irving M, Rusakiewicz S, Foukas PG, Martinon F, Dangaj Laniti D, Coukos G.
    • Cell Rep. 2021 Jul 20;36(3):109412. doi: 10.1016/j.celrep.2021.109412.

    Related:

    Research news:

    Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma.

    • Prediction of BRCA Gene Mutation in Breast Cancer Based on Deep Learning and Histopathology Images.
    • Wang X, Zou C, Zhang Y, Li X, Wang C, Ke F, Chen J, Wang W, Wang D, Xu X, Xie L, Zhang Y.
    • Front Genet. 2021 Jul 20;12:661109. doi: 10.3389/fgene.2021.661109.
    • Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
    • Berkel C, Cacan E.
    • Biochem Biophys Res Commun. 2021 Jul 14;570:74-81. doi: 10.1016/j.bbrc.2021.07.004. Epub ahead of print.
    • A computational and structural analysis of germline and somatic variants affecting the DDR mechanism, and their impact on human diseases.
    • Magraner-Pardo L, Laskowski RA, Pons T, Thornton JM.
    • Sci Rep. 2021 Jul 12;11(1):14268. doi: 10.1038/s41598-021-93715-6.
    • Suppression of DNA Polymerase ß Activity Is Synthetically Lethal in BRCA1-Deficient Cells.
    • Yuhas SC, Mishra A, DeWeese TL, Greenberg MM.
    • ACS Chem Biol. 2021 Jul 9. doi: 10.1021/acschembio.1c00385. Epub ahead of print.
    • Electronic characteristics of BRCA1 mutations in DNA.
    • He L, Zhang J, He C, Zhao B, Xie Z, Chen W, Sonawane MR, Patil SR.
    • Biopolymers. 2021 Jul 9:e23465. doi: 10.1002/bip.23465. Epub ahead of print.
    • Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
    • Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH.
    • NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028.
    • Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.
    • Kar SP, Considine DPC, Tyrer JP, Plummer JT, Chen S, Dezem FS, Barbeira AN, Rajagopal PS, Rosenow WT, Moreno F, Bodelon C, Chang-Claude J, Chenevix-Trench G, deFazio A, Dörk T, Ekici AB, Ewing A, Fountzilas G, Goode EL, Hartman M, Heitz F, Hillemanns P, Høgdall E, Høgdall CK, Huzarski T, Jensen A, Karlan BY, Khusnutdinova E, Kiemeney LA, Kjaer SK, Klapdor R, Köbel M, Li J, Liebrich C, May T, Olsson H, Permuth JB, Peterlongo P, Radice P, Ramus SJ, Riggan MJ, Risch HA, Saloustros E, Simard J, Szafron LM, Titus L, Thompson CL, Vierkant RA, Winham SJ, Zheng W, Doherty JA, Berchuck A, Lawrenson K, Im HK, Manichaikul AW, Pharoah PDP, Gayther SA, Schildkraut JM.
    • HGG Adv. 2021 Jul 8;2(3):100042. doi: 10.1016/j.xhgg.2021.100042. Epub 2021 Jun 16.
    • Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
    • Malka MM, Eberle J, Niedermayer K, Zlotos DP, Wiesmüller L.
    • Biomolecules. 2021 Jul 3;11(7):981. doi: 10.3390/biom11070981.
    • Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies.
    • Cunnea P, Fotopoulou C, Ploski J, Trillsch F, Mahner S, Kessler M.
    • Cancers (Basel). 2021 Jul 3;13(13):3349. doi: 10.3390/cancers13133349.
    • Understanding BRCA2 Function as a Tumor Suppressor Based on Domain-Specific Activities in DNA Damage Responses.
    • Andreassen PR, Seo J, Wiek C, Hanenberg H.
    • Genes (Basel). 2021 Jul 2;12(7):1034. doi: 10.3390/genes12071034.
    • Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
    • Huang M, Ren J, Wang Y, Chen X, Yang J, Tang T, Yang Z, Li X, Ji M, Cai J.
    • Chem Pharm Bull (Tokyo). 2021 [Jul 1];69(7):620-629. doi: 10.1248/cpb.c20-01018.
    • Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2.
    • Tang M, Pei G, Su D, Wang C, Feng X, Srivastava M, Chen Z, Zhao Z, Chen J.
    • Nucleic Acids Res. 2021 Jul 1:gkab540. doi: 10.1093/nar/gkab540. Epub ahead of print.
    • Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer.
    • Gonda K, Horita S, Maejima Y, Takenoshita S, Shimomura K.
    • Sci Prog. 2021 Jul-Sep;104(3):368504211039590. doi: 10.1177/00368504211039590.
    • Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
    • Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L.
    • Br J Cancer. 2021 Jul;125(1):7-14. doi: 10.1038/s41416-021-01295-z. Epub 2021 Mar 25.
    • Commentary, Review
    • BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    • Royfman R, Whiteley E, Noe O, Morand S, Creeden J, Stanbery L, Hamouda D, Nemunaitis J.
    • Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
    • Review
    • RASSF1A Suppression as a Potential Regulator of Mechano-Pathobiology Associated with Mammographic Density in BRCA Mutation Carriers.
    • Reye G, Huang X, Britt KL, Meinert C, Blick T, Xu Y, Momot KI, Lloyd T, Northey JJ, Thompson EW, Hugo HJ.
    • Cancers (Basel). 2021 Jun 29;13(13):3251. doi: 10.3390/cancers13133251.
    • Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    • Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Jonkers J, Johnson N, Turchi JJ, Rothenberg E, Cantor SB.
    • Mol Cell. 2021 Jun 26:S1097-2765(21)00458-5. doi: 10.1016/j.molcel.2021.06.011. Epub ahead of print.
    • BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
    • Pilyugin M, Ratajska M, Stukan M, Concin N, Zeillinger R, Irminger-Finger I.
    • Genes (Basel). 2021 Jun 25;12(7):969. doi: 10.3390/genes12070969.
    • The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
    • Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel E.
    • Cancers (Basel). 2021 Jun 23;13(13):3136. doi: 10.3390/cancers13133136.
    • Pfizer Studying Talzenna in Advanced Prostate Cancer Patients With DNA Damage Response Gene Defects.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Prostate Cancer. 2021 Jun 23.
    • Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
    • Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B.
    • Biomedicines. 2021 Jun 22;9(7):706. doi: 10.3390/biomedicines9070706.
    • Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
    • Uddin MH, Li Y, Khan HY, Muqbil I, Aboukameel A, Sexton RE, Reddy S, Landesman Y, Kashyap T, Azmi AS, Heath EI.
    • Int J Mol Sci. 2021 Jun 22;22(13):6676. doi: 10.3390/ijms22136676.
    • Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.
    • Chen M, Huang H, Wu K, Liu Y, Jiang L, Li Y, Tang G, Peng J, Cao X.
    • Drug Dev Res. 2021 Jun 21. doi: 10.1002/ddr.21843. Epub ahead of print.
    • Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    • Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A.
    • Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714. Epub ahead of print.
    • Breast specific molecular clocks comprised of ELF5 expression and promoter methylation identify individuals susceptible to cancer initiation.
    • Miyano M, Sayaman RW, Shalabi SF, Senapati P, Lopez JC, Angarola BL, Hinz S, Zirbes A, Anczukow O, Yee LD, Sedrak MS, Stampfer MR, Seewaldt VL, LaBarge MA.
    • Cancer Prev Res (Phila). 2021 Jun 17:canprevres.CAPR-20-0635-A.2020. doi: 10.1158/1940-6207.CAPR-20-0635. Epub ahead of print.
    • Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.
    • Shen J, Liu T, Bei Q, Xu S.
    • Front Oncol. 2021 Jun 17;11:685065. doi: 10.3389/fonc.2021.685065.
    • Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    • Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ.
    • Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8.
    • New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
    • Shkundina IS, Gall AA, Dick A, Cocklin S, Mazin AV.
    • Genes (Basel). 2021 Jun 16;12(6):920. doi: 10.3390/genes12060920.
    • The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks.
    • van Wijk LM, Kramer CJH, Vermeulen S, Ter Haar NT, de Jonge MM, Kroep JR, de Kroon CD, Gaarenstroom KN, Vrieling H, Bosse T, Vreeswijk MPG.
    • Cancers (Basel). 2021 Jun 15;13(12):2994. doi: 10.3390/cancers13122994.
    • The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
    • Turinetto M, Scotto G, Tuninetti V, Giannone G, Valabrega G.
    • Front Oncol. 2021 Jun 14;11:689829. doi: 10.3389/fonc.2021.689829.
    • Association between Predicted Effects of TP53 Missense Variants on Protein Conformation and Their Phenotypic Presentation as Li-Fraumeni Syndrome or Hereditary Breast Cancer.
    • Liu Y, Axell O, van Leeuwen T, Konrat R, Kharaziha P, Larsson C, Wright APH, Bajalica-Lagercrantz S.
    • Int J Mol Sci. 2021 Jun 14;22(12):6345. doi: 10.3390/ijms22126345.
    • Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
    • Orhan E, Velazquez C, Tabet I, Sardet C, Theillet C.
    • Cancers (Basel). 2021 Jun 11;13(12):2930. doi: 10.3390/cancers13122930.
    • Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis.
    • Imai S, Ooki T, Murata-Kamiya N, Komura D, Tahmina K, Wu W, Takahashi-Kanemitsu A, Knight CT, Kunita A, Suzuki N, Del Valle AA, Tsuboi M, Hata M, Hayakawa Y, Ohnishi N, Ueda K, Fukayama M, Ushiku T, Ishikawa S, Hatakeyama M.
    • Cell Host Microbe. 2021 Jun 9;29(6):941-958.e10. doi: 10.1016/j.chom.2021.04.006. Epub 2021 May 13.
    • PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
    • Li X, Fang T, Xu S, Jin P, Zhou D, Wang Z, Li H, Yang Z, Chen G, Zheng X, Xia Y, Wei X, Zhang Z, Yang X, Wang Y, Gao Q.
    • NPJ Precis Oncol. 2021 Jun 9;5(1):49. doi: 10.1038/s41698-021-00189-w.
    • Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    • Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS.
    • Eur Urol. 2021 Jun 5:S0302-2838(21)01799-1. doi: 10.1016/j.eururo.2021.05.030. Epub ahead of print.
    • Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance.
    • Lee M, Shorthouse D, Mahen R, Hall BA, Venkitaraman AR.
    • Nucleic Acids Res. 2021 Jun 4;49(10):5588-5604. doi: 10.1093/nar/gkab308.
    • The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target.
    • Sharp MF, Bythell-Douglas R, Deans AJ, Crismani W.
    • Mol Cell. 2021 Jun 3;81(11):2278-2289. doi: 10.1016/j.molcel.2021.04.023. Epub 2021 May 12.
    • Review
    • BRCA1-BRCT Mutations Alter the Subcellular Localization of BRCA1 In Vitro.
    • Drikos I, Boutou E, Kastritis PL, Vorgias CE.
    • Anticancer Res. 2021 Jun;41(6):2953-2962. doi: 10.21873/anticanres.15077.
    • Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
    • Zhong Q, Xiong Y, Ling C, Qian Y, Zhao X, Yang H.
    • Exp Biol Med (Maywood). 2021 Jun;246(11):1297-1306. doi: 10.1177/1535370221994077.
    • A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
    • Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Färkkilä A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D'Andrea AD.
    • Nat Cancer. 2021 Jun;2(6):598-610. doi: 10.1038/s43018-021-00203-x. Epub 2021 Jun 17.

    Related:

    Press: Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors (Clinical OMICs)

    • PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
    • Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y, Wang J.
    • Redox Biol. 2021 Jun;42:101928. doi: 10.1016/j.redox.2021.101928. Epub 2021 Mar 5.
    • Breast cancer type 1 and neurodegeneration: consequences of deficient DNA repair.
    • Leung E, Hazrati LN.
    • Brain Commun. 2021 May 27;3(2):fcab117. doi: 10.1093/braincomms/fcab117.
    • A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions.
    • Marhold M, Heinzel A, Merchant A, Perco P, Krainer M.
    • J Vis Exp. 2021 May 27;(171). doi: 10.3791/60328.
    • Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity.
    • Phung TN, Webster TH, Lenkiewicz E, Malasi S, Andreozzi M, McCullough AE, Anderson KS, Pockaj BA, Wilson MA, Barrett MT.
    • Sci Rep. 2021 May 19;11(1):10571. doi: 10.1038/s41598-021-90170-1.
    • Feasibility of predicting allele specific expression from DNA sequencing using machine learning.
    • Zhang Z, van Dijk F, de Klein N, van Gijn ME, Franke LH, Sinke RJ, Swertz MA, van der Velde KJ.
    • Sci Rep. 2021 May 19;11(1):10606. doi: 10.1038/s41598-021-89904-y.
    • Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers.
    • Hu L, Su L, Cheng H, Mo C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Zhang J, Xie Y.
    • Cancer Res. 2021 May 15;81(10):2600-2611. doi: 10.1158/0008-5472.CAN-20-2123. Epub 2021 Mar 16.
    • Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 May 15;81(10):2774-2787. doi: 10.1158/0008-5472.CAN-20-2912. Epub 2021 Jan 29.
    • DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    • Min A, Lee KH, Im SA.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:159-179. doi: 10.1007/978-981-32-9620-6_8.
    • Review, eBook chapter
    • The Potential Predictors in Chemotherapy Sensitivity.
    • Kim EK, Shin HC.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:381-389. doi: 10.1007/978-981-32-9620-6_19.
    • Review, eBook chapter
    • Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.
    • Paracchini L, D'Incalci M, Marchini S.
    • Cancers (Basel). 2021 May 14;13(10):2386. doi: 10.3390/cancers13102386.
    • The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
    • Gráf A, Enyedi MZ, Pintér L, Kriston-Pál É, Jaksa G, Bálind Á, Ezer É, Horváth P, Sükösd F, Kiss E, Haracska L.
    • Cancers (Basel). 2021 May 13;13(10):2354. doi: 10.3390/cancers13102354.
    • Identification of the core motif of the BRCA2 C-terminal RAD51-binding domain by comparing canine and human BRCA2.
    • Yoshikawa Y, Morimatsu M, Ochiai K, Ishiguro-Oonuma T, Morioka R, Okuda K, Orino K.
    • J Vet Med Sci. 2021 May 9;83(5):759-766. doi: 10.1292/jvms.21-0006. Epub 2021 Mar 16.
    • C/EBPß promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    • Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q.
    • Oncogene. 2021 May 8. doi: 10.1038/s41388-021-01788-4. Epub ahead of print.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • Tracing ovarian cancer research in Morocco: A bibliometric analysis.
    • El Bairi K, Al Jarroudi O, Afqir S.
    • Gynecol Oncol Rep. 2021 May 7;37:100777. doi: 10.1016/j.gore.2021.100777.
    • A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast.
    • Pal B, Chen Y, Vaillant F, Capaldo BD, Joyce R, Song X, Bryant VL, Penington JS, Di Stefano L, Tubau Ribera N, Wilcox S, Mann GB; kConFab, Papenfuss AT, Lindeman GJ, Smyth GK, Visvader JE.
    • EMBO J. 2021 May 5:e107333. doi: 10.15252/embj.2020107333. Epub ahead of print.
    • Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer.
    • Wu Z, Bai Y, Jin J, Jiang T, Shen H, Ju Q, Zhu Q, Xu Y.
    • Eur J Med Chem. 2021 May 5;217:113357. doi: 10.1016/j.ejmech.2021.113357. Epub 2021 Mar 10.
    • Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor.
    • Singh M, Rajawat J, Kuldeep J, Shukla N, Mishra DP, Siddiqi MI.
    • J Biomol Struct Dyn. 2021 May 5:1-14. doi: 10.1080/07391102.2021.1913229. Epub ahead of print.
    • Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.
    • Zhou Z, Li M.
    • JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
    • Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers.
    • Depypere H, Su Y, Dang N, Poppe B, Stanczyk F, Janssens J, Russo J.
    • Eur J Cancer Prev. 2021 May 1;30(3):195-203. doi: 10.1097/CEJ.0000000000000664.
    • Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
    • Zhang R, Wang T, Lin J.
    • Anticancer Res. 2021 May;41(5):2277-2286. doi: 10.21873/anticanres.15003.
    • Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis.
    • Yoshino Y, Fang Z, Qi H, Kobayashi A, Chiba N.
    • Cancer Sci. 2021 May;112(5):1679-1687. doi: 10.1111/cas.14859. Epub 2021 Mar 16.
    • Generation and characterization of induced pluripotent stem cells heterozygous for the Portuguese BRCA2 founder mutation.
    • Silva TP, Pereira CA, Raposo AC, Oliveira AR, Arez M, Cabral JMS, Milagre I, Carmo-Fonseca M, Rocha STD.
    • Stem Cell Res. 2021 May;53:102364. doi: 10.1016/j.scr.2021.102364. Epub 2021 Apr 23.
    • Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells.
    • Yang Q, Li Y, Sun R, Li J.
    • Front Pharmacol. 2021 Apr 29;12:637825. doi: 10.3389/fphar.2021.637825.
    • Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging.
    • O'Sullivan J, Mersaoui SY, Poirier G, Masson JY.
    • J Vis Exp. 2021 Apr 28;(170). doi: 10.3791/62553.
    • DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects.
    • Jegadesan NK, Branzei D.
    • Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2024258118. doi: 10.1073/pnas.2024258118.
    • BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.
    • Raimundo L, Paterna Â, Calheiros J, Ribeiro J, Cardoso D, Piga I, Neto SJ, Hegan D, Glazer PM, Indraccolo S, Mulhovo S, Costa JL, Ferreira MU, Saraiva L.
    • Br J Pharmacol. 2021 Apr 26. doi: 10.1111/bph.15506. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057.
    • Functional Genomic Analyses of the 21q22.3 Locus Identifying Functional Variants and Candidate Gene YBEY for Breast Cancer Risk.
    • Shidal C, Shu X, Wu J, Wang J, Huang S, Long J, Bauer JA, Ping J, Guo X, Zheng W, Shu XO, Cai Q.
    • Cancers (Basel). 2021 Apr 23;13(9):2037. doi: 10.3390/cancers13092037.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 23;13(9):2042. doi: 10.3390/cancers13092042.
    • BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis.
    • Li Q, Engebrecht J.
    • Front Cell Dev Biol. 2021 Apr 23;9:668309. doi: 10.3389/fcell.2021.668309.
    • Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.
    • Otsuka I.
    • Int J Mol Sci. 2021 Apr 23;22(9):4409. doi: 10.3390/ijms22094409.
    • Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
    • Tseng WC, Chen CY, Chern CY, Wang CA, Lee WC, Chi YC, Cheng SF, Kuo YT, Chiu YC, Tseng ST, Lin PY, Liou SJ, Li YC, Chen CC.
    • Int J Mol Sci. 2021 Apr 23;22(9):4422. doi: 10.3390/ijms22094422.
    • Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.
    • Huo Y, Selenica P, Mahdi AH, Pareja F, Kyker-Snowman K, Chen Y, Kumar R, Da Cruz Paula A, Basili T, Brown DN, Pei X, Riaz N, Tan Y, Huang YX, Li T, Barnard NJ, Reis-Filho JS, Weigelt B, Xia B.
    • NPJ Breast Cancer. 2021 Apr 23;7(1):45. doi: 10.1038/s41523-021-00253-5.
    • CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitors.
    • Xu Z, Vandenberg CJ, Lieschke E, Di Rago L, Scott CL, Majewski IJ.
    • Mol Cancer Res. 2021 Apr 16:molcanres.0791.2020. doi: 10.1158/1541-7786.MCR-20-0791. Epub ahead of print.
    • FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers.
    • Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM 3rd, Hickson I, Tatum NJ, Rakha EA, Madhusudan S.
    • Cancers (Basel). 2021 Apr 14;13(8):1866. doi: 10.3390/cancers13081866.
    • A new interaction between BRCA2 and DDX5 promotes the repair of DNA breaks at transcribed chromatin.
    • Gómez-González B, Sessa G, Carreira A, Aguilera A.
    • Mol Cell Oncol. 2021 Apr 14;8(3):1910474. doi: 10.1080/23723556.2021.1910474.
    • Commentary
    • In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
    • Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES.
    • Sci Rep. 2021 Apr 13;11(1):8042. doi: 10.1038/s41598-021-87325-5.
    • WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
    • Kaur A, Lim JYS, Sepramaniam S, Patnaik S, Harmston N, Lee MA, Petretto E, Virshup DM, Madan B.
    • EMBO Mol Med. 2021 Apr 9;13(4):e13349. doi: 10.15252/emmm.202013349. Epub 2021 Mar 4.
    • Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
    • Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, Hewitt G, Patel H, Goldstone R, Carell T, Boulton SJ, MacRae J, Taylor IA, West SC.
    • Science. 2021 Apr 9;372(6538):156-165. doi: 10.1126/science.abb4542.

    Related:

    Comment:

    Epigenetic nucleotides enhance therapy.

    • Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    • Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, Jiang Y, Shao Z, Wang Z.
    • J Exp Clin Cancer Res. 2021 Apr 8;40(1):122. doi: 10.1186/s13046-021-01930-w.
    • The dystonia gene THAP1 controls DNA double-strand break repair choice.
    • Shinoda K, Zong D, Callen E, Wu W, Dumitrache LC, Belinky F, Chari R, Wong N, Ishikawa M, Stanlie A, Multhaupt-Buell T, Sharma N, Ozelius L, Ehrlich M, McKinnon PJ, Nussenzweig A.
    • Mol Cell. 2021 Apr 6:S1097-2765(21)00229-X. doi: 10.1016/j.molcel.2021.03.034. Epub ahead of print.
    • Synthetic Lethality in Cancer Therapeutics: The Next Generation.
    • Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN.
    • Cancer Discov. 2021 Apr 1. doi: 10.1158/2159-8290.CD-20-1503. Epub ahead of print.
    • Review
    • Systemic alterations play a dominant role in epigenetic predisposition to breast cancer in offspring of obese fathers and is transmitted to a second generation.
    • Fontelles CC, da Cruz RS, Gonsiewski AK, Barin E, Tekmen V, Jin L, Cruz MI, Loudig O, Warri A, de Assis S.
    • Sci Rep. 2021 Apr 1;11(1):7317. doi: 10.1038/s41598-021-86548-w.
    • Molecular disruption of DNA polymerase ß for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    • Ali R, Alblihy A, Miligy IM, Alabdullah ML, Alsaleem M, Toss MS, Algethami M, Abdel-Fatah T, Moseley P, Chan S, Mongan NP, Narayan S, Rakha EA, Madhusudan S.
    • Oncogene. 2021 Apr;40(14):2496-2508. doi: 10.1038/s41388-021-01710-y. Epub 2021 Mar 5.
    • Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
    • Patel PS, Algouneh A, Hakem R.
    • Oncogene. 2021 Apr;40(17):3001-3014. doi: 10.1038/s41388-021-01744-2. Epub 2021 Mar 14.
    • Review
    • Structure analysis of deleterious nsSNPs in human PALB2 protein for functional inference.
    • Nawar N, Paul A, Mahmood HN, Faisal MI, Hosen MI, Shekhar HU.
    • Bioinformation. 2021 Mar 31;17(3):424-438. doi: 10.6026/97320630017424.
    • Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.
    • Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, Sainz B Jr, Malats N, Carrato A.
    • Cancers (Basel). 2021 Mar 31;13(7):1612. doi: 10.3390/cancers13071612. Erratum in: Cancers (Basel). 2021 Jul 22;13(15):3687.
    • Determinants of serum adiponectin levels: a cross-sectional study.
    • Sattarinezhad A, Rasekhi Kazerouni A, Omrani GR, Shams M.
    • Horm Mol Biol Clin Investig. 2021 Mar 31;42(3):321-324. doi: 10.1515/hmbci-2020-0057.
    • Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1.
    • Morris C, Durand S, Jalinot P.
    • Oncotarget. 2021 Mar 30;12(7):649-664. doi: 10.18632/oncotarget.27923.
    • Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.
    • Al-Mugotir M, Lovelace JJ, George J, Bessho M, Pal D, Struble L, Kolar C, Rana S, Natarajan A, Bessho T, Borgstahl GEO.
    • PLoS One. 2021 Mar 30;16(3):e0248941. doi: 10.1371/journal.pone.0248941.
    • Alteration of DNA Damage Response Causes Cleft Palate.
    • Yamaguchi H, Kitami K, Wu X, He L, Wang J, Wang B, Komatsu Y.
    • Front Physiol. 2021 Mar 29;12:649492. doi: 10.3389/fphys.2021.649492.
    • Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
    • Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S.
    • Sci Rep. 2021 Mar 29;11(1):7064. doi: 10.1038/s41598-021-85962-4.
    • SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
    • Pang JB, Castles B, Byrne DJ, Button P, Hendry S, Lakhani SR, Sivasubramaniam V, Cooper WA, Armes J, Millar EKA, Raymond W, Roberts-Thomson S, Kumar B, Burr M, Selinger C, Harvey K, Chan C, Beith J, Clouston D, O'Toole SA, Fox SB; kConFab.
    • Am J Surg Pathol. 2021 Mar 22. doi: 10.1097/PAS.0000000000001701. Epub ahead of print.
    • The Role of Exosomes in Breast Cancer Diagnosis.
    • Piombino C, Mastrolia I, Omarini C, Candini O, Dominici M, Piacentini F, Toss A.
    • Biomedicines. 2021 Mar 18;9(3):312. doi: 10.3390/biomedicines9030312.
    • Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines.
    • Amuzu S, Carmona E, Mes-Masson AM, Greenwood CMT, Tonin PN, Ragoussis J.
    • Cancers (Basel). 2021 Mar 15;13(6):1296. doi: 10.3390/cancers13061296.
    • Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
    • Bach K, Pensa S, Zarocsinceva M, Kania K, Stockis J, Pinaud S, Lazarus KA, Shehata M, Simões BM, Greenhalgh AR, Howell SJ, Clarke RB, Caldas C, Halim TYF, Marioni JC, Khaled WT.
    • Nat Commun. 2021 Mar 9;12(1):1502. doi: 10.1038/s41467-021-21783-3.

    Related:

    Research news:

    Early effects of BRCA1 mutations in the breast.

    • Replication Gaps Underlie BRCA Deficiency and Therapy Response.
    • Panzarino NJ, Krais JJ, Cong K, Peng M, Mosqueda M, Nayak SU, Bond SM, Calvo JA, Doshi MB, Bere M, Ou J, Deng B, Zhu LJ, Johnson N, Cantor SB.
    • Cancer Res. 2021 Mar 1;81(5):1388-1397. doi: 10.1158/0008-5472.CAN-20-1602. Epub 2020 Nov 12.

    Related:

    Commentary:

    Which Holds the Key to BRCAness: Inability to Repair the Break, Protect the Fork, or Prevent the Gap?

    • [Involvement of Variants in the Genes Encoding BRCA1-Associated Genome Surveillance Complex (BASC) in the Development of Human Common Diseases].
    • Babushkina NP, Postrigan AE, Kucher AN.
    • Mol Biol (Mosk). 2021 Mar-Apr;55(2):318-337. Russian. doi: 10.31857/S0026898421020038.
    • Review, [Article in Russian]
    • LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
    • Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z.
    • Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341.
    • Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    • Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.
    • Cancer Lett. 2021 Feb 27:S0304-3835(21)00092-6. doi: 10.1016/j.canlet.2021.02.018. Epub ahead of print.
    • BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    • Li Y, Wang Y, Zhang W, Wang X, Chen L, Wang S.
    • Sci Rep. 2021 Feb 26;11(1):4774. doi: 10.1038/s41598-021-82990-y.
    • FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo.
    • Brückner L, Reinshagen A, Hoang NA, Höhn AK, Lordick F, Bechmann I, Aktas B, Nel I, Kallendrusch S.
    • Cancers (Basel). 2021 Feb 25;13(5):956. doi: 10.3390/cancers13050956.
    • The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
    • Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Chen S, Huang Z, Zheng X, Huang D, Hu Y.
    • Clin Med Insights Oncol. 2021 Feb 25;15:1179554921996288. doi: 10.1177/1179554921996288.
    • Single-Strand Annealing in Cancer.
    • Blasiak J.
    • Int J Mol Sci. 2021 Feb 22;22(4):2167. doi: 10.3390/ijms22042167.
    • Patient-derived xenograft models of BRCA-associated pancreatic cancers.
    • Golan T, Atias D, Stossel C, Raitses-Gurevich M.
    • Adv Drug Deliv Rev. 2021 Feb 19:S0169-409X(21)00044-2. doi: 10.1016/j.addr.2021.02.010. Epub ahead of print.
    • Review
    • Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production.
    • Zhou S, Liu Y, Jin L, Guo P, Liu Q, Shan J, Luo X, He H, Ma W, Zhang T.
    • J Steroid Biochem Mol Biol. 2021 Feb 19:105853. doi: 10.1016/j.jsbmb.2021.105853. Epub ahead of print.
    • Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    • Chen MK.
    • FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
    • Commentary
    • Generation and characterization of induced pluripotent stem cells from a family carrying the BRCA1 mutation c.3612delA.
    • Silva TP, Pereira CA, Oliveira AR, Raposo AC, Arez M, Cabral JMS, Milagre I, Carmo-Fonseca M, da Rocha ST.
    • Stem Cell Res. 2021 Feb 11;52:102242. doi: 10.1016/j.scr.2021.102242. Epub ahead of print.
    • RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
    • Patel PS, Abraham KJ, Guturi KKN, Halaby MJ, Khan Z, Palomero L, Ho B, Duan S, St-Germain J, Algouneh A, Mateo F, El Ghamrasni S, Barbour H, Barnes DR, Beesley J, Sanchez O, Berman HK, Brown GW, Affar EB, Chenevix-Trench G, Antoniou AC, Arrowsmith CH, Raught B, Pujana MA, Mekhail K, Hakem A, Hakem R.
    • J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105.
    • Insufficient evidence of endocervical origin in germline BRCA1 and MSH2-associated tumors.
    • Kertowidjojo E, Park KJ, Hodgson A.
    • Tumori. 2021 Feb 1:300891621991674. doi: 10.1177/0300891621991674. Epub ahead of print.
    • Letter
    • Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
    • Cho EJ, Kim JK, Baek HJ, Kim SE, Park EJ, Choi BK, Kim TH, Shin DH, Lim YK, Deng CX, Kim SS.
    • Int J Biol Sci. 2021 Jan 31;17(3):689-701. doi: 10.7150/ijbs.53667.
    • Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation.
    • Waissi W, Nicol A, Jung M, Rousseau M, Jarnet D, Noel G, Burckel H.
    • Cancers (Basel). 2021 Jan 30;13(3):527. doi: 10.3390/cancers13030527.
    • Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 Jan 29:canres.2912.2020. doi: 10.1158/0008-5472.CAN-20-2912. Epub ahead of print.
    • DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
    • Pillay N, Brady R, Dey M, Morgan RD, Taylor SS.
    • Prog Biophys Mol Biol. 2021 Jan 29:S0079-6107(21)00005-5. doi: 10.1016/j.pbiomolbio.2021.01.004. Epub ahead of print.
    • Review
    • ANKLE1 as New Hotspot Mutation for Breast Cancer in Indian Population and Has a Role in DNA Damage and Repair in Mammalian Cells.
    • Bakshi D, Katoch A, Chakraborty S, Shah R, Sharma B, Bhat A, Verma S, Bhat GR, Nagpal A, Vaishnavi S, Goswami A, Kumar R.
    • Front Genet. 2021 Jan 27;11:609758. doi: 10.3389/fgene.2020.609758.
    • iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression.
    • Portier L, Desterke C, Chaker D, Oudrhiri N, Asgarova A, Dkhissi F, Turhan AG, Bennaceur-Griscelli A, Griscelli F.
    • Int J Mol Sci. 2021 Jan 27;22(3):1227. doi: 10.3390/ijms22031227.
    • Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
    • Janysek DC, Kim J, Duijf PHG, Dray E.
    • Transl Oncol. 2021 Jan 27;14(3):101012. doi: 10.1016/j.tranon.2021.101012. Epub ahead of print.
    • RUNX3 Transcript Variants Have Distinct Roles in Ovarian Carcinoma and Differently Influence Platinum Sensitivity and Angiogenesis.
    • Heinze K, Hölzer M, Ungelenk M, Gerth M, Thomale J, Heller R, Morden CR, McManus KJ, Mosig AS, Dürst M, Runnebaum IB, Häfner N.
    • Cancers (Basel). 2021 Jan 26;13(3):476. doi: 10.3390/cancers13030476.
    • Possible Beneficial Effects of N-Acetylcysteine for Treatment of Triple-Negative Breast Cancer.
    • Kwon Y.
    • Antioxidants (Basel). 2021 Jan 24;10(2):169. doi: 10.3390/antiox10020169.
    • PDGFRß is an essential therapeutic target for BRCA1-deficient mammary tumors.
    • Bai F, Liu S, Liu X, Hollern DP, Scott A, Wang C, Zhang L, Fan C, Fu L, Perou CM, Zhu WG, Pei XH.
    • Breast Cancer Res. 2021 Jan 21;23(1):10. doi: 10.1186/s13058-021-01387-x.
    • Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
    • Zhang D, Singh B, Moerland J, Mitchell O, Lockwood L, Carapellucci S, Sridhar S, Liby KT.
    • Sci Rep. 2021 Jan 13;11(1):1234. doi: 10.1038/s41598-020-79663-7.
    • Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    • Moustafa D, Elwahed MRA, Elsaid HH, Parvin JD.
    • PLoS One. 2021 Jan 7;16(1):e0235025. doi: 10.1371/journal.pone.0235025.
    • Reduced translation efficiency due to novel splicing variants in 5' untranslated region and identification of novel cis-regulatory elements in canine and human BRCA2.
    • Yoshikawa Y, Kozuma H, Morimatsu M, Sugawara K, Orino K.
    • BMC Mol Cell Biol. 2021 Jan 6;22(1):2. doi: 10.1186/s12860-020-00336-4.
    • BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
    • Trusler O, Goodwin J, Laslett AL.
    • Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188459. doi: 10.1016/j.bbcan.2020.188459. Epub 2020 Oct 29.
    • Review
    • Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    • Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
    • Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.
    • Review
    • Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
    • Natoli M, Gallon J, Lu H, Amgheib A, Pinato DJ, Mauri FA, Marafioti T, Akarca AU, Ullmo I, Ip J, Aboagye EO, Brown R, Karadimitris A, Ghaem-Maghami S.
    • J Immunother Cancer. 2021 Jan;9(1):e001519. doi: 10.1136/jitc-2020-001519.
    • Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
    • Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL.
    • Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7. Epub 2020 Dec 14.

    Related:

    Research news: PARP Inhibitor Breast Cancer Treatments May Be Improved by Targeting Immunosuppressive Macrophages (Clinical OMICs)

    • Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
    • Ryan K, Bolaños B, Smith M, Palde P, Cuenca PD, VanArsdale TL, Niessen S, Zhang L, Behenna D, Ornelas MA, Tran KT, Kaiser S, Lum L, Stewart A, Gajiwala KS.
    • J Biol Chem. 2020 Dec 24:jbc.RA120.016573. doi: 10.1074/jbc.RA120.016573. Epub ahead of print.
    • The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.
    • Du ZH, Xia Y, Yang Q, Gao S.
    • Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289. [First Published December 24, 2020.]
    • CRISPR-Cas12a-Based Nucleic Acid Amplification-Free DNA Biosensor via Au Nanoparticle-Assisted Metal-Enhanced Fluorescence and Colorimetric Analysis.
    • Choi JH, Lim J, Shin M, Paek SH, Choi JW.
    • Nano Lett. 2020 Dec 21. doi: 10.1021/acs.nanolett.0c04303. Epub ahead of print.
    • XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
    • Ali R, Alblihy A, Toss MS, Algethami M, Al Sunni R, Green AR, Rakha EA, Madhusudan S.
    • Ther Adv Med Oncol. 2020 Dec 21;12:1758835920974201. doi: 10.1177/1758835920974201.
    • MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/ß-catenin in serous ovarian cancers.
    • Sun Y, Wu J, Dong X, Zhang J, Meng C, Liu G.
    • Transl Oncol. 2020 Dec 21;14(2):100987. doi: 10.1016/j.tranon.2020.100987. Epub ahead of print.
    • PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    • Gralewska P, Gajek A, Marczak A, Mikula M, Ostrowski J, Sliwinska A, Rogalska A.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9715. doi: 10.3390/ijms21249715.
    • PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
    • Riad A, Gitto SB, Lee H, Winters HD, Martorano PM, Hsieh CJ, Xu K, Omran DK, Powell DJ Jr, Mach RH, Makvandi M.
    • Molecules. 2020 Dec 19;25(24):E6029. doi: 10.3390/molecules25246029.
    • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors.
    • Chakraborty G, Khan Patail N, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq MO, Jehane L, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila DC, Kantoff PW.
    • Clin Cancer Res. 2020 Dec 17:clincanres.2483.2020. doi: 10.1158/1078-0432.CCR-20-2483. Epub ahead of print.
    • Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    • Cho HY, Kim YB, Park WH, No JH.
    • Cancer Res Treat. 2020 Dec 16. doi: 10.4143/crt.2020.1013. Epub ahead of print.
    • Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
    • Karche NP, Bhonde M, Sinha N, Jana G, Kukreja G, Kurhade SP, Jagdale AR, Tilekar AR, Hajare AK, Jadhav GR, Gupta NR, Limaye R, Khedkar N, Thube BR, Shaikh JS, Rao Irlapati N, Phukan S, Gole G, Bommakanti A, Khanwalkar H, Pawar Y, Kale R, Kumar R, Gupta R, Praveen Kumar VR, Wahid S, Francis A, Bhat T, Kamble N, Patil V, Nigade PB, Modi D, Pawar S, Naidu S, Volam H, Pagdala V, Mallurwar S, Goyal H, Bora P, Ahirrao P, Singh M, Kamalakannan P, Naik KR, Kumar P, Powar RG, Shankar RB, Bernstein PR, Gundu J, Nemmani K, Narasimham L, George KS, Sharma S, Bakhle D, Kamboj RK, Palle VP.
    • Bioorg Med Chem. 2020 Dec 15;28(24):115819. doi: 10.1016/j.bmc.2020.115819. Epub 2020 Oct 14.
    • A very long-acting Poly(ADP-ribose) polymerase inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models.
    • Fontaine SD, Ashley GW, Houghton PJ, Kurmasheva RT, Diolaiti M, Ashworth A, Peer CJ, Nguyen R, Figg WD, Beckford-Vera DR, Santi DV.
    • Cancer Res. 2020 Dec 15:canres.1741.2020. doi: 10.1158/0008-5472.CAN-20-1741. Epub ahead of print.
    • Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells.
    • Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB.
    • Biochem Pharmacol. 2020 Dec 4:114359. doi: 10.1016/j.bcp.2020.114359. Epub ahead of print.
    • Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer.
    • Cheng HW, Chiang CS, Ho HY, Chou SH, Lai YH, Shyu WC, Chen SY.
    • J Control Release. 2020 Dec 2:S0168-3659(20)30718-5. doi: 10.1016/j.jconrel.2020.11.061. Epub ahead of print.
    • Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer.
    • Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.
    • Mol Cancer Ther. 2020 Dec 2:molcanther.0365.2020. doi: 10.1158/1535-7163.MCT-20-0365. Epub ahead of print.
    • Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    • Boussios S, Moschetta M, Karihtala P, Samartzis EP, Sheriff M, Pappas-Gogos G, Ozturk MA, Uccello M, Karathanasi A, Tringos M, Rassy E, Pavlidis N.
    • Ann Transl Med. 2020 Dec;8(24):1706. doi: 10.21037/atm.2020.03.156.
    • The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    • Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD.
    • Gynecol Oncol. 2020 Dec;159(3):850-859. doi: 10.1016/j.ygyno.2020.09.018. Epub 2020 Sep 23.
    • Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    • Ciccone MA, Adams CL, Bowen C, Thakur T, Ricker C, Culver JO, Maoz A, Melas M, Idos GE, Jeyasekharan AD, Matsuo K, Roman LD, Gruber SB, McDonnell KJ.
    • Gynecol Oncol. 2020 Dec;159(3):869-876. doi: 10.1016/j.ygyno.2020.09.040. Epub 2020 Oct 5.
    • Homologous recombination deficiency real-time clinical assays, ready or not?
    • Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A.
    • Gynecol Oncol. 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20.
    • Review
    • Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    • Zhang Z, Chang X, Zhang C, Zeng S, Liang M, Ma Z, Wang Z, Huang W, Shen Z.
    • J Enzyme Inhib Med Chem. 2020 Dec;35(1):1606-1615. doi: 10.1080/14756366.2020.1804382.
    • Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    • Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL.
    • Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.
    • Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
    • Wu X, Li Q, Zhang F, Wang L, Wang J, Fan J, Di G, Guo C.
    • Food Chem Toxicol. 2020 Nov 30:111892. doi: 10.1016/j.fct.2020.111892. Epub ahead of print.
    • Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens.
    • Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM, Wang HG, De S, Moldovan GL.
    • Nat Commun. 2020 Nov 30;11(1):6118. doi: 10.1038/s41467-020-19961-w.
    • A Review of Natural Therapies Potentially Relevant in Triple Negative Breast Cancer Aimed at Targeting Cancer Cell Vulnerabilities.
    • Webb MJ, Kukard C.
    • Integr Cancer Ther. 2020 Jan-Dec;19:1534735420975861. doi: 10.1177/1534735420975861. [First Published November 27, 2020.]
    • Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
    • Xiang HY, Chen JY, Huan XJ, Chen Y, Gao ZB, Ding J, Miao ZH, Yang CH.
    • Bioorg Med Chem Lett. 2020 Nov 24:127710. doi: 10.1016/j.bmcl.2020.127710. Epub ahead of print.
    • Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER Positive Breast Cancer Therapy.
    • P SS, Jubie S, Naresh P, A J, Wadhwani A, M SK.
    • Mini Rev Med Chem. 2020 Nov 24. doi: 10.2174/1389557520999201124212347. Epub ahead of print.
    • Commentary
    • Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
    • Wei Y, Ou T, Lu Y, Wu G, Long Y, Pan X, Yao D.
    • PeerJ. 2020 Nov 24;8:e10414. doi: 10.7717/peerj.10414.
    • Glucose Concentration in Cell Culture Medium Influences the BRCA1-Mediated Regulation of the Lipogenic Action of IGF-I in Breast Cancer Cells.
    • Koobotse MO, Schmidt D, Holly JMP, Perks CM.
    • Int J Mol Sci. 2020 Nov 17;21(22):E8674. doi: 10.3390/ijms21228674.
    • The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    • Yan S, Xuan J, Brajanovski N, Tancock MRC, Madhamshettiwar PB, Simpson KJ, Ellis S, Kang J, Cullinane C, Sheppard KE, Hannan KM, Hannan RD, Sanij E, Pearson RB, Chan KT.
    • Br J Cancer. 2020 Nov 11. doi: 10.1038/s41416-020-01158-z. Epub ahead of print.
    • Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers.
    • Pejovic T, Joshi S, Campbell S, Thisted S, Xu F, Xu J.
    • Oncotarget. 2020 Nov 10;11(45):4104-4114. doi: 10.18632/oncotarget.27803.
    • Comprehensive characterization of amino acid positions in protein structures reveals molecular effect of missense variants.
    • Iqbal S, Pérez-Palma E, Jespersen JB, May P, Hoksza D, Heyne HO, Ahmed SS, Rifat ZT, Rahman MS, Lage K, Palotie A, Cottrell JR, Wagner FF, Daly MJ, Campbell AJ, Lal D.
    • Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28201-28211. doi: 10.1073/pnas.2002660117. Epub 2020 Oct 26.
    • PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.
    • Perini V, Schacke M, Liddle P, Vilchez-Larrea S, Keszenman DJ, Lafon-Hughes L.
    • Int J Mol Sci. 2020 Nov 5;21(21):8288. doi: 10.3390/ijms21218288.
    • BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Nov 1;80(21):4601-4609. doi: 10.1158/0008-5472.CAN-20-1830. Epub 2020 Aug 3.
    • Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.
    • Rajarajan S, C E A, Jose B, Correa M, Sengupta S, Prabhu JS.
    • Mol Clin Oncol. 2020 Nov;13(5):57. doi: 10.3892/mco.2020.2128. Epub 2020 Sep 1.
    • Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    • Xu Z, Li X, Li H, Nie C, Liu W, Li S, Liu Z, Wang W, Wang J.
    • Oncogene. 2020 Nov;39(47):7051-7062. doi: 10.1038/s41388-020-01482-x. Epub 2020 Sep 28.
    • RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status.
    • Sinha A, Saleh A, Endersby R, Yuan SH, Chokshi CR, Brown KR, Kuzio B, Kauppinen T, Singh SK, Baker SJ, McKinnon PJ, Katyal S.
    • Cancers (Basel). 2020 Oct 29;12(11):3178. doi: 10.3390/cancers12113178.
    • Regulation of breast cancer oncogenesis by the cell of origin's differentiation state.
    • Petrova SC, Ahmad I, Nguyen C, Ferrell SD Jr, Wilhelm SR, Ye Y, Barsky SH.
    • Oncotarget. 2020 Oct 27;11(43):3832-3848. doi: 10.18632/oncotarget.27783.
    • Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
    • Tavares TS, Hofman J, Lekešová A, Želazková J, Wsól V.
    • Cancers (Basel). 2020 Oct 26;12(11):3127. doi: 10.3390/cancers12113127.
    • BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
    • Sniadecki M, Brzezinski M, Darecka K, Klasa-Mazurkiewicz D, Poniewierza P, Krzeszowiec M, Kmiec N, Wydra D.
    • Genes (Basel). 2020 Oct 24;11(11):1251. doi: 10.3390/genes11111251.
    • Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
    • [No author given]
    • GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.
    • Exploring role of 5hmC as potential marker of chemoresistance.
    • Kharat SS, Sharan SK.
    • Mol Cell Oncol. 2020 Oct 22;7(6):1827904. doi: 10.1080/23723556.2020.1827904.
    • Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
    • Song L, Tang Z, Peng C, Yang Y, Guo C, Wang D, Guo L, Chen J, Liu C.
    • BMC Cancer. 2020 Oct 21;20(1):1020. doi: 10.1186/s12885-020-07524-7.
    • Lessons learned from setting up a prospective, longitudinal, multicenter study with women at high risk for breast cancer.
    • Patuleia SIS, Hagenaars SC, Moelans CB, Ausems MGEM, van Gils CH, Tollenaar RAEM, Van Diest PJ, Mesker WE, van der Wall E.
    • Cancer Epidemiol Biomarkers Prev. 2020 Oct 20:cebp.0770.2020. doi: 10.1158/1055-9965.EPI-20-0770. Epub ahead of print.
    • Review
    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review
    • Ultrasensitive colorimetric biosensor for BRCA1 mutation based on multiple signal amplification strategy.
    • Bai Y, Li H, Xu J, Huang Y, Zhang X, Weng J, Li Z, Sun L.
    • Biosens Bioelectron. 2020 Oct 15;166:112424. doi: 10.1016/j.bios.2020.112424. Epub 2020 Jul 11.
    • The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    • De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
    • Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.
    • Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
    • Sanese P, Fasano C, Buscemi G, Bottino C, Corbetta S, Fabini E, Silvestri V, Valentini V, Disciglio V, Forte G, Lepore Signorile M, De Marco K, Bertora S, Grossi V, Guven U, Porta N, Di Maio V, Manoni E, Giannelli G, Bartolini M, Del Rio A, Caretti G, Ottini L, Simone C.
    • iScience. 2020 Oct 7;23(10):101604. doi: 10.1016/j.isci.2020.101604.
    • Prioritizing disease biomarkers using functional module based network analysis: A multilayer consensus driven scheme.
    • Jha M, Roy S, Kalita JK.
    • Comput Biol Med. 2020 Oct 6;126:104023. doi: 10.1016/j.compbiomed.2020.104023. Epub ahead of print.
    • Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
    • Park D, Bergin SM, Jones D, Ru P, Koivisto CS, Jeon YJ, Sizemore GM, Kladney RD, Hadjis A, Shakya R, Ludwig T.
    • Cancer Res. 2020 Oct 1;80(19):4172-4184. doi: 10.1158/0008-5472.CAN-20-0486. Epub 2020 Jul 30.

    Related:

    Comment, Research review:

    BRCA1 and PALB2 in a Messy Breakup.

    • Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    • Lentz SE, Powell CB, Haque R, Armstrong MA, Anderson M, Liu Y, Jiang W, Chillemi G, Shaw S, Alvarado MM, Kushi LH, Skates SJ.
    • Gynecol Oncol. 2020 Oct 1:S0090-8258(20)33914-7. doi: 10.1016/j.ygyno.2020.09.021. Epub ahead of print.
    • The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
    • van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG.
    • Cancers (Basel). 2020 Sep 29;12(10):2805. doi: 10.3390/cancers12102805.
    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC.
    • Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.
    • Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor.
    • Liu J, Adhav R, Miao K, Su SM, Mo L, Chan UI, Zhang X, Xu J, Li J, Shu X, Zeng J, Zhang X, Lyu X, Pardeshi L, Tan K, Sun H, Wong KH, Deng C, Xu X.
    • Nat Commun. 2020 Sep 25;11(1):4875. doi: 10.1038/s41467-020-18637-9.
    • Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition.
    • Milletti G, Strocchio L, Pagliara D, Girardi K, Carta R, Mastronuzzi A, Locatelli F, Nazio F.
    • Cancers (Basel). 2020 Sep 20;12(9):2684. doi: 10.3390/cancers12092684.
    • Identification of Antitumor Constituents in Toad Venom by Spectrum-Effect Relationship Analysis and Investigation on Its Pharmacologic Mechanism.
    • Wu JH, Cao YT, Pan HY, Wang LH.
    • Molecules. 2020 Sep 18;25(18):E4269. doi: 10.3390/molecules25184269.
    • BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    • Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.
    • EBioMedicine. 2020 Sep 11;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub ahead of print.
    • Potential doxorubicin-mediated dual-targeting chemotherapy in FANC/BRCA-deficient tumors via modulation of cellular formaldehyde concentration.
    • Nakamura J.
    • Chem Res Toxicol. 2020 Sep 2. doi: 10.1021/acs.chemrestox.0c00288. Epub ahead of print.
    • Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.
    • Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX.
    • Am J Cancer Res. 2020 Sep 1;10(9):2813-2831.
    • XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells.
    • Eckelmann BJ, Bacolla A, Wang H, Ye Z, Guerrero EN, Jiang W, El-Zein R, Hegde ML, Tomkinson AE, Tainer JA, Mitra S.
    • NAR Cancer. 2020 Sep;2(3):zcaa013. doi: 10.1093/narcan/zcaa013. Epub 2020 Aug 1.
    • Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant cancers.
    • Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwala N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL.
    • Cancer Res. 2020 Aug 28:canres.3971.2019. doi: 10.1158/0008-5472.CAN-19-3971. Epub ahead of print.
    • Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
    • Goncalves A, Mezni E, Bertucci F.
    • Curr Opin Oncol. 2020 Aug 26. doi: 10.1097/CCO.0000000000000680. Epub ahead of print.
    • Review
    • Monitoring Homologous Recombination Activity in Human Cells.
    • Vugic D, Ehlén Å, Carreira A.
    • Methods Mol Biol. 2021;2153:115-126. doi: 10.1007/978-1-0716-0644-5_9. [First Online: 26 August 2020.]
    • Book Chapter
    • BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target.
    • Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J.
    • JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077. doi: 10.1093/jncics/pkaa077.
    • Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells.
    • Avraham A, Feldman S, Cho SS, Kol A, Heler L, Riklin-Nahmias E, Sella A, Karni T, Allweis TM, Sukumar S, Evron E.
    • Cancers (Basel). 2020 Aug 21;12(9):E2367. doi: 10.3390/cancers12092367.
    • Junshi Biosciences, Impact Therapeutics to Co-Develop PARP Inhibitor Senaparib in China.
    • [No author given]
    • Precision Oncology News. 2020 Aug 20.
    • Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial.
    • Pace LE, Lee YS, Tung N, Hamilton JG, Gabriel C, Raja SC, Jenkins C, Braswell A, Domchek SM, Symecko H, Spielman K, Karlan BY, Lester J, Kamara D, Levin J, Morgan K, Offit K, Garber J, Keating NL.
    • BMC Med Res Methodol. 2020 Aug 17;20(1):210. doi: 10.1186/s12874-020-01086-9.
    • Moving Beyond BRCA - Incorporating Molecular Assays into Ovarian Cancer trials.
    • McMullen M, Karakasis K, Oza AM.
    • Clin Cancer Res. 2020 Aug 14. doi: 10.1158/1078-0432.CCR-20-2429. Epub ahead of print.
    • News
    • Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors.
    • Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P.
    • Front Oncol. 2020 Aug 12;10:1415. doi: 10.3389/fonc.2020.01415.
    • The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    • Gatti M, Imhof R, Huang Q, Baudis M, Altmeyer M.
    • Cell Rep. 2020 Aug 4;32(5):107985. doi: 10.1016/j.celrep.2020.107985.
    • AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
    • Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM.
    • Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
    • Special bioactive compounds and functional foods may exhibit neuroprotective effects in patients with dementia (Review).
    • Murakami M, Ikeda Y, Nakagawa Y, Tsuji A, Kitagishi Y, Matsuda S.
    • Biomed Rep. 2020 Aug;13(2):1. doi: 10.3892/br.2020.1310. Epub 2020 Jun 2.
    • Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
    • Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, Akahane T, Kameyama K, Yamagami W, Kataoka F, Aoki D.
    • Sci Rep. 2020 Jul 28;10(1):12581. doi: 10.1038/s41598-020-69488-9.
    • Variants of the human RAD52 gene confer defects in ionizing radiation resistance and homologous recombination repair in budding yeast.
    • Clear AD, Manthey GM, Lewis O, Lopez IY, Rico R, Owens S, Negritto MC, Wolf EW, Xu J, Kenjic N, Perry JJP, Adamson AW, Neuhausen SL, Bailis AM.
    • Microb Cell. 2020 Jul 20;7(10):270-285. doi: 10.15698/mic2020.10.732.
    • Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
    • Go A, Jang JW, Lee W, Ha JD, Kim HJ, Nam HJ.
    • Eur J Med Chem. 2020 Jul 19;204:112635. doi: 10.1016/j.ejmech.2020.112635. Epub ahead of print.
    • The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
    • Zhao Y, Zhang LX, Jiang T, Long J, Ma ZY, Lu AP, Cheng Y, Cao DS.
    • Eur J Med Chem. 2020 Jul 15;203:112570. doi: 10.1016/j.ejmech.2020.112570. Epub ahead of print.
    • Review
    • FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
    • Guo E, Ishii Y, Mueller J, Srivatsan A, Gahman T, Putnam CD, Wang JYJ, Kolodner RD.
    • Proc Natl Acad Sci U S A. 2020 Jul 27:202009237. doi: 10.1073/pnas.2009237117. Epub ahead of print.
    • Current and Emerging Biologic Therapies for Triple Negative Breast Cancer.
    • Shaikh SS, Emens LA.
    • Expert Opin Biol Ther. 2020 Jul 25. doi: 10.1080/14712598.2020.1801627. Epub ahead of print.
    • Review
    • Electrochemical DNA Sensor for Sensitive BRCA1 Detection Based on DNA Tetrahedral-Structured Probe and Poly-Adenine Mediated Gold Nanoparticles.
    • Feng D, Su J, He G, Xu Y, Wang C, Zheng M, Qian Q, Mi X.
    • Biosensors (Basel). 2020 Jul 20;10(7):E78. doi: 10.3390/bios10070078.
    • Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.
    • Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG.
    • J Cell Mol Med. 2020 Jul 20. doi: 10.1111/jcmm.15655. Epub ahead of print.
    • BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining.
    • Kamp JA, van Schendel R, Dilweg IW, Tijsterman M.
    • Nat Commun. 2020 Jul 17;11(1):3615. doi: 10.1038/s41467-020-17455-3.
    • Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
    • Ratnakumar A, Weinhold N, Mar JC, Riaz N.
    • PLoS Genet. 2020 Jul 17;16(7):e1008903. doi: 10.1371/journal.pgen.1008903. Epub ahead of print.
    • Shared genomic segment analysis with equivalence testing.
    • Horpaopan S, Fann CSJ, Lathrop M, Ott J.
    • Genet Epidemiol. 2020 Jul 16. doi: 10.1002/gepi.22335. Epub ahead of print.
    • Inhibition of the ATR kinase enhances 5-FU sensitivity independently of non-homologous end-joining and homologous recombination repair pathways.
    • Ito SS, Nakagawa Y, Matsubayashi M, Sakaguchi YM, Kobashigawa S, Matsui TK, Nanaura H, Nakanishi M, Kitayoshi F, Kikuchi S, Kajihara A, Tamaki S, Sugie K, Kashino G, Takahashi A, Hasegawa M, Mori E, Kirita T.
    • J Biol Chem. 2020 Jul 16:jbc.RA120.013726. doi: 10.1074/jbc.RA120.013726. Epub ahead of print.
    • Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition.
    • Luo ML, Zheng F, Chen W, Liang ZM, Chandramouly G, Tan J, Willis NA, Chen CH, Taveira MO, Zhou XZ, Lu KP, Scully R, Wulf GM, Hu H.
    • Cancer Res. 2020 Jul 15;80(14):3033-3045. doi: 10.1158/0008-5472.CAN-19-2739. Epub 2020 Mar 19.

    Related:

    Commentary:

    A Novel Mechanism to Induce BRCAness in Cancer Cells.

    • A low fouling electrochemical biosensor based on the zwitterionic polypeptide doped conducting polymer PEDOT for breast cancer marker BRCA1 detection.
    • Wang J, Wang D, Hui N.
    • Bioelectrochemistry. 2020 Jul 13;136:107595. doi: 10.1016/j.bioelechem.2020.107595. Epub ahead of print.
    • Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
    • McLaughlin LJ, Stojanovic L, Kogan AA, Rutherford JL, Choi EY, Yen RC, Xia L, Zou Y, Lapidus RG, Baylin SB, Topper MJ, Rassool FV.
    • Proc Natl Acad Sci U S A. 2020 Jul 10:202003499. doi: 10.1073/pnas.2003499117. Epub ahead of print.
    • Calibration of pathogenicity due to variant-induced leaky splicing defects by using BRCA2 exon 3 as a model system.
    • Tubeuf H, Caputo SM, Sullivan T, Rondeaux J, Krieger S, Caux-Moncoutier V, Hauchard J, Castelain G, Fiévet A, Meulemans L, Révillion F, Léone M, Boutry-Kryza N, Delnatte C, Guillaud-Bataille M, Cleveland L, Reid S, Southon E, Soukarieh O, Drouet A, Di Giacomo D, Vezain M, Bonnet-Dorion F, Bourdon V, Larbre H, Muller D, Pujol P, Vaz F, Audebert-Bellanger S, Colas C, Venat-Bouvet L, Solano AR, Stoppa-Lyonnet D, Houdayer C, Frebourg T, Gaildrat P, Sharan SK, Martins A.
    • Cancer Res. 2020 Jul 8:canres.0895.2020. doi: 10.1158/0008-5472.CAN-20-0895. Epub ahead of print.
    • Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
    • Varanda AB, Martins-Logrado A, Ferreira MG, Fior R.
    • Cancers (Basel). 2020 Jul 2;12(7):E1769. doi: 10.3390/cancers12071769.
    • RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers.
    • Krais JJ, Wang Y, Bernhardy AJ, Clausen E, Miller JA, Cai KQ, Scott CL, Johnson N.
    • Cancer Res. 2020 Jul 1;80(13):2848-2860. doi: 10.1158/0008-5472.CAN-19-3033. Epub 2020 Mar 25.

    Related:

    Commentary:

    Not Black or White but Shades of Gray: Homologous Recombination Deficiency as a Continuous Variable Modulated by RNF168.

    • An overview of cancer genetics with focus on involvement of BRCA1/2 genes in breast carcinomas.
    • Tahir DE, Rehman MS, Rehman MU.
    • J Pak Med Assoc. 2020 Jul;70(7):1240-1247. doi: 10.5455/JPMA.20351.
    • BReast CAncer susceptibility gene 2 deficiency exacerbates oxidized LDL-induced DNA damage and endothelial apoptosis.
    • Singh S, Nguyen H, Michels D, Bazinet H, Matkar PN, Liu Z, Esene L, Adam M, Bugyei-Twum A, Mebrahtu E, Joseph J, Ehsan M, Chen HH, Qadura M, Singh KK.
    • Physiol Rep. 2020 Jul;8(13):e14481. doi: 10.14814/phy2.14481.
    • The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    • Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ.
    • Hum Reprod. 2020 Jun 30:deaa128. doi: 10.1093/humrep/deaa128. Epub ahead of print.
    • NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
    • Miao K, Lei JH, Valecha MV, Zhang A, Xu J, Wang L, Lyu X, Chen S, Miao Z, Zhang X, Su SM, Shao F, Rajendran BK, Bao J, Zeng J, Sun H, Chen P, Tan K, Chen Q, Wong KH, Xu X, Deng CX.
    • Nat Commun. 2020 Jun 26;11(1):3256. doi: 10.1038/s41467-020-16936-9.
    • Roles of Chk2/CHEK2 in guarding against environmentally-induced DNA damage and replication-stress.
    • Mustofa MK, Tanoue Y, Tateishi C, Vaziri C, Tateishi S.
    • Environ Mol Mutagen. 2020 Jun 24. doi: 10.1002/em.22397. Epub ahead of print.
    • Review
    • Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer.
    • Evangelisti G, Barra F, Moioli M, Sala P, Stigliani S, Gustavino C, Costantini S, Ferrero S.
    • Expert Opin Investig Drugs. 2020 Jun 15. doi: 10.1080/13543784.2020.1783238. Epub ahead of print.
    • Review
    • Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
    • Gomez MK, Illuzzi G, Colomer C, Churchman M, Hollis RL, O'Connor MJ, Gourley C, Leo E, Melton DW.
    • Cancers (Basel). 2020 Jun 9;12(6):E1503. doi: 10.3390/cancers12061503.
    • RECQ1 Helicase in Genomic Stability and Cancer.
    • Debnath S, Sharma S.
    • Genes (Basel). 2020 Jun 5;11(6):E622. doi: 10.3390/genes11060622.
    • Review
    • Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    • Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N.
    • NPJ Breast Cancer. 2020 Jun 5;6(1):19. doi: 10.1038/s41523-020-0160-4.

    Duplicate of:

    • Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    • Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N.
    • NPJ Breast Cancer. 2020 Jun 5;6:19. doi: 10.1038/s41523-020-0160-4.
    • Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.
    • Álvarez-Quilón A, Wojtaszek JL, Mathieu MC, Patel T, Appel CD, Hustedt N, Rossi SE, Wallace BD, Setiaputra D, Adam S, Ohashi Y, Melo H, Cho T, Gervais C, Muñoz IM, Grazzini E, Young JTF, Rouse J, Zinda M, Williams RS, Durocher D.
    • Mol Cell. 2020 Jun 2:S1097-2765(20)30341-5. doi: 10.1016/j.molcel.2020.05.021. Epub ahead of print.
    • Natural Selection Shapes Codon Usage in the Human Genome.
    • Dhindsa RS, Copeland BR, Mustoe AM, Goldstein DB.
    • Am J Hum Genet. 2020 Jun 1:S0002-9297(20)30158-0. doi: 10.1016/j.ajhg.2020.05.011. Epub ahead of print.
    • Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.
    • He G, Xie X, Siddik ZH.
    • Cancer Chemother Pharmacol. 2020 May 28. doi: 10.1007/s00280-020-04085-1. Epub ahead of print.
    • The evolving management of metastatic triple negative breast cancer.
    • Malhotra MK, Emens LA.
    • Semin Oncol. 2020 May 28:S0093-7754(20)30044-0. doi: 10.1053/j.seminoncol.2020.05.005.
    • Review
    • Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.
    • Lõhmussaar K, Kopper O, Korving J, Begthel H, Vreuls CPH, van Es JH, Clevers H.
    • Nat Commun. 2020 May 27;11(1):2660. doi: 10.1038/s41467-020-16432-0.
    • Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy.
    • Blasiak J, Pawlowska E, Chojnacki J, Szczepanska J, Fila M, Chojnacki C.
    • Int J Mol Sci. 2020 May 23;21(10):E3670. doi: 10.3390/ijms21103670.
    • Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    • Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, Jones GN, James N, Chabbert CD, Stott J, Dean E, Lau A, Young LA.
    • Oncogene. 2020 May 23. doi: 10.1038/s41388-020-1328-y. Epub ahead of print.
    • Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
    • Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, Taylor-Harding B, Tanaka H, Orsulic S, Junza A, Yanes O, Muñoz-Pinedo C, Palomero L, Pujana MÀ, Perales JC, Viñals F.
    • EMBO Mol Med. 2020 May 13:e11217. doi: 10.15252/emmm.201911217. Epub ahead of print.
    • Novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor DDHCB inhibits proliferation of BRCA mutant breast cancer cell in vitro and in vivo through a synthetic lethal mechanism.
    • Wang L, Zhang S, Yu X, Guo C.
    • Chem Res Toxicol. 2020 May 12. doi: 10.1021/acs.chemrestox.0c00087. Epub ahead of print.
    • Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.
    • Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S.
    • Nat Commun. 2020 May 12;11(1):2375. doi: 10.1038/s41467-020-16078-y.
    • Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    • Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    • J Pathol Clin Res. 2020 May 11. doi: 10.1002/cjp2.168. Epub ahead of print.
    • Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes.
    • Singer CF.
    • Horm Mol Biol Clin Investig. 2020 May 7;41(3):/j/hmbci.2020.41.issue-3/hmbci-2019-0057/hmbci-2019-0057.xml. doi: 10.1515/hmbci-2019-0057.
    • Review
    • Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability.
    • Zarrizi R, Higgs MR, Voßgröne K, Rossing M, Bertelsen B, Bose M, Kousholt AN, Rösner HI, Ejlertsen B, Stewart GS, Nielsen FC, Sørensen C.
    • J Clin Invest. 2020 May 7. pii: 127521. doi: 10.1172/JCI127521. [Epub ahead of print]
    • Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers.
    • Liptay M, Barbosa JS, Rottenberg S.
    • Front Oncol. 2020 May 5;10:670. doi: 10.3389/fonc.2020.00670.
    • Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line.
    • Kobayashi M, Ishizaki Y, Owaki M, Matsumoto Y, Kakiyama Y, Hoshino S, Tagawa R, Sudo Y, Okita N, Akimoto K, Higami Y.
    • Oncotarget. 2020 May 5;11(18):1653-1665. doi: 10.18632/oncotarget.27581.
    • A DNA-encoded library for the identification of natural product binders that modulate poly (ADP-ribose) polymerase 1, a validated anti-cancer target.
    • Li J, Li Y, Lu F, Liu L, Ji Q, Song K, Yin Q, Lerner RA, Yang G, Xu H, Ma P.
    • Biochem Biophys Res Commun. 2020 May 4. pii: S0006-291X(20)30746-4. doi: 10.1016/j.bbrc.2020.04.022. [Epub ahead of print]
    • Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
    • Vikas P, Borcherding N, Chennamadhavuni A, Garje R.
    • Front Oncol. 2020 Apr 28;10:570. doi: 10.3389/fonc.2020.00570.
    • BRCA1 Mutational Complementation Induces Synthetic Viability.
    • Nacson J, Di Marcantonio D, Wang Y, Bernhardy AJ, Clausen E, Hua X, Cai KQ, Martinez E, Feng W, Callén E, Wu W, Gupta GP, Testa JR, Nussenzweig A, Sykes SM, Johnson N.
    • Mol Cell. 2020 Apr 22. pii: S1097-2765(20)30232-X. doi: 10.1016/j.molcel.2020.04.006. [Epub ahead of print]
    • Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    • Gralewska P, Gajek A, Marczak A, Rogalska A.
    • J Hematol Oncol. 2020 Apr 21;13(1):39. doi: 10.1186/s13045-020-00874-6.
    • Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.
    • McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA.
    • JAMA Oncol. 2020 Apr 16. doi: 10.1001/jamaoncol.2020.0334. [Epub ahead of print]
    • Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
    • Douvdevani A, Bernstein-Molho R, Asraf K, Doolman R, Laitman Y, Friedman E.
    • Cancer Biomark. 2020 Apr 10. doi: 10.3233/CBM-190718. [Epub ahead of print]
    • Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis.
    • Geerts D, Chopra C, Connelly L.
    • Front Oncol. 2020 Apr 7;10:462. doi: 10.3389/fonc.2020.00462. eCollection 2020.
    • Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    • Montfort A, Owen S, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Böhm S, Pharoah P, McDermott J, Balkwill FR, Brenton JD.
    • Br J Cancer. 2020 Apr 6. doi: 10.1038/s41416-020-0822-x. [Epub ahead of print]
    • Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells.
    • Smith HL, Prendergast L, Curtin NJ.
    • Cancers (Basel). 2020 Apr 4;12(4). pii: E878. doi: 10.3390/cancers12040878.
    • CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
    • Li J, Zhi X, Chen S, Shen X, Chen C, Yuan L, Guo J, Meng D, Chen M, Yao L.
    • Am J Cancer Res. 2020 Apr 1;10(4):1140-1155. eCollection 2020.
    • Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
    • Zhang B, Lyu J, Yang EJ, Liu Y, Wu C, Pardeshi L, Tan K, Chen Q, Xu X, Deng CX, Shim JS.
    • Acta Pharm Sin B. 2020 Apr;10(4):615-627. doi: 10.1016/j.apsb.2019.08.008. Epub 2019 Sep 5.
    • Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells.
    • Wang H, Zhang S, Song L, Qu M, Zou Z.
    • Oncogene. 2020 Apr;39(14):2905-2920. doi: 10.1038/s41388-020-1191-x. Epub 2020 Feb 6.
    • Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
    • Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.
    • Oncol Lett. 2020 Apr;19(4):2629-2638. doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31.
    • Mechanistic basis for microhomology identification and genome scarring by polymerase theta.
    • Carvajal-Garcia J, Cho JE, Carvajal-Garcia P, Feng W, Wood RD, Sekelsky J, Gupta GP, Roberts SA, Ramsden DA.
    • Proc Natl Acad Sci U S A. 2020 Mar 31. pii: 201921791. doi: 10.1073/pnas.1921791117. [Epub ahead of print]
    • Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
    • Keung MY, Wu Y, Badar F, Vadgama JV.
    • J Clin Med. 2020 Mar 30;9(4). pii: E940. doi: 10.3390/jcm9040940.
    • Risk of Alzheimer's Disease in Cancer Patients: Analysis of Mortality Data from the US SEER Population-Based Registries.
    • Mezencev R, Chernoff YO.
    • Cancers (Basel). 2020 Mar 26;12(4). pii: E796. doi: 10.3390/cancers12040796.
    • A critical evaluation of methods to interpret drug combinations.
    • Twarog NR, Connelly M, Shelat AA.
    • Sci Rep. 2020 Mar 20;10(1):5144. doi: 10.1038/s41598-020-61923-1.
    • The tubal epigenome - An emerging target for ovarian cancer.
    • Reavis HD, Drapkin R.
    • Pharmacol Ther. 2020 Mar 17:107524. doi: 10.1016/j.pharmthera.2020.107524. [Epub ahead of print]
    • Review
    • The RAD52-S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
    • Adamson AW, Ding YC, Mendez-Dorantes C, Bailis AM, Stark JM, Neuhausen SL.
    • Mol Oncol. 2020 Mar 16. doi: 10.1002/1878-0261.12665. [Epub ahead of print]
    • ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
    • Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP.
    • Cancers (Basel). 2020 Mar 14;12(3). pii: E687. doi: 10.3390/cancers12030687.
    • Cell-type-specific role of CHK2 in mediating DNA damage-induced G2 cell cycle arrest.
    • van Jaarsveld MTM, Deng D, Ordoñez-Rueda D, Paulsen M, Wiemer EAC, Zi Z.
    • Oncogenesis. 2020 Mar 13;9(3):35. doi: 10.1038/s41389-020-0219-y.
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer.
    • Knowlson C, Haddock P, Bingham V, McQuaid S, Mullan PB, Buckley NE.
    • Ther Adv Med Oncol. 2020 Mar 9;12:1758835920906047. doi: 10.1177/1758835920906047. eCollection 2020.
    • RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
    • Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN.
    • Cancers (Basel). 2020 Mar 7;12(3). pii: E620. doi: 10.3390/cancers12030620.
    • 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
    • Chen J, Li P, Song L, Bai L, Huen , Liu Y, Lu LY.
    • Cell Death Differ. 2020 Mar 5. doi: 10.1038/s41418-020-0521-4. [Epub ahead of print]
    • Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.
    • Abbasi-Radmoghaddam Z, Riahi S, Gharaghani S, Mohammadi-Khanaposhtanai M.
    • Mol Divers. 2020 Mar 5. doi: 10.1007/s11030-020-10063-9. [Epub ahead of print]
    • Curcumin induces re-expression of BRCA1 and suppression of g synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    • Al-Yousef N, Shinwari Z, Al-Shahrani B, Al-Showimi M, Al-Moghrabi N.
    • Oncol Rep. 2020 Mar;43(3):827-838. doi: 10.3892/or.2020.7473. Epub 2020 Jan 20.
    • Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
    • Widschwendter M, Dubeau L.
    • Cancers (Basel). 2020 Feb 27;12(3). pii: E547. doi: 10.3390/cancers12030547.
    • Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
    • Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
    • Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.
    • miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    • Pessôa-Pereira D, Evangelista AF, Causin RL, da Costa Vieira RA, Abrahão-Machado LF, Santana IVV, da Silva VD, de Souza KCB, de Oliveira-Silva RJ, Fernandes GC, Reis RM, Palmero EI, Marques MMC.
    • BMC Cancer. 2020 Feb 22;20(1):143. doi: 10.1186/s12885-020-6640-y.
    • Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.
    • Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM.
    • Diagnostics (Basel). 2020 Feb 22;10(2). pii: E121. doi: 10.3390/diagnostics10020121.
    • Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    • Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.
    • J Surg Res. 2020 Feb 21;250:200-208. doi: 10.1016/j.jss.2019.12.040. [Epub ahead of print]
    • Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
    • Askeland C, Wik E, Finne K, Birkeland E, Arnes JB, Collett K, Knutsvik G, Krüger K, Davidsen B, Aas T, Eide GE, Stefansson IM, Foulkes WD, Akslen LA.
    • Sci Rep. 2020 Feb 19;10(1):2914. doi: 10.1038/s41598-020-59728-3.
    • Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    • Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, Lewis SJ, Relton CL, Martin RM.
    • JAMA. 2020 Feb 18;323(7):646-655. doi: 10.1001/jama.2020.0150.
    • BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
    • Chen Q, Lei JH, Bao J, Wang H, Hao W, Li L, Peng C, Masuda T, Miao K, Xu J, Xu X, Deng CX.
    • Adv Sci (Weinh). 2020 Feb 14;7(6):1903616. doi: 10.1002/advs.201903616. eCollection 2020 Mar.
    • BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
    • Guo C, Zhang F, Wu X, Yu X, Wu X, Shi D, Wang L.
    • Int J Biol Macromol. 2020 Feb 10. pii: S0141-8130(19)39269-4. doi: 10.1016/j.ijbiomac.2020.02.069. [Epub ahead of print]
    • PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1.
    • Belotserkovskaya R, Raga Gil E, Lawrence N, Butler R, Clifford G, Wilson MD, Jackson SP.
    • Nat Commun. 2020 Feb 10;11(1):819. doi: 10.1038/s41467-020-14563-y.
    • TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy.
    • Kim JW, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ.
    • Cancers (Basel). 2020 Feb 3;12(2). pii: E334. doi: 10.3390/cancers12020334.
    • Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
    • Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC.
    • Am J Cancer Res. 2020 Feb 1;10(2):648-661. eCollection 2020.
    • Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
    • Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J.
    • Cancer Res. 2020 Feb 1;80(3):394-405. doi: 10.1158/0008-5472.CAN-19-1036. Epub 2019 Nov 27.

    Related:

    Press: Triple negative breast cancer might not actually be ‘breast cancer’. (Clinical OMICs)

    • Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.
    • De A, De A, Sharma R, Suo W, Sharma M.
    • J Cancer. 2020 Jan 29;11(7):1927-1939. doi: 10.7150/jca.36919. eCollection 2020.
    • Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib.
    • Li J, Xiao D, Liu L, Xie F, Li W, Sun W, Yang X, Zhou X.
    • Molecules. 2020 Jan 18;25(2). pii: E407. doi: 10.3390/molecules25020407.
    • Divergent metabolic responses dictate vulnerability to NAMPT-inhibition in ovarian cancer.
    • Kudo K, Nomura M, Sakamoto Y, Ito S, Morita M, Kawai M, Yamashita Y, Ito K, Yamada H, Shima H, Yaegashi N, Tanuma N.
    • FEBS Lett. 2020 Jan 17. doi: 10.1002/1873-3468.13736. [Epub ahead of print]
    • Declining BRCA-Mediated DNA Repair in Sperm Aging and its Prevention by Sphingosine-1-Phosphate.
    • Stobezki R, Titus S, Halicka D, Darzynkiewicz Z, Oktay K.
    • Reprod Sci. 2020 Jan 8. doi: 10.1007/s43032-019-00098-1. [Epub ahead of print]
    • The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition.
    • Yusoh NA, Leong SW, Chia SL, Harun SN, Abdul Rahman MB, Vallis KA, Gill MR, Ahmad H.
    • ACS Chem Biol. 2020 Jan 3. doi: 10.1021/acschembio.9b00843. [Epub ahead of print]
    • CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
    • Mintz RL, Lao YH, Chi CW, He S, Li M, Quek CH, Shao D, Chen B, Han J, Wang S, Leong KW.
    • Bioeng Transl Med. 2020 Jan 2;5(1):e10152. doi: 10.1002/btm2.10152. eCollection 2020 Jan.
    • MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
    • Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S.
    • J Exp Clin Cancer Res. 2020 Jan 2;39(1):3. doi: 10.1186/s13046-019-1490-7.
    • Color Data v2: a user-friendly, open-access database with hereditary cancer and hereditary cardiovascular conditions datasets.
    • Berger MJ, Williams HE, Barrett R, Zimmer AD, McKennon W, Hong H, Ginsberg J, Zhou AY, Neben CL.
    • Database (Oxford). 2020 Jan 1;2020:baaa083. doi: 10.1093/database/baaa083.

Continue to Older References